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Introduction: In this decade, the CTX-M family of enzymes are considered to be the 
most common type of extended-spectrum β-lactamases (ESBLs). The production of 
these Class A β-lactamases are noted to be most prevalent in the 
Enterobacteriaceaeae family. Many global reports indicated that CTX-M-15, of the 
CTX-M-1 group, is a growing concern, causing resistance to different classes of 
antibiotics. Worrisome trends of the spread of this enzyme have been indicated in 
nosocomial and community settings worldwide. Moreover, the same predicament is 
faced along the Middle East area, especially in the absence of restricted antibiotic 
usage policies. Many reports from Kuwait indicated the spread of a multi-drug 
resistant (MDR) blaCTX-M-15 gene in different hospitals. blaCTX-M-15 genes are often 
known to be carried on large transferable plasmids. Usually, the mobilization of 
these plasmid-encoded enzymes is carried out by insertion sequence like ISEcp1. 
Aims: This work aims to investigate the distribution of blaCTX-M genes in five major 
hospitals in Kuwait and to study and analyse the genetic environment of the 
described blaCTX-M genes. 
Materials and methods: One hundred and seven isolates of E. coli (84) (78.50%) 
and K. pneumoniae (23) (21.49%) were collected between 2006 and 2010 from five 
distantly located hospitals in Kuwait. All of the collected isolates were identified as 
ESBL-producers using Vitek 2 system. The production of cefotaximases was 
detected using disc diffusion with cefotaxime and clavulanic acid according to 
Clinical and Laboratory Standards Institute (CLSI) criteria. Conformation of CTX-M 
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production was maintained by PCR amplification and further sequencing. The 
minimum inhibitory concentrations (MICs) of the collected isolates were 
determined by the double dilutions agar method described by the CLSI. Four 
different classes of antibiotics were used (aminoglycosides, different generations of 
cephalosporins, fluoroquinolones, and 3 different carbapenems). The genotypic 
relatedness of the collected strains was assessed by the use of an enhanced Pulsed-
field gel electrophoresis (PFGE) method. Further amplifications with primer walking 
and simplex PCR were done to seek the genetic context of the MDR strains. S1 
nuclease was used to size plasmids carrying the described blaCTX-M genes and 
conjugation studies were implemented to detect the transferability of the plasmids 
carrying the reported blaCTX-M genes. 
Results: All of the collected strains showed to be ESBL-producers and in particular 
cefotaximases-producers. Upon amplification, CTX-M-1 group was the only CTX-M-
group present in the collected strains. When sequenced, blaCTX-M-15 was found to be 
the most prevalent. In addition, strains carrying the blaCTX-M-3 gene were identified, 
these have previously been found in the Middle East; however, this thesis has the 
first descriptions of blaCTX-M-28, blaCTX-M-55, and blaCTX-M-117 in this region.  After the 
determination of the MICs of the collected strains, 94 (87.85%) were resistant to 
cefepime, 107 (100%) to cefotaxime, 48 (44.85%) to cefoxitin, 78 (72.89%) 
ciprofloxacin, and 71 (66.35%) to gentamicin. All of the strains were susceptible to 
carbapenems. Twenty-eight strains (26.2%) showed MDR pattern. With the 
enhanced PFGE method, only 22 isolates exhibited banding patterns that allowed 
grouping them into 10 distinct PFGE clusters. Notably, strains sharing ≥85% were 
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from the same hospitals (isolates 1 with 2, 21 with 22, and 91 with 92 from the 
maternity hospital (M), 52 with 53 from Kuwait Oil Company hospital (KOC), 78 with 
79 and 83 with 84 from Infectious Diseases Hospital (IDH), 97 with 98 and 95 with 
96 from Al-Amiri hospital(A) ). Primer walking and simplex PCR experiments used 
for the genetic environment studies yielded 7 different genetic constructions for the 
described blaCTX-M genes. All of the described blaCTX-M genes were carried on 
plasmids ranging in size from 60 – 271 kb. Only 3 of the selected strains were of 
IncFII and the rest wereindeterminate. Possibly, two blaCTX-M-15 genes are likely to be 
carried on the chromosome. All of the described blaCTX-M genes are considered to be 
transferable except for blaCTX-M-28. The sizes of the conjugative plasmids and 
incompatibility groups are the same as their parental plasmids. 
Conclusion: In conclusion, blaCTX-M-15 is the most common ESBL gene found in 
Kuwaiti hospitals. It is also causing a MDR pattern with resistance to 3 different 
generations of cephalosporins and to two other classes (aminoglycosides and 
gentamicin), but sensitive to carbapenems. This led to restricting the treatment 
option into carbapenems. Antibiotic selective pressure could have played a major 
role in the development of blaCTX-M-15 derivatives such as blaCTX-M-28, blaCTX-M-55, and 
blaCTX-M-117. The probable explanation of the spread of blaCTX-M-15 is horizontal gene 
transfer carried by ISEcp1 and the conjugative properties of the plasmids carrying 
blaCTX-M-15. Variability of the genetic environments obtained explains the non-
conditional existence of ISEcp1 to the ‘’W’’ region. Absence of the ISEcp1 in one of 
the reported structures of blaCTX-M-15 genetic contexts is noted. Therefore, the 
5 
 
existence of blaCTX-M-15 could be due to the presence of another insertion sequences 
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10 
 
ID Infectious diseases 
Inc Incompatibility 
K. Kluyvera 
Kb Kilo-base pairs 
KOC Kuwait oil company 
K. pneumoniae Klebsiella pneumoniae 
L Litre 
MBLs Metallo-β-lactamases 
MGE Mobile Genetic elements 
MDR Multi-drug resistance/resistant 
Mg Milligram 




MGE Mobile genetic elements 
µ micro 
µg microgram 
NCBI National Centre of Biotechnology Information 
NCCLS National Committee for Clinical Laboratory Standards 
P. aeruginosa Pseudomonas aeruginosa 
PBP Penicillin-binding protein 
PCR Polymerase chain reaction 
PFGE Pulsed-field gel electrophoresis 
pH Measure of acidity or basicity of a solution 




Rpm Revolutions per minute 
S seconds 
S. aureus Staphylococcus aureus 
SDS Sodium dodecyl sulphate 
Spp. species 
TAE Tris/acetic acid/ethylenediaminetetraacetic acid 
TBE Tris/Borate/ethylenediaminetetraacetic acid 
TE Tris/EDTA 
U Units 
UTI Urinary tract infection 
V Volts 













Abstract ........................................................................................................................ 2 
Declaration ................................................................................................................... 6 
Acknowledgments ........................................................................................................ 7 
Papers presented ......................................................................................................... 8 
Abbreviations ............................................................................................................... 9 
Contents ..................................................................................................................... 12 
List of tables ............................................................................................................... 15 
List of figures .............................................................................................................. 18 
1 Introduction ....................................................................................................... 21 
1.1 Prologue ...................................................................................................... 21 
1.2 Antibiotic Resistance: a closer look ............................................................. 22 
1.2.1 Consensus definition of resistance ...................................................... 22 
1.2.2 The spread of antibiotic resistance ...................................................... 24 
1.2.3 Genetics of antibiotic resistance .......................................................... 25 
1.3 β-lactam drugs ............................................................................................. 26 
1.4 β-lactam resistance ..................................................................................... 31 
1.5 Extended spectrum β-lactamases (ESBLs): a brief history .......................... 32 
1.6 ESBLs definition ........................................................................................... 33 
1.7 ESBL classification ........................................................................................ 37 
1.7.1 The Ambler molecular classification system ........................................ 38 
1.7.1 The Bush functional classification ........................................................ 42 
1.7.2 Clinical classification of ESBLs .............................................................. 45 
13 
 
1.8 CTX-M family of enzymes ............................................................................ 46 
1.9 Definition of CTX-M enzymes ...................................................................... 47 
1.10 Classification and origin of CTX-Ms ......................................................... 48 
1.11 Evolution of CTX-M-βlactamases ............................................................. 53 
1.12 Spread of CTX-Ms in Enterobacteriaceaeae ............................................ 57 
1.13 Spread of CTX-Ms in the world, in the Middle East, and in Kuwait ......... 58 
2 Objectives ........................................................................................................... 67 
3 Materials and Methods ...................................................................................... 68 
3.1 Determination of minimum inhibitory concentrations (MICs) ................... 73 
3.2 Phenotypic and molecular identification of blaCTX-M genes ........................ 76 
3.3 Pulsed-field gel electrophoresis (PFGE) ...................................................... 80 
3.3.1 Prolonged PFGE method ...................................................................... 80 
3.3.2 Enhanced rapid PFGE method ............................................................. 83 
3.3.3 Validation of the enhanced PFGE method ........................................... 84 
3.4 Sequencing with plasmid and genetic environment studies ...................... 85 
3.4.1 Selection of strains for the detection of the most prevalent CTX-M 
family member ................................................................................................... 87 
3.4.2 Selection of strains for plasmid and genetic environment studies ..... 90 
3.4.3 Genome Walking and Simplex PCR for genetic environment studies . 90 
3.4.4 Plasmid sizing and grouping ................................................................. 94 
3.4.5 Conjugation studies .............................................................................. 96 
3.5 Examination of the structural models of CTX-Ms found ............................. 97 
4 Results ................................................................................................................ 98 
4.1 Determination of MICs ................................................................................ 98 
4.2 Phenotypic and molecular identification of blaCTX-M genes ...................... 107 
14 
 
4.3 Pulsed-field gel electrophoresis ................................................................ 109 
4.3.1 Enhanced rapid method ..................................................................... 109 
4.3.2 Prolonged PFGE method .................................................................... 112 
4.3.3 Validation of the enhanced PFGE method ......................................... 119 
4.4 Sequencing with plasmid and genetic environment studies .................... 124 
4.4.1 Selection of strains for the detection of the most prevalent CTX-M 
family member ................................................................................................. 124 
4.4.2 Selection of strains for plasmid and genetic environment studies ... 137 
4.4.3 Genome Walking and Simplex PCR for genetic environment studies 148 
4.4.4 Plasmid sizing and grouping ............................................................... 154 
4.4.5 Conjugation studies ............................................................................ 157 
4.5 Examination of the structural models of CTX-Ms found ........................... 159 
5 Discussion ......................................................................................................... 169 
5.1 Phenotypic and molecular identification of blaCTX-M genes ...................... 169 
5.2 Pulsed-field gel electrophoresis ................................................................ 173 
5.3 Sequencing with plasmid and genetic environment studies .................... 175 
5.4 Examination of the structural models of the CTX-Ms found .................... 195 
6 Conclusion ........................................................................................................ 200 
7 References ........................................................................................................ 203 
8 Appendices ....................................................................................................... 234 
Appendix (A) ......................................................................................................... 234 




List of tables 
 
Table 1: β-lactam groups and most commonly used types. ...................................... 31 
Table 2: Updated functional classification of ESBLs aligned with Ambler 
classification. ...................................................................................................... 44 
Table 3: The clinical classification scheme for the classification of ESBLs. ................ 46 
Table 4: CTX-M sub-groups and members. ................................................................ 51 
Table 5: Most common CTX-M member reported in countries of the Middle East. . 62 
Table 6: Isolates and clinical data.. ............................................................................ 72 
Table 7: Sources of samples. ...................................................................................... 73 
Table 8: Antimicrobial agents name, class, breakpoint and manufacturer. .............. 75 
Table 9: Primers used for the detection of blaCTX-M genes. ....................................... 79 
Table 10: Subset of strains selected to be typed by both methods. ......................... 82 
Table 11: Strains selected for sequencing and plasmid and genetic environment 
studies. ............................................................................................................... 86 
Table 12: Strains selected for Identification of CTX-M-I group member.. ................. 88 
Table 13: Primers sequences, annealing temperature and PCR conditions for GW-
PCR for the detection of the up-stream environment of blaCTX-M-1 group. ........ 92 
Table 14: Primers sequences, annealing temperature and PCR conditions for GW-
PCR for the detection of the down-stream environment of blaCTX-M-1 group. ... 93 
Table 15: Plasmid replicon typing primers with their annealing temperatures, 
product sizes, and references. ........................................................................... 95 
16 
 
Table 16: Minimum inhibitory concentration values (mg/L) with four classes of 
antibiotics.. ....................................................................................................... 104 
Table 17: Proportion of resistance in E. coli isolates. .............................................. 105 
Table 18: Proportion of resistance in K. pneumoniae isolates. ............................... 105 
Table 19: MIC50 and MIC90 of E. coli and K. pneumoniae. ........................................ 106 
Table 20: Similarity values of strains ≥85% similarity. ............................................. 117 
Table 21: Similarity values of identical strains pulsed by the prolonged PFGE method 
and the enhanced rapid method and analysed by BioNumerics software, 
version 4. .......................................................................................................... 117 
Table 22: Similarity values of epidemiologically unrelated E. coli strains pulsed by 
the prolonged PFGE method and the enhanced rapid method and analysed by 
BioNumerics software, version 4. .................................................................... 118 
Table 32: Comparison between Miranda et al and the enhanced PFGE protocol. . 123 
Table 23: PCR sequencing and amplification results. .............................................. 127 
Table 24: Amino acid changes of the reported CTX-Ms genes in this study. .......... 130 
Table 25: Similarity of blaCTX-M genes genetic environments of Kuwaiti isolates with 
non-Kuwaiti isolates. ........................................................................................ 153 
Table 26: Plasmid sizes and incompatibility grouping of the selected strains for 
plasmids studies. .............................................................................................. 156 
Table 27: Properties of amino acids found at positions 78, 177, 242, and 288. ..... 159 
Table 28: A comparison of the MIC values of ceftazidime and cefoxitin in strains 
carrying blaCTX-M-15 and blaCTX-M-55. ................................................................... 160 
17 
 
Table 29: A comparison of the MIC values of ceftazidime and cefoxitin in strains 
carrying blaCTX-M-15 and blaCTX-M-117. .................................................................. 163 
Table 30: A comparison of the MIC values of ceftazidime and cefoxitin in strains 
carrying blaCTX-M-15 and blaCTX-M-3. ..................................................................... 165 
Table 31: A comparison of the MIC values of ceftazidime and cefoxitin in strains 
carrying blaCTX-M-15 and blaCTX-M-28. ................................................................... 167 
18 
 
List of figures 
Figure 1:The basic chemical structure of β-lactam family. The common part is the β-
lactam ring in all β-lactam family. ...................................................................... 29 
Figure 2: Time line figure showing the first description of the first member of β-
lactamase family with the first introduction of the β-lactam drug. .................. 35 
Figure 3: Schematic diagram of the updated Ambler classification system. ............. 41 
Figure 4: CTX-M family. .............................................................................................. 52 
Figure 5: World map of the distribution of blaCTX-M-15.. ............................................. 60 
Figure 6: Middle East map and the prevalence of most common CTX-M enzymes. . 63 
Figure 7: Locations of hospitals in Kuwait with different Kuwait districts. ............... 66 
Figure 8: PCR products using CTX-M consensus primers (Saladin et al., 2002). ...... 108 
Figure 9: PCR products using CTX-M-1 group designed primers.. ........................... 108 
Figure 10: PFGE banding patterns with E. coli Strains. ............................................ 110 
Figure 11: PFGE banding patterns with K. pneumoniae Strains. ............................. 111 
Figure 12: PFGE banding patterns obtained with six E. coli strains. ........................ 113 
Figure 13: PFGE banding patterns obtained with six E. coli strains. PFGE 
fingerprinting patterns obtained with the enhanced Durmaz et al. method. . 113 
Figure 14: PFGE banding patterns obtained with four K. pneumoniae strains. DNA 
band profiles using the traditional PFGE protocol, showing 100% similarity for 
most of all of the strains. ................................................................................. 114 
Figure 15: PFGE banding patterns obtained with four K. pneumoniae strains. PFGE 
fingerprinting patterns obtained with the enhanced Durmaz et al. method. . 114 
19 
 
Figure 16: PFGE banding patterns obtained with 30 E. coli strains. DNA band profiles 
using the traditional PFGE protocol. ................................................................ 115 
Figure 17: PFGE banding patterns obtained with 30 E. coli strains. PFGE 
fingerprinting patterns obtained with the enhanced Durmaz et al. method. . 116 
Figure 18: PCR products with primers described by (Dutour et al., 2002). ............. 126 
Figure 19: Nucleotide differences between isolates sharing 98-99% similarity with 
blaCTX-M-15 sequences. ....................................................................................... 128 
Figure 20: Alignment of CTX-M-15 protein with the translation of the amino acid 
sequence obtained from our strains. ............................................................... 131 
Figure 21: Alignment of CTX-M-28 protein with the translation of the amino acid 
sequence obtained from isolate 86. ................................................................ 132 
Figure 22: Alignment of CTX-M-55 protein with the translation of the amino acid 
sequence obtained from isolate 89. ................................................................ 133 
Figure 23: Alignment of CTX-M-117 protein with the translation of the amino acid 
sequence obtained from isolate 97.  ............................................................... 134 
Figure 24: Alignment of CTX-M-3 protein with the translation of the amino acid 
sequence obtained from isolate 102. .............................................................. 135 
Figure 25: Alignment of the amino acid sequence of all of the CTX-Ms found in this 
study.  ............................................................................................................... 136 
Figure 26: PFGE banding patterns obtained for strains selected for genetic 
environment studies. E. coli strains. ................................................................ 139 
Figure 27: PFGE banding patterns obtained for strains selected for genetic 
environment studies. K. pneumoniae strains. ................................................. 140 
20 
 
Figure 28: GW PCR for the upstream area. .............................................................. 142 
Figure 29: PCR Results for the downstream area.. .................................................. 143 
Figure 30: Genetic environments of all of the strains. ............................................ 147 
Figure 31: Sizing of plasmids obtained from strains selected for plasmid studies 
using s1 nuclease. ............................................................................................ 155 
Figure 32: Sizing of plasmids obtained from transconjugants using S1 nuclease. .. 158 
Figure 33: Glycine residue at position 242 in CTX-M-15. ......................................... 161 
Figure 34: Valine residue at position 78 in CTX-M-55. ............................................ 162 
Figure 35: Glutamate residue at position 177 in CTX-M-117.. ................................ 164 
Figure 36: Aspartate residue at position 242 in CTX-M-3.. ...................................... 166 
Figure 37: Asparagine residue at position 288 in CTX-M-28. .................................. 168 
Figure 39: CTX-M reported in this study with mutations and hydrolytic activity 







During the Second World War, antimicrobial drugs were introduced as sulfonamides 
and penicillins. The rise of this antimicrobial era developed into using newer β-
lactams. It was also considered to be the ‘’golden age’’ of antimicrobials (Biondi et 
al., 2011). After 40 years of extensive use of antibiotics, major problems with β-
lactam drugs were reported (Andersson et al., 2001, Biondi et al., 2011). It was 
formidable how bacterial resistance developed with proficiency to become a serious 
concern and a source of threat in the medical settings (Andersson et al., 2001, 
Canton et al., 2012, Chong et al., 2011, Walsh and Wright, 2009). Bacterial 
resistance to antimicrobial drugs was discerned to be a worldwide phenomenon 
that led to dramatic increase in morbidity, mortality, and treatment costs; affecting 
the medical field, public health, and economy (Frost et al., 2005, Hawkey and Jones, 
2009). The study of bacterial resistance to antimicrobial drugs must be increased 




1.2 Antibiotic Resistance: a closer look 
1.2.1 Consensus definition of resistance 
The term ‘’susceptibility’’ can be construed by two different means; biological or 
pharmacological (Livermore, 1995). The biological term defines a bacterial pathogen 
as resistant if the minimum inhibitory concentrations (MICs) exceed the reference 
values regardless of the resistance mechanism. On the other hand, the 
pharmacological definition of susceptibility defines a bacterial pathogen as resistant 
in relation to the drug concentration achieved in vivo and considers the resistance 
mechanism. Large clinical organization bodies such as the Clinical Laboratory 
Standards Institute (CLSI),the British Society for Antimicrobial Chemotherapy (BSAC) 
(Livermore, 1995), and European committee on antimicrobial susceptibility testing 
(EUCAST) use the pharmacological definition of susceptibility rather than the 
biological term. The CLSI (Previously called the National Committee for Clinical 
Laboratory Standards or NCCLS), in the United States, publishes the guidelines for 
setting the breakpoints required for the definition of susceptibility. On the other 
hand, BSAC publishes those breakpoints in the United Kingdom and EUCAST in the 
European countries. The above mentioned bodies set the breakpoints required to 
define a pathogen as (susceptible, intermediate, or resistant) based on the 
knowledge of assessing the pharmacokinetics and pharmacodynamics of the 
antibacterial used, the wild-type distribution of MICs,  and  the clinical outcomes of 
infections when the antibacterial is used (Turnidge and Paterson, 2007). The 
biological definition of susceptibility is used by clinicians and microbiologists. 
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A noteworthy fact is that there are no single standard criteria for the definition of 
breakpoints, different countries define breakpoints with different criteria (Barger et 
al., 2003). The breakpoint values set by the CLSI are usually higher that those set by 
BSAC (MacGowan and Wise, 2001). The differences between the values of the 
breakpoints set by BSAC, CLSI, or EUCAST mainly due to the differences in the 
guidelines used for therapy. These differences are also due to different resistant 
rates reported by different surveillance studies even when the MIC distribution is 
the same. 
The standards used for defining the breakpoints are usually (susceptible, 
intermediate, and resistant). Generally, susceptible is implied to a bacterial 
pathogen that will probably respond to antibiotics. The term ‘’intermediate’’ is 
commonly used to a bacterial pathogen that is less likely to respond to antibiotics 
and, in some cases, would responds to increased doses. A bacterial pathogen is 
defined as resistant when it does not respond to antibiotics (MacGowan and Wise, 
2001). The guidelines are established by recognised standard-setting organizations 
(such as the CLSI) and are based on the analysis of achievable serum levels, in vitro 
susceptibilities of bacteria, and human clinical trials (Rice, 2012).  
Despite the use of the pharmacological definition of susceptibility by recognised 
bodies (such as the BSAC), the biological definition is preferred to be used on the 
clinical basis. The use of the biological definition can be justified by the fact that this 
definition signifies the reduction of the MICs even if it is small and enables clinicians 
to monitor such incidents. On the other hand, the pharmacological definition could 
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disregard such change, leading to mistakenly considering a bacterial pathogen 
susceptible or intermediate when it is gaining resistance. Therefore, affecting the 
therapeutic choice making (Livermore, 1995). 
The term ‘’bacterial resistance’’ used in both definitions is not only governed by the 
MIC, but also by other factors. These include the drug concentration at the site of 
infection and the metabolic state of the infection encountered. A simple example of 
the latter is when an organism is susceptible in vitro but, if present in biofilms 
attached to a foreign body, it behaves as resistant (Rice, 2012). In other words, 
there is no firm definition of resistance that can be applicable to all bacterial 
pathogens. Instead, to make appropriate decision for treatment, the clinical cases 
and the variability of the individual clinical circumstances should all be taken into 
account (Rice, 2012). 
 
1.2.2 The spread of antibiotic resistance 
The onset of antimicrobial resistance has limited appropriate choice making in 
antibiotics used for treatment (Bush, 2010, Lee et al., 2012). Moreover, these 
infections are not only restricted to hospital settings; rather, they infiltrate into the 
community as well (Bush, 2010, Rice, 2012). In fact, the trend in which antibiotic 
resistance is developing is worrisome and is precluding the use of most 
antimicrobial agents available in the market (Andersson et al., 2001, Rice, 2012). 
Furthermore, it has been officially stated that the spread of antibiotic resistant 
bacteria represents a ‘’growing challenge’’ for the development of newer 
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antimicrobial agents capable of concurring this problematic issue (Bassetti et al., 
2011b, Chroma and Kolar, 2010). 
 
1.2.3 Genetics of antibiotic resistance 
The development of antibiotic resistance is considered to be an evolutionary 
response made by bacteria naturally, upon the exposure to antimicrobial drugs. In 
fact, it is a bacterial populations’s means of survival in the face of the inhibition 
concentration of antimicrobials. Bacterial resistance may be either inherited, or 
acquired by various mechanisms (Chroma and Kolar, 2010, Livermore, 2003). 
Intrinsic bacterial resistance is most commonly involved with chromosomal 
resistance mechanisms, the presence of efflux pumps, or the lack of affinity for the 
target drug and is unique to a certain bacterial genus (Chroma and Kolar, 2010, 
Giedraitiene et al., 2011). An example of intrinsic (innate) bacterial resistance is the 
resistance of Escherichia coli (E. coli) to vancomycin (Giedraitiene et al., 2011). On 
the other hand, bacteria from different species may acquire resistance by (i) 
exogenous DNA transfer, (ii) mutation of cellular genes, or (iii) a combination of 
both mechanisms (Giedraitiene et al., 2011, Livermore, 2003). The acquisition of 
exogenous resistance determinants applies to transferable plasmids, chromosomes, 
transposons, integrons, and bacteriophages (Giedraitiene et al., 2011, Rice, 2012). 
Antimicrobial resistance genes are often plasmid-mediated. The main mechanism 
by which resistance genes are transferred from one bacterium to another is by the 
transfer of plasmids (Giedraitiene et al., 2011). This mode of transfer is called 
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‘’horizontal gene transfer’’ (HGT).  Moreover, HGT is thought to be the main 
causative agent for the transmission and dissemination of multi-drug resistant 
bacterial pathogens. It is remarkable how horizontal transfer influence bacterial 
communities and allows the spread of different resistance patterns as well as 
epidemics (Bassetti et al., 2011b). Nevertheless, horizontal transfer plays a major 
role in bacterial diversity and evolution (Livermore, 2003, Slater et al., 2008). 
However, the factors that favour this mode of transfer are poorly understood 
(Livermore, 2003). 
 
1.3 β-lactam drugs 
One of the most widely used antibiotics is β-lactam antibiotics. Penicillin was the 
first β-lactam drug discovered (reviewed by Andersson, 2001). Later, newer β-
lactams have been discovered and used to treat infections with Gram-positive and 
Gram-negative bacteria (Biondi et al., 2011). β-lactam antimicrobials are not active 
against species that lack cell wall in their structure (such as Chlamydia spp) or 
bacterial strains with impermeable cell walls (such as Mycobacterium spp.). In 
addition, β-lactam drugs are also not active against intracellular bacterial species 
(such as Brucella or Legionella). However, these antimicrobials share high 
therapeutic index and are thought to be safe to be used even in pregnancy (Mims, 
2004). Most likely, the usage of these drugs is for the treatment of different 
infections as well as urinary tract infections as they are eliminated unchanged by 




β-lactam drugs are antimicrobial agents possessing a four-membered nitrogen-
containing β-lactam rings, usually hydrolysed by β-lactamases (Samaha-Kfoury and 
Araj, 2003). The main action of these antimicrobial agents is targeted on the 
bacterial cell wall synthesis (Page, 2002). In fact, the β-lactam ring inhibits the cell 
wall synthesis by binding to cell wall synthesis enzymes known as penicillin-binding-
proteins or transpeptidases (PBPs) (Page, 2002, Rice, 2012). PBPs are thought to be 
responsible for the action of cross-linkage of the structure of the bacterial cell wall. 
The binding of β-lactams to PBPs inhibit their action resulting in the accumulation of 
the cell units and inhibition of cell growth. Eventually, leading to the activation of 
the cell’s autolysis system and ultimate cell lysis (Mims, 2004, Rice, 2012). The 
action of β-lactams is considered to be bactericidal. β-lactam drugs consist of four 
major groups that differ from one another by the presence of additional rings. 
These groups are; penicillins, cephalosporins, carbapenems, and monobactams. The 
additional ring present in each group is; thiazolidine ring in penicillins, cephem 
nucleus in cephalosporins and a double ring structure in carbapenems. By contrast, 
monobactams do not contain an additional ring to the β-lactam ring (Samaha-
Kfoury and Araj, 2003). The basic chemical structures of the mentioned β-lactams 
are seen in Figure 1. Each group of β-lactam drugs consist of sub-groups. Penicillins 
consist of Penicillin G, penicillin resistant penicillins, aminopenicillins, 
carboxypenicillins, or ureidopencillins. Moreover, there are four generations of 
cephalosporins (reviewed by Harrison 2008). In case of carbapenems, they consist 
of imipenem, meropenem, and ertapenem. The only monobactam is aztreonam 
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(Samaha-Kfoury and Araj, 2003). The β-lactam group and their examples are 






Figure 1:The basic chemical structure of β-lactam family. The common part is 
the β-lactam ring in all β-lactam family. The R denotes the sites of variation of the 
additional ring that is different in each group. Penicillins and cephalosporins represent 
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Table 1: β-lactam groups and most commonly used types. *cephamycin can be considered as a 
group of cephalosporins or as a second generation cephalosporin. Cefoxitin, cefotetan, and 
cefmetazole are examples of cephamycins 
 
1.4 β-lactam resistance 
β-lactam resistance is caused by four main mechanisms; the production of β-
lactamases that bind and hydrolyse β-lactam drugs, alteration of the active site of  
PBPs, decreased expression of outer membrane proteins (OMPs) that leads to 
reduced permeability, reducing access to PBPs, and an induction of an efflux pump 
leading to the export of relevant substrates from the periplasm of the bacteria to 
the surrounding area (Drawz and Bonomo, 2010, Page, 2002, Rice, 2012, Samaha-
Kfoury and Araj, 2003). Another mechanism of resistance to β-lactam drugs is the 
alteration of the target sites PBPs. This mechanism is mostly encountered when 
dealing with methicillin-resistant bacteria (Chambers, 2001, Llarrull et al., 2010). 
The third and fourth mechanisms are most commonly encountered in Gram-
negative bacteria (Llarrull et al., 2010, Page, 2002). 
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The production of β-lactamases is thought to be the major threat to β-lactam 
antibiotics (Andersson et al., 2001, Bassetti et al., 2011b, Biondi et al., 2011, Drawz 
and Bonomo, 2010, Oteo et al., 2010). Inevitably, the alarming trends of the 
presence of β-lactamases are becoming the challenge of the antibiotic era. 
Moreover, β-lactamase enzymes such as blaTEM, blaSHV, and blaCTX-M are reported to 
be the main causative agents for β-lactam drugs resistance (Bassetti et al., 2011b, 
Paterson and Bonomo, 2005). Interestingly, the spread of these enzymes by 
transferable genetic elements in Enterobacteriaceaeae is magnifying this challenge 
faced in the infectious disease communities (Bassetti et al., 2011b, Bush, 2010, 
Malloy and Campos, 2011). Not only have the infectious disease communities 
addressed this issue, but also the Infectious Diseases Society of America identified 
Enterobacteriaceaeae as one of the most β-lactam resistant pathogens being 
difficult to treat (Lee et al., 2012). 
 
1.5 Extended spectrum β-lactamases (ESBLs): a brief history 
Bacterial strains can adapt different mechanisms for mediating β-lactamase 
resistance (Drawz and Bonomo, 2010, Page, 2002, Rice, 2012, Samaha-Kfoury and 
Araj, 2003). ESBLs are considered to be only a subset of β-lactamases but not 
representing all (Malloy and Campos, 2011). The emergence of the first clinical β-
lactamase enzyme ‘’TEM-1’’ was documented in the early 1960s in association with 
the use of ampicillin (reviewed by Medierios, 1984). Although the actual first β-
lactamase was identified earlier in 1940 before the introduction of penicillin 
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(Abraham and Chain, 1940). TEM-1 enzyme was isolated from a patient in Greece 
named Temoneira, therefore the designation ‘’TEM’’ was used (Medeiros, 1984). It 
was believed that TEM-1 was plasmid-mediated β-lactamase enzyme. More 
importantly, the spectrum of activity of TEM-1 enzyme towards β-lactam drugs was 
noted to be narrow and only resistant to ampicillin (Datta and Kontomichalou, 
1965). Within a few years of the TEM-1 report and in 1972, the first description of 
blaSHV-1 was documented (reviewed by Du Bois et al, 1995) (Du Bois et al., 1995). 
The designation of SHV is for the presence of sulphydryl variable group within this 
family of enzymes (Pitton, 1972). In the 1980’s, different reports of ESBL-enzymes of 
TEM and SHV-types with extended-spectrum-activity towards cephalosporins were 
described (Jacoby and Medeiros, 1991, Rice, 2012). The spread of CTX-M family of 
β-lactamases started in 1990 (Bauernfeind et al., 1990, Tzouvelekis et al., 2000) and 
increased ever since becoming the most prevalent family of β-lactamases described 
in E. coli (Qi et al., 2010). Shortly, after the accumulated reports of CTX-M enzymes, 
carbapenemases were described (Gupta et al., 2011, Queenan and Bush, 2007) 
(Figure 2). 
 
1.6 ESBLs definition  
The term ‘’ESBLs’’ was referred to later β-lactamases that were discovered after the 
emergence of SHV-1 and were closely related to TEM-1 and TEM-2 enzymes but 
conferred resistance to broadened-spectrum cephalosporins (Paterson and 
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Bonomo, 2005). Most commonly, plasmid-mediated ESBLs of the TEM, SHV, and 







 (Abraham and 
Chain, 1940) 
First Clinical use of 
penicillin 
1942 














First Clinical use of 
cefotaxime 
1979 







et al., 1990) 
















Figure 2: Time line figure showing the first description of the first member of β-lactamase family with the first introduction of the β-




ESBLs have arisen, and different β-lactamase investigators proposed different 
definitions (Ambler et al., 1991, Bush et al., 1995, Bush et al., 2009, Bush and 
Jacoby, 2010, Giske et al., 2009, Lee et al., 2012). Regardless, the Health Protection 
Agency (HPA) did define ESBLs but that definition did not cover all ESBLs. The HPA 
stated that infections-producing ESBLs are resistant to cephalosporins, penicillins, 
fluoroquinolones, trimethoprim, tetracycline and some other antibiotics limiting 
treamtment options to nitrofurantoin and fosfomycin http://www.hpa.org.uk last 
accessed (15th August 2012). 
 
Yet, scientists could not depend on the definition of ESBLs set by the HPA. The issue 
of scientists not being able to maintain a specific definition of these enzymes is due 
to two main reasons; one of which is the wide substrate specificity of these 
enzymes’ active site, and the other is that ESBLs are constantly developing with 
rapid, complex, and dynamic evolution (Gniadkowski, 2001). Therefore, the 
resistance pattern of ESBLs is constantly changing over the years, leading to the use 
of a definition that is probably subject to change whenever their resistance profile 
changes (Paterson and Bonomo, 2005). Nevertheless, ESBLs can be defined as a 
group of acquired (transferable) rather than inherited β-lactamases capable of 
hydrolysing a broad spectrum of oxyimino-β-lactam drugs such as penicillins, 
expanded-spectrum of cephalosporins, and monobactams but not cephamysins or 
carbapenems. Mainly their action is inhibited by the presence of a site directed-β-
37 
 
lactamase inhibitor such as clavulanic acid (Bush et al., 2009, Bush and Fisher, 2011, 
Gniadkowski, 2001, Livermore, 2008, Paterson and Bonomo, 2005). 
 
1.7 ESBL classification 
Ever since the discovery of the first β-lactamase enzyme ’’TEM-1’’, increasing 
number of reports of ESBLs of different types have been documented in literature 
(Gniadkowski, 2001, Samaha-Kfoury and Araj, 2003). At present, more than 1200 
different ESBLs variants are known (http://www.lahey.org/studies/webt.htm) last 
accessed (15th August 2012). These ESBL variants have been classified into fifteen 
distinct structural/evolutionary families on the basis of similarities between their 
amino acid sequences. These families are OXA, TEM, SHV, CTX-M, CMY, AmpC, imp, 
VIM, GES, Carb, KPC, IND, PER, VEB, and SME (Gniadkowski, 2001) 
(http://www.lahey.org/studies/webt.htm) last accessed (15th August 2012). 
 
 
Three classification schemes are used to classify β-lactamases; Ambler molecular 
classification scheme (Ambler et al., 1991), a functional classification scheme 
adopted by Bush-Jacoby (Bush et al., 1995, Bush and Jacoby, 2010), and a clinical 
classification proposed by Giske (Giske et al., 2009). Different studies used to 
classify β-lactamase genes (bla) on the basis of their genetic location. However, this 
classical classification system is no longer of use. Owing to the fact that plasmid-
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mediated bla genes can be mobilized and integrated into the chromosome. Another 
reason is the exclusive localization of the bla genes on the chromosome or the 
plasmid solely without being mobilized and integrated to one another (Canton et 
al., 2012, Coelho et al., 2010, Toleman et al., 2006). β-lactamase genes are mainly 
plasmid-mediated. But also, in Gram-negative bacteria, bla genes are commonly 
found on the chromosome (Canton et al., 2012). 
 
 
Each classification system has limitations especially in the face of new resistance 
patterns and the discovery of new ESBL families (Giske et al., 2009). Therefore, 
classification systems have to be updated as the definition of the ESBL enzymes is 
evolving in relation to their resistance pattern (Hall and Barlow, 2005). 
 
1.7.1 The Ambler molecular classification system 
The Ambler classification scheme categorizes ESBLs on the basis of amino acid 
sequence similarities (Bush and Fisher, 2011). It is also described to classify ESBLs 
according to the enzymes’ active site (Malloy and Campos, 2011). Ambler 
classification is the most commonly used scheme especially by scientists, but it 
renders confusion to clinicians and microbiologists (Gniadkowski, 2001, Hall and 
Barlow, 2005, Hall and Barlow, 2004, Singh et al., 2009). This issue was faced due to 
the diversity of the molecular and functional characteristics of ESBLs (Singh et al., 
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2009). ESBLs may inherit the molecular active site structure from their parent 
enzymes but with wider substrate-binding cavity leading to the increase in the 
range of their hydrolytic activity (Gniadkowski, 2001). The classical Ambler scheme 
focuses on the structure of the enzyme and neglects its function Therefore, some 
ESBLs with certain amino acid substitution can be mis-classified into a certain 
Ambler group having different functionality (Bush and Fisher, 2011). 
 
Ambler classification categorizes ESBLs into four groups; A, B, C, and D (Ambler et 
al., 1991, Hall and Barlow, 2005). Originally, Ambler specified only two classes; class 
A, where the active site is serine β-lactamases, and class B, which are metallo-β-
lactamases (MBLs) requiring a bivalent metal ion (usually Zn+2) for their action 
(Ambler et al., 1991). An updated Ambler classification uses four classes, class A, C, 
and D with serine acting as the active site and sharing little sequence similarities 
(Ambler et al., 1991). The three Ambler classes A, C, and D share high structural 
similarities (Ambler et al., 1991, Hall and Barlow, 2005, Hall and Barlow, 2004). 
Ambler class A-β-lactamases are known to be penicillinases, while class C β-
lactamases are known to be AmpC-β-lactamases and both with serine serving as the 
active site (Jaurin and Grundstrom, 1981) with cephalosporin as the preferential 
substrate. Another class with Ambler classification that has serine acting as the 
active site is class D, these β-lactamases are OXA-ESBLs (Ouellette et al., 1987). All 
of the Ambler classes with serine active site have different origins (Hall and Barlow, 
2005). This made them to be grouped into different classes despite the same active 
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site (Hall and Barlow, 2005). Previously, Ambler classification considered all class B 
(MBLs) are the same and closely related. However, this problem was addressed and 
corrected in the updated Ambler classification. The revised Ambler classification 
proposed that class B-ESBLs are divided into sub-groups (i.e. B1, B2, and B3) based 
on their sequence similarities (Hall and Barlow, 2005). The sub-groups serve those 
ESBLs that hydrolyse carbapenems escaping the serine active site (MBLs). The 
discovery of new MBLs sharing less amino-acid sequence similarity with earlier 
members led to the need to update the Ambler classification system (Hall and 
Barlow, 2005, Singh et al., 2009). The updated Ambler classification scheme is 




















1.7.1 The Bush functional classification 
The functional classification of ESBLs was originally proposed in 1973 (Richmond 
and Sykes, 1973). Later in 1995, Bush maintained to classify ESBLs based on their 
hydrolytic and inhibitory profiles (Bush et al., 1995). Nevertheless, not all β-
lactamases (in certain species) were successfully classified with the Bush 
classification. Some showed to be indistinguishable with the functional classification 
(Gniadkowski, 2001). Also, upon the discovery of newer ESBLs with expanded and 
variable hydrolytic and inhibitory profiles, there was a need to update the 
functional classification (Bush and Jacoby, 2010, Malloy and Campos, 2011). Hence, 
the Bush classification was updated in 2010 (Bush and Jacoby, 2010). Admittedly, 
grouping ESBLs based on their functionality is more subjective than classifying them 
based on their protein structure (as in Ambler classification). The functional 
classification provides clinicians and microbiologists a more practical mean to 
correlate the properties of a specific ESBL member with the results of the 
susceptibility testing of a clinical isolate. In the Bush classification, ESBLs are 
classified into 3 groups; group 1, group 2, and group 3. Group 1 represents 
cephalosporinases not inhibited by clavulanic acid, which belongs to Ambler class C. 
Group 1 has a subgroup (i.e. 1e) which has an expanded-spectrum of activity to 
cephalosporins. Group 2 serine-β-lactamases includes Ambler class A and D and 
represents most of the ESBLs. The functional group 2 preferentially hydrolyse 
benzylpenicillin and many penicillin derivatives and not necessarily inhibited by 
clavulanic acid. It is sub-divided into eleven sub-groups (2a, 2b, 2be, 2br, 2ber, 2c, 
2d, 2de, 2df, 2e, and 2f). The subdivision of each group was maintained on the basis 
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of the hydrolytic activity towards antibiotics and inhibition by β-lactam inhibitors, 
indicating variable activity of the members of the sub-divisions towards extended-
spectrum β-lactam drugs and β-lactam inhibitors (Bush and Jacoby, 2010). The most 
widely spread β-lactamases (such as blaCTX-M-15) fall into functional group 2be. This 
functional group shows increased hydrolytic activity towards extended-spectrum 
oxyimino-β-lactams (such as cefotaxime, ceftazidime, ceftriaxone, cefepime, and 
aztreonam). Also, they are distinguished by their susceptibility towards clavulanic 
acid and tazobactam, but resistance towards ethylenediaminetetraacetic acid 
(EDTA) (Bush and Jacoby, 2010). Functional group 3 is mainly composed of metallo-
β-lactamases (MBL) (Bush and Jacoby, 2010). The updated Bush functional scheme 
is aligned with the molecular Ambler scheme with few examples of the most 






Molecular class Selected enzymes (most common) 
1 C 
E. coli and Pseudomonas aeruginosa  (P. 
aeruginosa) AMPC, CMY-2, FOX-1, MIR-1, P99 
1e C GC1, CMY-37 
2a A PC1 and other staphylococcal penicillinase 
2b A SHV-1, TEM-1, TEM-2, TLE-1 (TEM-90) 
2be A 
CTX-M-15, CTX-M-44 (Toho-1), PER-1, SFO-1, SHV-
5, TEM-10, TEM-26, VEB-1 
2br A TEM-30, TEM-76, TEM-103, SHV-10, SHV-26 
2ber A TEM-50, TEM-68, TEM-89 
2c A PSE-1, CARB-3 
2d D OXA-1, OXA-10 
2de D OXA-11, OXA-15 
2df D OXA-23, OXA-48 
2e A CapA 
2f A IMI-1, KPC-2, KPC-3, SME-1, GES-2 
3a B IMP-1, L1, NDM-1, VIM-1 
3b B CphA, Sfh-1 




1.7.2 Clinical classification of ESBLs 
The establishment of the clinical classification of ESBLs was to simplify the definition 
of these enzymes to clinicians and to the infection control use (Giske et al., 2009). 
For scientific purposes, the designation of the enzyme with the enzyme’s family 
would be sufficient (Livermore, 2008). The proposal of the clinical scheme for 
classifying ESBLs was not to replace the Ambler or the Bush classification. It was set 
to complement the two, mainly for the use of health care professionals. Therefore, 
many differences within each group established by this classification may be 
neglected. Moreover, operational criteria are approached in this mode of 
categorization. These approaches are mainly of clinical use, such as the detection of 
the group of enzymes and the synergy with clavulanate. In the clinical classification 
ESBLs are categorized into three main classes; ESBLA, ESBLM, and ESBLCARBA. ESBLA 
are mainly those ESBLs not susceptible to expanded-spectrum cephalosporins and 
show synergy with clavulanate. On the other hand, ESBLM are those ESBLs which 
represent miscellaneous group. The latter group is subdivided into ESBLM-C 
representing plasmid-mediated AmpC class C. Another sub-division of ESBLM is 
ESBLM-D, which are mainly OXA-ESBLs of class D. The third category of the clinical 
classification is ESBLCARBA which members show activity against carbapenems (Giske 
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and at least one 
carbapenem 
Table 3: The clinical classification scheme for the classification of ESBLs. 
 
1.8 CTX-M family of enzymes 
CTX-M family is a rapidly growing group of enzymes belonging to ESBLs family 
(Baraniak et al., 2002, Pitout, 2010). In fact, CTX-M family of enzymes has been 
shown to be the most successful type of ESBLs spreading around the globe (Canton 
and Coque, 2006, Cullik et al., 2010, Pitout and Laupland, 2008, Rossolini et al., 
2008). The first case of CTX-M-β-lactamase was isolated in 1986 in Munich 
(Matsumoto et al., 1988). In reference to the time line of ESBL descriptions (Figure 
2), CTX-M outbreaks exploded during the 1990’s (Bonnet, 2004, Chen et al., 2005, 
Radice et al., 2002, Rice, 2012, Tzouvelekis et al., 2000). In the last decade, CTX-M 
enzymes were reported to be spreading world-wide causing hospital and 
community urinary tract infections (UTIs) being called ‘’the CTX-M pandemic’’ (Ben-
Ami et al., 2006, Bonnet, 2004, Canton et al., 2003, Canton and Coque, 2006, Chen 
et al., 2005, Johnson et al., 2010, Malloy and Campos, 2011, Nicolas-Chanoine et al., 
2008, Rogers et al., 2011, Romero et al., 2005). In addition, different reports 
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indicated the infiltration of CTX-M family of enzymes in community settings (Bush 
and Fisher, 2011, Canton and Coque, 2006, Coque et al., 2008). In Kuwait, blaCTX-M-15 
gene was described in to be most prevalent in Kuwaiti hospital settings (Al Hashem 
et al., 2011, Al Sweih et al., 2010, Al Sweih et al., 2011, Coque et al., 2008, Dashti et 
al., 2010b, Ensor et al., 2009, Jamal et al., 2010, Rotimi et al., 2008). Additionally, 
blaCTX-M-14 was reported in Kuwait by  Al-Hashem et al. (2011). 
Moreover, different reports described the detection of some CTX-M family 
members in pets, farm animals, food products, and waste disposals (Brisse and 
Duijkeren, 2005, Frye and Fedorka-Cray, 2007, Geser et al., 2012, Ho et al., 2010, 
Jouini et al., 2007, Kojima et al., 2005, Li et al., 2010, Pitout et al., 2005, Romero et 
al., 2005, Sun et al., 2010, Tian et al., 2012, Zheng et al., 2012). The most successful 
family member of the CTX-M-ESBLs is known to be CTX-M-15 enzyme (Boyd et al., 
2004, Bush and Fisher, 2011, Canton et al., 2008, Hawkey, 2008b). The spread of 
CTX-M-15 is mainly due to the spread of epidemic clones (such as ST131), or due to 
horizontal transfer plasmids carrying this gene (Pitout, 2010). The accumulating 
numbers of reports indicating the wide-spread of blaCTX-M-15 gene. Also, points out 
the importance of studying this gene and possible causes for its spread. 
 
1.9 Definition of CTX-M enzymes 
The CTX-Ms are a heterogeneous family of enzymes that have earned this 
designation due to their resistance pattern to cefotaxime and to ceftazidime to a 
milder extent (Canton and Coque, 2006, Cartelle et al., 2004). Nevertheless, with 
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their continual diversification their hydrolytic activity towards ceftazidime is 
compromised (Bush, 2010). Certain members of the CTX-M family have been 
reported to show enhanced efficiency for ceftazidime hydrolysis, such as blaCTX-M-15 
(Bush, 2010, Paterson and Bonomo, 2005, Pitout, 2010, Poirel et al., 2002a). 
Moreover, CTX-M-ESBLs retain susceptibility to tazobactam and clavulanate 
inhibitors rather than sulbactam as β-lactamase inhibitors (Bush, 2010, Chroma and 
Kolar, 2010). CTX-M family of enzymes are of molecular class A (Ambler et al., 1991, 
Hall and Barlow, 2005), functional group 2be (Bush et al., 1995, Bush and Jacoby, 
2010), and ESBLA (Giske et al., 2009). Despite the fact that CTX-M-ESBLs are 
categorized into Ambler class A with TEM and SHV, they are not closely related to 
those two families (Bradford, 2001). With the Ambler classification, CTX-Ms share 
serine as their active site (same as TEM and SHV-ESBLs). In addition, key amino 
acids in CTX-Ms sequences at certain positions were reported to play a crucial role 
in the hydrolytic activity of CTX-M-β-lactamases. These amino acids are; Asn104, 
Asn132, Ser237, and Asp240 (Bonnet, 2004, Perez et al., 2007). Mutations around 
these key amino acids may cause specific interactions leading to improved activity 
against ceftazidime and cefotaxime (Perez et al., 2007). 
 
1.10 Classification and origin of CTX-Ms 
The suggested hypothesis of the origin of blaCTX-M genes is that they were naturally 
produced from chromosomal bla genes of environmental Kluyvera spp. (Canton et 
al., 2008, Canton et al., 2012, Eisner et al., 2006). Kluyvera spp. are known to be 
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present in human intestines as normal microbes but with low bacterial counts. They 
are also considered to be saprophytic opportunistic pathogens (Farmer et al., 1981). 
Moreover, these species have rarely been reported from clinical specimens. Less 
likely, they have been isolated from urine and skin tissues (Sarria et al., 2001). Most 
reports of Kluyvera spp. are from environment (such as water, soil, and sewage) 
(Decousser et al., 2001, Farmer et al., 1981, Humeniuk et al., 2002). It is believed 
that some blaCTX-M genes originated by means of mobilization from those 
chromosomal bla genes (Canton et al., 2012). This hypothesis is supported by high 
amino acid similarities of CTX-M-type β-lactamases to chromosomal β-lactamase 
Kluyvera spp. genes (Paterson and Bonomo, 2005). In addition, CTX-M-β-lactamase 
genes are not closely related to TEM or SHV families, indicating different 
progenitors (Humeniuk et al., 2002). Moreover, the hypothesis of the origin of CTX-
M-ESBLs can also be supported by their horizontal mobilization from Kluyvera spp. 
to Enterobacteriaceaeae and non-pathogenic bacteria (Novais et al., 2010, 
Rodriguez et al., 2004). In comparison with TEM and SHV-ESBL, CTX-Ms have shown 
to express high rate of mobilization and reside on various genetic grounds (Barlow 
et al., 2008). The CTX-M genes are thought to be captured from Kluyvera spp. and 
mobilized to other bacteria by mobile genetic elements (MGE) (such as ISEcp1) 
(Pitout, 2010, Poirel et al., 2005). 
In terms of classification, CTX-M family of enzymes is diverged into five evolutionary 
groups based on their amino acid sequences homology. Namely, the described sub-
groups are; CTX-M-1 group, CTX-M-2 group, CTX-M-8 group, CTX-M-9 group, and 
CTX-M-25 group (Baraniak et al., 2002, Boyd et al., 2004, Cartelle et al., 2004, 
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Dutour et al., 2002). Interestingly, a recent study showed that CTX-M-74 and CTX-
M-75, members of CTX-M-2 subgroup, could be classified into a sixth distinct CTX-M 
subgroup (Stepanova et al., 2008). It is described that the members of each 
subgroup share ˃ 95% similarity based on their amino acid sequence similarities. On 
the other hand, the members of each distinctive group utilize ≤ 90% similarity with 
the members of other CTX-M sub-groups (Bonnet, 2004, Pitout and Laupland, 2008, 
Rossolini et al., 2008). Up to date, ninety-eight CTX-M variants have been curated 
by George Jacoby and Dr Karen Bush through the website 
(www.lahey.org/studies/webt.asp - last accessed (15th August 2012). The members 
of the each sub-group are described in Table 4. The CTX-M subfamilies are also 
represented in a dendogram in Figure 4. Previous propositions indicated that the 
possible progenitor of some CTX-M-1 group of enzymes is blaKLUC-1 and blaKLUC-2 
from Kluyvera cryocrscenes (K. cryocrscenes) (Poirel et al., 2008). Nevertheless, a 
recent study indicated that the real ancestor of this CTX-M subgroup might still be 
undetermined (Novais et al., 2010). Other studies suggested that the probable 
natural parent of CTX-M-2 subgroup is blaKLUA-1 from Kluyvera ascorbata (K. 
ascorbata) based  on the high homology between both genes (Canton and Coque, 









CTX-M family members 
CTX-M-1 cluster 
 
CTX-M-1, CTX-M-3, CTX-M-10, CTX-M-11, CTX-M-12, CTX-M-15, CTX-M-
22, CTX-M-28, CTX-M-29, CTX-M-30, CTX-M-32, CTX-M-33, CTX-M-34, 
CTX-M-36, CTX-M-37, CTX-M-42, CTX-M-52, CTX-M-53, CTX-M-54, CTX-
M-55, CTX-M-57, CTX-M-58, CTX-M-60, CTX-M-61, CTX-M-62, CTX-M-
64, CTX-M-66, CTX-M-68, CTX-M-69, CTX-M-71, CTX-M-79, CTX-M-82, 
CTX-M-89, CTX-M-101, CTX-M-107, CTX-M-108, CTX-M-109, CTX-M-




CTX-M-2, CTX-M-4, CTX-M-5, CTX-M-6, CTX-M-7, CTX-M-20, CTX-M-31, 









CTX-M-9, CTX-M-13, CTX-M-14, CTX-M-16, CTX-M-17, CTX-M-18, CTX-
M-19, CTX-M-21, CTX-M-24, CTX-M-27, CTX-M-38, CTX-M-51, CTX-M-
65, CTX-M-67, CTX-M-83, CTX-M-84, CTX-M-85, CTX-M-86, CTX-M-90, 
CTX-M-98, CTX-M-99, CTX-M-102, CTX-M-104, CTX-M-105, CTX-M-106, 
CTX-M-110, CTX-M-111, CTX-M-112, CTX-M-113, CTX-M-121, CTX-M-




CTX-M-25, CTX-M-26, CTX-M-39, CTX-M-41, 91, and CTX-M-94. 
 




Figure 4: CTX-M family. This figure was constructed with Genious software, Version 5.6.4. Using cost matrix with 65% similarity, open 
gap penalty of 12, and gap extension penalty of 3. The nucleotide sequences of the provided CTX-Ms were aligned by the global 
alignment with free ends gaps and the genetic model of Jukes-Cantor. The tree build-up method was Neighbour joining. CTX-M-1 
cluster is highlighted with light blue colour, CTX-M-2 group with green colour, CTX-M-8 cluster with pink colour, CTX-M-9 group with 
orange colour, and CTX-M-25 with purple colour.
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Poirel et al (2002b) and Edelsteins et al (2003) suggested that the potential natural 
producer of CTX-M-8 subgroup is blaKLUG-1 of Kluyvera georgiana (K. georgiana). It 
was proved that the chromosomal blaKLUG-1 shares 83-88% amino acid identity with 
blaCTX-M-8 (Poirel et al., 2002b). On the other hand, Olson has identified K. georgiana 
as a possible progenitor of CTX-M-9 subgroup (Olson et al., 2005). In addition, K. 
georgiana is also thought to be the probable ancestor of CTX-M-25 subgroup 
(Rodriguez et al., 2010). Notably, two of K. georgiana chromosomal genes were 
proposed to be the possible precursors of two clusters of CTX-M enzymes. On the 
other hand, CTX-M-1 cluster is related to K. ascorbata and K. cryocrscenes (Canton 
et al., 2012, Decousser et al., 2001, Rodriguez et al., 2004). This finding suggests the 
presence of other evolutionary trajectories (Canton et al., 2012). 
 
1.11 Evolution of CTX-M-βlactamases 
The explosive reporting of the global un-controlled antibiotic resistance (AR) is the 
result of evolutionary processes and microbial variations (Martinez et al., 2007). The 
investigation of the past mutational pathways and prediction of the hypothetical 
evolutionary trajectories and scenarios of AR-genes could enable scientists to 
predict future trends of AR (Martinez et al., 2007, Novais et al., 2010).  
 
Long ago, the evolution of AR of bacterial strains was present in nature. This was 
considered as a self defence mechanism against natural antibiotics (Pallecchi et al., 
2008). Nevertheless, this mode of resistance evolved rapidly and invaded the 
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clinical settings (Gniadkowski, 2008). Seemingly, many factors manipulated the 
evolution of AR-genes, some of which are; the large population and the earlier 
diversity of the microbial species encoding the AR-genes (Gniadkowski, 2008, 
Martinez et al., 2007), the strong selective pressure exerted by the extensive use of 
antimicrobial drugs (Gniadkowski, 2008, Pallecchi et al., 2008), the presence of 
mutational hot-spots (Gniadkowski, 2008), and extensive HGT (Suzuki et al., 2010). 
 
The evolution of β-lactamases presumably occurred from the combat with β-lactam 
antibiotics present in nature produced by Streptomyces, Lysobacter, filamentous 
fungi, or Acremonium (Bassetti et al., 2011a, Bassetti et al., 2011b). However, soon 
after the introduction of β-lactam antibiotics into the clinical practice and their 
extensive use, β-lactamases evolved rapidly limiting treatment options (Bassetti et 
al., 2011a, Bassetti et al., 2011b, Hawkey, 2008a, Smet et al., 2010). Of ESBLs, class 
A are considered to be the largest diversified group (Gniadkowski, 2008). In 
comparison with blaTEM and blaSHV, CTX-M β-lactamases were the most successful 
family in terms of distribution, prevalence, dissemination, and evolution (Canton et 
al., 2012). Clearly, different factors drove the evolutionary pathways of these 
enzymes to the presence of various CTX-M alleles and with more efficient 
phenotypic profiles (Cartelle et al., 2004, Novais et al., 2008, Poelwijk et al., 2007, 
Poirel et al., 2002b, Weinreich et al., 2006). CTX-M-1 sub-group is considered to be 
the most diversified sub-group (Novais et al., 2010). This is indicated by the 
increased number of variants of this group described in the last few years. Most 
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importantly, these evolutionary processes occurred in a considerable short period 
of time (Canton et al., 2012, Novais et al., 2010). The resulting alleles proved to 
express an enhanced resistance phenotype with more powerful hydrolytic activity 
towards cefotaxime and ceftazidime (Mamlouk et al., 2006, Novais et al., 2010, 
Poelwijk et al., 2007, Perez-Llarena et al., 2011).  
 
The first evolutionary phase of CTX-M family of enzymes led to their diversification 
from Kluyvera spp. into five sub-groups. Then, the evolutionary processes directed 
the generation of members of each sub-group (Gniadkowski, 2008). The later 
diversification was associated with the extensive use of cefotaxime and ceftazidime 
acting as a selective pressure directing the rapid increase in the derivatives of CTX-
M-3 gene as a member of CTX-M-1 group (Biondi et al., 2011, Hawkey, 2008b, 
Hawkey and Jones, 2009, Livermore, 2003, Rice, 2009). The evolutionary hot-spots 
found in both nature and directed mutagenesis of CTX-M enzymes have indicated 
changes are most prevalent at positions Asn104, Asn132, Ser237, and Asp240 
(Gniadkowski, 2008, Perez et al., 2007). Other key factors involved in the rapid 
evolution of CTX-M family of enzymes is HGT by MGE (Boto, 2010, Choi and Kim, 
2007, Ensor et al., 2009, Gangoue-Pieboji et al., 2005, Frost et al., 2005, Smet et al., 
2010, Suzuki et al., 2010). HGT is a mean of the acquisition of new genes and 
functions (Boto, 2010). The impact of HGT on evolutionary process is still 
controversial. Regardless, some studies proved that HGT affects evolution act as a 
driving force in the evolution of CTX-M enzymes (Hawkey and Jones, 2009, Pallecchi 
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et al., 2008). The acquisition of CTX-M genes is mainly driven by the action of 
insertion elements (Frost et al., 2005). These MGE are well documented in literature 
to be responsible for the mobilization and transposition of CTX-M genes (Lartigue et 
al., 2004, Diestra et al., 2009). 
 
Insertion elements are compact DNA sequences that are relatively small in size (less 
than 2.5 Kb in length) (Mahillon et al., 1999). These DNA segments encode genes for 
their function. The main function of these elements is to transpose and translocate 
between genomes (Mahillon et al., 1999). With the ability of these small sequences 
for transposition, they promote genetic rearrangements (such as deletions, 
inversions, or fusion of replicons). Hence, insertion sequences (IS) elements play a 
major role in the plasticity of the prokaryotic genomes (Mahillon and Chandler, 
1998). One of the most common IS elements that was highly associated with certain 
CTX-M family member ISEcp1 with members of CTX-M-1 group (Lartigue et al., 
2004). 
 
Eventually, all of these factors together increased the rapidity of the evolutionary 
processes of CTX-M enzymes and led to extensive reports in literature as well as 
increased activity towards cefotaxime and ceftazidime (Gniadkowski, 2008, Novais 




1.12 Spread of CTX-Ms in Enterobacteriaceaeae 
CTX-M-β-lactamases are increasingly being reported in Enterobacteriaceaeae family 
(Boyd et al., 2004). Many reports indicated the increased prevalence of blaCTX-M 
genes with Enterobacteriaceaeae (Bassetti et al., 2011b, Bassetti et al., 2011a, Bush, 
2010, Dutour et al., 2002, Eckert et al., 2006, Gangoue-Pieboji et al., 2005, Karisik et 
al., 2006, Lavollay et al., 2006, Naseer et al., 2009, Woodford et al., 2006). Some 
members of these family carrying blaCTX-M genes are involved in nosocomial and 
community infections (Karisik et al., 2006). Interestingly, blaCTX-M genes are being 
increasingly reported to be associated with E. coli especially from UTIs (Ho et al., 
2010, Jouini et al., 2007, Kanj et al., 2008, Oteo et al., 2010, Peirano and Pitout, 
2010, Pitout, 2010, Rice, 2012). Moreover, K. pneumoniae encoding blaCTX-M genes is 
globally reported to be causing serious hospital-acquired infections (Bagattini et al., 
2006, Brisse et al., 2004, Brisse and Verhoef, 2001, Diancourt et al., 2005, Wang et 
al., 2009, Shi et al., 2009). A serious attention should be given to the spread of CTX-
M enzymes in E. coli and K. pneumoniae, in particular blaCTX-M-15 which was 
witnessed from different hospital around the world (Coelho et al., 2010, Karisik et 
al., 2006, Lavollay et al., 2006, Malloy and Campos, 2011, Mamlouk et al., 2006, 





1.13 Spread of CTX-Ms in the world, in the Middle East, and in 
Kuwait 
The presence of a certain member of CTX-M family is not restricted to a specific 
geographical area; rather variable CTX-Ms members are present in different 
geographical areas (Jean and Hsueh, 2011). Earlier studies pointed out the presence 
of certain CTX-M variants to be related with specific geographical regions (Hawkey 
and Jones, 2009). Admittedly, there is a dominant CTX-M gene in every country, but 
this does not necessarily indicate that this specific gene is restricted to one area 
than other areas as suggested by Hawkey (Hawkey and Jones, 2009). Notably, CTX-
M-1 and CTX-M-9 group members are the most successful members in terms of 
spread. In particular CTX-M-15 and CTX-M-14 respectively (Malloy and Campos, 
2011). Surveillance of recent studies allowed us to conclude that the latter two 
enzymes are most common and most likely to cause endemics in Asia, Europe, 
South America, and the United States (Hawkey and Jones, 2009). All studies agree 
of the widespread and dissemination of blaCTX-M-15 gene in clinical and community 
settings causing a ‘’pandemic’’ (Canton and Coque, 2006). CTX-M-15 continues to 
be the most commonly reported CTX-M enzyme in Europe, with the exception of 
Spain where CTX-M-14 is the most prevalent (Karisik et al., 2006, Lartigue et al., 
2004, Malloy and Campos, 2011, Mamlouk et al., 2006, Mena et al., 2006, Menezes 
et al., 2010, Nicolas-Chanoine et al., 2008). Moreover, CTX-M-15 is the most 
prevalent enzyme in the United States and Africa (Lartigue et al., 2004, Malloy and 
Campos, 2011, Menezes et al., 2010, Peirano and Pitout, 2010). In addition, CTX-M-
15 is the most prevalent enzyme in Asia (Jean and Hsueh, 2011, Lartigue et al., 
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2004, Malloy and Campos, 2011, Menezes et al., 2010, Nicolas-Chanoine et al., 




Figure 5: World map of the distribution of blaCTX-M-15. The areas shaded in grey represent reports from countries with blaCTX-M-15. Adopted 
from Pitout et al (2010). 
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In the Middle East, CTX-M-15 was reported to be the most common enzyme of CTX-
M family (Jean and Hsueh, 2011, Lartigue et al., 2004, Malloy and Campos, 2011, 
Menezes et al., 2010, Nicolas-Chanoine et al., 2008, Novais et al., 2007). 
Unfortunately, lack of reports from some countries of the Middle East is observed 
from some countries like Cyprus, Jordan, Lebanon, Palestine, Qatar, Syria, and 
Yemen. It is of note that the reporting of CTX-M enzymes is less than required and 
small amount of information is maintained. The situation in the Middle East in 
terms of CTX-M prevalence should be studied more thoroughly. In Table 5, the most 
prevalent member of CTX-M family is reported from countries of the Middle East. 
However, blaCTX-M-15 is noted to be the most common member of CTX-M family in 
the Middle East (Table 5). 
 
Most of the reports from Kuwait described blaCTX-M-15 to be the most common ESBL 
enzyme (Al Hashem et al., 2011, Al Sweih et al., 2010, Al Sweih et al., 2011, Coque 
et al., 2008, Dashti et al., 2010b, Ensor et al., 2009, Jamal et al., 2010, Rotimi et al., 
2008). However, one report described indicated the presence of blaCTX-M-14 (Al 
Hashem et al., 2011). Nevertheless, the description of blaCTX-M-15 from Kuwaiti 
hospitals is thought to be preliminary and a lot has been left undiscovered. A map 
illustrating the most common CTX-M enzyme in each country in the Middle East is 





Country CTX-M member Reference 
Bahrain No reports available — 




blaCTX-M-15 (Ahmed and Shimamoto, 2011, Fam et al., 2011, 




(AbdelGhani et al., 2010, Khalaf et al., 2009, Tham 








(Mohamed Al-Agamy et al., 2006) 
Iran blaCTX-M-15 (Feizabadi et al., 2010a, Feizabadi et al., 2010b, 
Hamidian et al., 2009, Ranjbar et al., 2010, 
Tajbakhsh et al., 2012) 
Iraq blaCTX-M-15 (Huang et al., 2012, Pfeifer et al., 2009) 
Jordan No reports available — 
 
Kuwait 
blaCTX-M-15 (Al Hashem et al., 2011, Al Sweih et al., 2010, Al 
Sweih et al., 2011, Coque et al., 2008, Dashti et al., 
2010b, Ensor et al., 2009, Jamal et al., 2010, 
Rotimi et al., 2008)  
blaCTX-M-14 (Al Hashem et al., 2011) 
Lebanon blaCTX-M-15 (Kanj et al., 2008, Matar et al., 2005, Matar et al., 
2007, Matar et al., 2008, Matar et al., 2010, 
Moubareck et al., 2005a, Moubareck et al., 2005b, 
Sabra et al., 2009) 
Oman blaCTX-M-15 (Poirel et al., 2011) 
   
Palestine No reports available — 
Qatar No reports available — 




blaCTX-M-15 (Aktas et al., 2008, Aktas et al., 2012, Azap et al., 
2010, Carrer et al., 2008, Celik et al., 2010, Gonullu 
et al., 2008, Kilic et al., 2011, Nazik et al., 2008, 
Randall et al., 2011, Yumuk et al., 2008, Weill et 
al., 2004) 
blaCTX-M-3 (Acikgoz et al., 2008, Agin et al., 2011, Bahar et al., 
2006, Galimand et al., 2005, Nazik et al., 2008, 
Samuelsen et al., 2009) 
blaCTX-M-1 (Wasyl et al., 2012) 
United Arab 
Emirates 
blaCTX-M-15 (Sonnevend et al., 2006, Rotimi et al., 2008) 
Yemen No reports available — 
Table 5: Most common CTX-M member reported in countries of the Middle East. 
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In Kuwait, there are 13 governmental hospitals; mainly there is one in each district 
though more than one hospital can be located in the same district as they may 
serve specialized conditions (e.g. hospitals for maternity cases, hospitals specialized 
in chest infections or hospitals dealing with infectious diseases only). There are 
however, five main districts in Kuwait. These are Hawali district, Al-Kuwait district, 
Al-Farwaniya district, Al-Jahra district, and Mubarak Al-Kabeer with Al-Ahmadi 
district. In Al-Jahra district most of the specialized hospitals serving as an integrated 
medical area and a part of that district. Usually, cases of emergency and serious 
illnesses are treated in one of the five main hospitals (Amiri, Mubarak AlKabeer, 
Adan, Farwaniya, and Al-Jahra hospitals) and specialized conditions are referred to 
one of the specialized hospitals in the Al-Jahra district, depending on the diagnosis 
(e.g. patients diagnosed with HIV or tuberculosis are referred to Infectious diseases 
hospital). 
The Al-Amiri hospital is in the Al-Kuwait district, serving populations only living in 
that area. While, the Infectious Diseases, Maternity, and Ibn-Sina hospitals, are all 
located in the Al-Jahra district, serve populations from different areas in Kuwait as 
they are specialized hospitals for infectious diseases, maternity and neonate cases, 
bone and rheumatic disorders, respectively. The KOC hospital is in the private 
sector, only serving workers in the Kuwait Oil Company and relatives of those 
workers. The populations being served in the latter hospital are heterogeneous and 
not restricted to a certain districts. Locations of the hospitals in districts are shown 




Previous reports indicated that the most common blaCTX-M gene in Kuwaiti hospitals 
is blaCTX-M-15 (Rotimi et al., 2008, Ensor et al., 2009, Dashti et al., 2010b, Dashti et al., 
2010a, Al Sweih et al., 2010, Al Sweih et al., 2011, Al Hashem et al., 2011). The 
second most common blaCTX-M gene in Kuwaiti hospitals is blaCTX-M-14 (Al Hashem et 
al., 2011). The hospitals from which isolates were collected in earlier reports were 
Al-Adan, Alamiri, farwaniya, Ibn-sina, al-Jahra, maternity, Mubarak, and Al sabah 
hospitals. However, previous studies did not obtain any information from the 
infectious diseases hospital and Kuwait oil company hospitals. The hospitals from 
which information regarding the prevalence of blaCTX-M enzymes in Kuwait are 










 8  9




















1. To detect the spread of CTX-M-β-lactamases in Kuwaiti hospitals from which 
the strains were collected. 
2. To detect the resistance profiles of the collected isolates and determine 
MDR patterns. 
3. To detect the genotypic relatedness using PFGE among the collected isolates 
and possible spread of a certain clone. 
4. To detect the most common member of CTX-M family of enzymes. 
5. To provide analysis of the genetic environment of blaCTX-M genes.  





3 Materials and Methods 
 
Sample collection and storage 
One hundred and seven isolates of cefotaxime-resistant E. coli (84) and K. 
pneumoniae (23) were collected between 2006 and 2010 from five hospitals in 
Kuwait; the Al-Amiri hospital (A), the Ibn-sina hospital (IB), the Infectious Diseases 
hospital (ID), the Kuwait Oil Company hospital (KOC) and the Maternity hospital 
(M). The isolates were transported from the hospital laboratory to the university 
research laboratories of Kuwait University onto Nutrient agar plates (Oxoid Ltd, 
Basingstoke, UK) after overnight incubation at 37⁰C. All of the transported strains 
were stored at -70⁰C. All the strains used in this study, 84 (78.50%) E. coli and 23 
(21.49%) K. pneumoniae along with their clinical data are listed in Table 6. The 
sources of the isolates were as follows; 65 (60.74%) from urine, 17 (15.88%) from 
wound swabs, 8 (7.47%) from vaginal swabs, 5 (4.67%) from Endotracheal tip, 3 
(2.80%) from blood cultures, 3 (2.80%) from sputum, 3 (2.80%) from rectal swabs, 1 
(0.9%) from body fluids, 1 (0.9%) catheter tips and 1 (0.9%) pus. Summary of the 








Number Hospital Strain Specimen Source Gender 
1  M E. coli Urine F 
2  M E. coli Urine F 
3  M E. coli Urine F 
4  M E. coli Endotracheal Tip F 
5  M K. pneumoniae Vaginal Swab F 
6  M E. coli Urine F 
7  M K. pneumoniae Wound Swab F 
8  M E. coli Urine F 
9  M K. pneumoniae Wound Swab F 
10  M E. coli Urine F 
11  M E. coli Urine F 
12  M E. coli Vaginal Swab F 
13  M E. coli Wound Swab F 
14  M E. coli Urine F 
15  M E. coli Wound Swab F 
16  M K. pneumoniae Blood Culture F 
17  M E. coli Urine F 
18  M K. pneumoniae Rectal Swab F 
19  M K. pneumoniae Vaginal Swab F 
20  M K. pneumoniae Urine F 
21  M E. coli Vaginal Swab F 
22  M E. coli Urine F 
23  M E. coli Endotracheal Tip F 
24  M E. coli Urine F 
25  M E. coli Urine F 
26  M E. coli Wound swab F 
27  M E. coli Urine F 
28  M K. pneumoniae Urine F 
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Number Hospital Strain Specimen Source Gender 
29  M K. pneumoniae Urine F 
30  M E. coli Wound Swab F 
31  M K. pneumoniae Urine F 
32  M K. pneumoniae Endotracheal Tip F 
33  M E. coli Urine F 
34  M E. coli Urine F 
35  M E. coli Vaginal Swab F 
36  M E. coli Urine F 
37  M K. pneumoniae Blood Culture F 
38  M K. pneumoniae Blood Culture F 
39  M E. coli Urine F 
40  M E. coli Vaginal Swab F 
41  M K. pneumoniae Vaginal Swab F 
42  M E. coli Vaginal Swab F 
43  M K. pneumoniae Urine F 
44  M K. pneumoniae Rectal Swab F 
45  M K. pneumoniae Rectal Swab F 
46  M K. pneumoniae Urine F 
47  M E. coli Wound Swab F 
48  M E. coli Wound Swab F 
49  M E. coli Urine F 
50  M E. coli Pus F 
51  M E. coli Urine F 
52  K E. coli Urine F 
53  K E. coli Urine M 
54  K E. coli Urine F 
55  K E. coli Urine F 
56  K E. coli Urine M 
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Number Hospital Strain Specimen Source Gender 
57  K E. coli Urine F 
58  K E. coli Urine F 
59  K E. coli Urine F 
60  K E. coli Wound Swab F 
61  K E. coli Catheter Tip M 
62  K E. coli Urine F 
63  K E. coli Urine F 
64  K E. coli Urine F 
65  K E. coli Urine M 
66  K E. coli Urine F 
67  K E. coli Urine F 
68  K E. coli Urine F 
69  K E. coli Urine F 
70  ID E. coli Urine F 
71  ID E. coli Wound Swab F 
72  ID E. coli Wound Swab F 
73  ID E. coli Wound Swab F 
74  ID E. coli Urine F 
75  ID E. coli Urine F 
76  ID E. coli Urine M 
77  ID E. coli Wound Swab M 
78  ID E. coli Urine M 
79  ID E. coli Wound Swab M 
80  ID K. pneumoniae Urine M 
81  ID E. coli Urine F 
82  ID K. pneumoniae Urine M 
83  ID E. coli Wound Swab F 
84  ID E. coli Wound Swab F 
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85  ID K. pneumoniae Urine F 
86  ID E. coli Urine M 
87  ID E. coli Urine F 
88  A K. pneumoniae Urine F 
89  A K. pneumoniae Urine F 
90  A E. coli Urine F 
91  A E. coli Urine M 
92  A E. coli Urine M 
93  A E. coli Urine F 
94  A E. coli Urine F 
95  A E. coli Urine F 
96  A E. coli Urine M 
97  A E. coli Urine M 
98  A E. coli Urine F 
99  A E. coli Urine F 
100  IB E. coli Urine F 
101  IB E. coli Sputum M 
102  IB E. coli Drain Fluid M 
103  IB E. coli Sputum M 
104  IB E. coli Sputum M 
105  IB E. coli Wound Swab M 
106  IB E. coli Endotracheal Tip F 
107  IB E. coli Endotracheal Tip F 
Table 6: Isolates and clinical data. A refers to the Al-Amiri hospital, IB refers to the Ibn-
Sina hospital, ID refers to the Infectious Diseases hospital, KOC refers to the Kuwait Oil 






Source                                                                                                      No. (%) of patients 
 
Blood Culture...........................................................................................3 (2.80%) 
Catheter Tip..............................................................................................1 (0.90%) 
Drain Fluid................................................................................................1 (0.90%) 
Endotracheal Tip......................................................................................5 (4.67%) 
Pus............................................................................................................1 (0.90%) 
Rectal Swab..............................................................................................3 (2.80%) 
Sputum.....................................................................................................3 (2.80%) 
Urine.....................................................................................................65 (60.74%) 
Vaginal Swab............................................................................................8 (7.47%) 
Wound Swab........................................................................................17 (15.88%) 
Table 7: Sources of samples. 
 
3.1 Determination of minimum inhibitory concentrations (MICs) 
All isolates were tested for their susceptibility to four different classes of antibiotics 
to detect their spectrum of activity. The antibiotics used were; gentamicin 
(aminoglycoside); ertapenem, imipenem and meropenem (carbapenems); 
cefepime, cefoxitin, cefotaxime, and ceftazidime (cephalosporins); and ciprofloxacin 
as fluoroquinolone. The MICs were determined by double dilutions agar method 
described by the BSAC (Andrews, 2010). The breakpoints of the antibiotics used 
were in reference to Andrews (2012)(Andrews, 2012). All agars and broth used in 
MIC determination were from Oxoid (Basingstoke, Hants). The normal saline used 
was prepared from 0.85% NaCl with sterile distilled water. The control strains used 
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were E. coli ATCC 25922, P. aeruginosa ATCC 27853, and Staphylococcus aureus (S. 
aureus) NCTC 6571. The antibiotic classes, breakpoints and manufacturers are listed 






Name of the 
antimicrobial 
agent 



























1 mg/L (Bayer AG, Germany) 
Gentamicin Aminoglycoside 4 mg/L Sigma-Aldrich  
Imipenem Carbapenem 8 mg/L 
(Merck Sharpe Dohme, 









(Merck Sharpe Dohme, 
Rahway, NJ, USA) 
Gentamicin Aminoglycoside 4mg/L Sigma-Aldrich  
Table 8: Antimicrobial agents name, class, breakpoint and manufacturer. 
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3.2 Phenotypic and molecular identification of blaCTX-M genes 
For ESBL screening, the strains were identified phenotypically with Vitek 2 system 
and Double Disc Diffusion (DDD) method. Screening of ESBL production was 
maintained with Vitek 2 system (Bio Merieux, Marcy L’Etoile, France) (Paterson and 
Bonomo, 2005). Then, confirmation of ESBL-production was carried out by disc 
diffusion with cefotaxime and clavulanic acid (Oxoid) according to CLSI criteria 
(National Committee for Clinical Laboratory Standards., Clinical and Laboratory 
Standards Institute., 2005) (Malloy and Campos, 2011). The DDD method, uses two 
discs containing cefotaxime and ceftazidime Sigma-Aldrich Company (Poole, UK Ltd) 
of 30 µg that are placed onto two different plates of Iso-sensitest agar (IST) agar 
(Oxoid) inoculated with the strain. Then, the plates are inoculated at 37⁰C overnight 
with the presence of clavulanate disc. The presence of an inhibition zone between 
cefotaxime or ceftazidime and clavulanate discs is indicative of ESBL production. 
CTX-M-producers will show a bigger zone with cefotaxime than ceftazidime (Clinical 
and Laboratory Standards Institute., 2005). 
 
The genotypic identification of blaCTX-M genes was achieved using polymerase chain 
reaction (PCR). First, consensus primers were used for the detection of any of the 
blaCTX-M genes (Saladin et al., 2002). Then, primers specific for each CTX-M groups 
were used (i.e. CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 groups). The 
annealing temperatures and product sizes of the primers are listed in Table 9. The 
primers used for CTX-M-1 group were designed using Primer3 software in an online 
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website (http://frodo.wi.mit.edu/primer3/input.htm - last accessed (15th August 
2012) and manufactured by Invitrogen™, UK. For amplification, the strains were 
sub-cultured overnight at 37⁰C on MacConkey agar plates (Oxoid) and the DNA was 
extracted by boiling loop-full colonies in 100 µL sterile distilled water for 10 
minutes. PCRs were performed in 25 µL volumes containing 3 µL of DNA, 2.5 µL of 
5X Green Go Taq Flexi Buffer, 1.5 mM (2 µL) MgCl2, 0.1 mM (1 µL) PCR nucleotide 
mix, 0.2 Units of Taq, and 0.1 mM (1 µL) of each primer (Promega, Southampton. 
UK). Distilled water was used as a diluent for all amplification reactions. PCR 
products were analysed on 1.4% w/v agarose gels (GenSieve LE agarose, Flowgen 
Bioscience, UK) with 1X Tris-acetic acid EDTA (TAE) loading buffer. The preparation 
of 1X TAE buffer was performed by diluting a stock 10XTAE buffer 1:10. The stock 
10X TAE buffer was prepared from 3.72g EDTA, 11.4 ml glacial acetic acid 
(Biokeystone Co LLC, California, USA). The final volume of the buffer was rectified to 
1L and the pH was adjusted to 8.0. 
The marker used was 100bp ladder (New England Biolabs, UK). The gels were run 
for 45 minutes with 120 volts. Then, the gels were stained using 3X staining solution 
of gelRed dye (Biotium, Hayward, USA), which was prepared from a stock reagent of 
The 3X staining solution was prepared with 45 mL sterile distilled water, 5 mL of (1 
M) NaCl, and 15 μL of the stock solution and kept at room temperature for storage 
and future use. After running, the gels were visualized under Ultra Violet 
transilluminator Bio-Rad Gel Doc 2000 (Bio-Rad, Hemel Hemstead, UK). 
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At this stage no sequencing for further identification of the CTX-M family members 
was done. Rather, the determination of the MICs was performed first to later 
selecting of strains with MDR pattern in reference to Zhanel et al (2008) criteria for 
defining MDR (Zhanel et al., 2008). 
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3.3 Pulsed-field gel electrophoresis (PFGE) 
All of the isolates producing blaCTX-M genes were genotyped using an enhanced rapid 
PFGE protocol that was modified from Durmaz (2009) method (see below). DNA 
fingerprinting profiles for the isolates were analysed digitally with BioNumerics 
software (Applied Maths, Gent, Belgium) to describe the clonal relationship among 
the collected isolates and to detect their epidemiologic relatedness.  
Only subsets of isolates were typed by the Miranda (1996) method. Validation of 
the enhanced PFGE protocol was made by analysing and comparing the results of 
the subsets of isolates obtained from both procedures. 
 
3.3.1 Prolonged PFGE method 
The prolonged PFGE method was followed exactly as described previously without 
modifications (Miranda et al., 1996). Isolates found to be identical with the 
enhanced rapid PFGE protocol were also genotyped with the traditional PFGE 
method. These isolates were 3 sets of identical E. coli strains and 3 sets of K. 
pneumoniae strains. Also, 30 isolates found to be different with the rapid PFGE 
method were genotyped with the prolonged PFGE protocol. These isolates were 30 
E. coli strains sharing <85% similarity. The strains selected to be genotyped using 
both methods are listed in Table 10. Genotyping, both identical and different 
subsets of isolates, was done for validation purposes of the enhanced rapid method 
described in this study. The original method requires longer time than the enhanced 
shorter method to yield banding patterns for the strains. Lysis step requires two 
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days with two different buffers (i. e. lysis buffer and ESP buffer [0.4 M EDTA, 1% 
sodium lauroyl sarcosine, and 0.5 mg/ml of proteinase K (PK) (Sigma), pH 8.0]). This 
method is labour-intensive as there are different buffers used (PIV buffer, lysis 












































































Table 10: Subset of strains selected to be typed by both methods. The strains 
highlighted in green are similar and identical. 
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3.3.2 Enhanced rapid PFGE method 
The method used was modified from that of Durmaz (2009). There were three basic 
steps in which the method of Durmaz (2009) was modified; cell suspension 
preparation, cell lysis, and washing the agarose plugs. 
Cell suspension preparation: Cell suspension was prepared by emulsifying 5-10 
colonies of pure 18 hours bacterial cultures into 2 mL of 1X phosphate 
Buffered Saline (PBS) (Sigma-aldrich). The cell concentration was adjusted to 
absorbance value of 1 OD unit measured at 590 nm. The cell suspension was 
not vortexed to avoid cell breakage; rather it was gently inverted. Then, 2 mL 
of 1.6% certified megabase agarose (CMA) (Bio-Rad, Hemel Hempstead, UK) 
with 1% sodium dodecyl sulphate (SDS) (Fisher Scientific) was added without 
further mixing. About 500 µL of this mixture was dispensed into plug moulds 
(Bio-Rad) and kept at 4⁰C for 30-45 minutes.  
Cell lysis: Lysis step involved the use of a single cell lysis solution (CLS) comprising, 
50 mM Tris base, 50 mM EDTA, lysozyme [2.5 mg/ml], pH 8.0) (Fisher-
Scientific) plus an increased concentration of (PK) (Fisher-Scientific) (1.5 
mg/ml) present. Plugs were lysed in 2 mL of CLS and placed in a shaking 
water bath at 37⁰C for one hour. 
Washing of the agarose plugs: The agarose plugs were washed 3 times; the first 
wash was with 5 mL of pre-heated sterile distilled water, and the other two 
washes were with 5 mL of pre-heated 0.1X TE buffer. The 0.1X TE buffer was 
prepared from 1X TE buffer (10 mM Tris, 1 mM EDTA, pH 7.6). All washes 
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were maintained at 55⁰C in a shaking water bath, with each wash lasting 
exactly 15 minutes. Cold TE buffer was placed after the last wash and stored 
at 4⁰C until further processing. 
Restriction and running of plugs: restriction and running conditions were the same 
for both methods. The plugs were restricted with 40 Units of XbaI enzyme 
(Promega) with overnight incubation at 37⁰C. For the gel itself, 1.2% pulsed-field 
certified agarose (Bio-Rad) was prepared. The running buffer was prepared from 
10X Tris-Boric acid-EDTA buffer (TBE) (0.89 M Tris, 0.89 M Boric acid, 25 mM EDTA, 
pH 8.3) (Fisher) to a final concentration of 0.5X TBE. In the enhanced method 
further optimization was done by the addition of 50 µM Thiourea (Sigma) into the 
running buffer (Corkill et al., 2000). As for running conditions, the gel was run for 20 
hours at 14°C using CHEF-DRII system (Bio-Rad). The initial pulse was set at 5 
seconds and the final pulse was altered to 40 seconds with a voltage of 6 (V/cm3). 
The gels were then visualized using gelRed dye (Biotium) (Durmaz et al., 2009, Koort 
et al., 2002, Gautom, 1997). 
 
3.3.3 Validation of the enhanced PFGE method 
The enhanced method was validated by assessing its ability to type, power of 
discrimination and reproducibility. Results obtained from both methods were 
analysed using TIFF images with BioNumerics software, version 4. Clustering was 
performed using the un-weighted pair group method, arithmetic averages with Dice 
coefficient, position tolerance and an optimization of 1%. The cutoff clonal 
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relationship was defined based on the relationship of PFGE banding patterns to a 
single genetic event. In PFGE analysis, the value of such genetic event (e.g. point 
mutation, insertion or deletion of DNA) corresponds to 85% similarity (Ejrnaes et al., 
2006, Tenover et al., 1995). Strains were referred as similar if they share ≥ 85% 
similarity. Strains were considered to be identical if they share 100% similarity 
(Ejrnaes et al., 2006). 
 
3.4 Sequencing with plasmid and genetic environment studies 
The genetic environments of blaCTX-M genes found in our strains were studied using 
Genome Walking PCR (GW-PCR) as well as simplex PCR. Moreover, plasmid studies 
were employed to confirm the location of blaCTX-M genes on specific plasmids. In 
addition, studies included the detection of the sizes and the incompatibility groups 
(Inc) of the plasmids carrying blaCTX-M genes. The transferability of the plasmids 





Isolate № Hospital Strain 
15 M E. coli 
20 M K. pneumoniae 
37 M K. pneumoniae 
47 M E. coli 
57 K E. coli 
61 K E. coli 
74 ID E. coli 
75 ID E. coli 
80 ID K. pneumoniae 
82 ID K. pneumoniae 
86 ID E. coli 
88 A K. pneumoniae 
89 A K. pneumoniae 
90 A E. coli 
91 A E. coli 
92 A E. coli 
93 A E. coli 
94 A E. coli 
95 A E. coli 
96 A E. coli 
97 A E. coli 
98 A E. coli 
99 A E. coli 
100 IB E. coli 
102 IB E. coli 
Table 11: Strains selected for sequencing and plasmid and genetic environment 
studies. A refers to the Al-Amiri hospital, IB the refers to the Ibn-Sina hospital, ID 
refers to the Infectious Diseases hospital, KOC refers to the Kuwait Oil Company 




3.4.1 Selection of strains for the detection of the most prevalent 
CTX-M family member 
 
PFGE was done to detect the clonal relatedness among the collected isolates. PFGE 
with MICs determination were supposed to help in selecting strains for further 
identification of the most prevalent CTX-M family member. Hypothetically, a 
representative strain from each clone with MDR pattern was to be amplified and 
sequenced. Unfortunately, no clonal relatedness was found among the strains 
except for 22 isolates. Therefore, strains were chosen for sequencing based on their 
MDR solely and disregarding their clonal pattern. In total, twenty two strains from 
all hospitals were used for further amplification. Upon sequencing, one CTX-M 
member of CTX-M-1 family was found to be most prevalent. Interestingly, 
derivatives of that member were reported and one parent enzyme. For further 
confirmation of the most prevalent CTX-M member, ten more strains were chosen 
for sequencing. Of the thirty-two isolates, twenty-one showed MDR pattern in 
reference to Zhanel (2008) criteria. The selection of more strains confirmed the 
commonest CTX-M member prevalent in all of the hospitals mentioned in this 







4 M E. coli 
15 M E. coli 
17 M E. coli 
20 M K. pneumoniae 
37 M K. pneumoniae 
47 M E. coli 
55 K E. coli 
57 K E. coli 
60 K E. coli 
61 K E. coli 
74 ID E. coli 
75 ID E. coli 
80 ID K. pneumoniae 
82 ID K. pneumoniae 
86 ID E. coli 
87 ID E. coli 
88 A K. pneumoniae 
89 A K. pneumoniae 
90 A E. coli 
91 A E. coli 
92 A E. coli 
93 A E. coli 
94 A E. coli 
95 A E. coli 
96 A E. coli 
97 A E. coli 
98 A E. coli 
99 A E. coli 
100 IB E. coli 
101 IB E. coli 
102 IB E. coli 
105 IB E. coli 
Table 12: Strains selected for Identification of CTX-M-I group member. A refers to 
the Al-Amiri hospital, IB the refers to the Ibn-Sina hospital, ID refers to the 
Infectious Diseases hospital, KOC refers to the Kuwait Oil Company hospital, and M 
refers to the Maternity hospital. The strains highlighted in light yellow colour are 




For the identification of CTX-M-1 group members PCR amplification and sequencing 
was done with F 5’-CTTCCAGAATAAGGAATC-3’ and R 5’-CCGTTTCCGCTATTACAA-3’ 
at 52°C (Dutour et al., 2002). All strains with a product size of 903 bp were 
sequenced. For sequencing, PCR products were purified using a QIAquick PCR 
Purification Kit (Qiagen, Crawley, UK) and sequenced using ABI3730 capillary 
sequencer (Applied Biosystems, Warrington, UK). The analysis of DNA sequencing 
results was done using BioEdit, Multalin, EXPASY, Basic Local Alignment Search Tool 
(BLAST), and European Bioinformatics Institute (EMBL) search engines. The resulting 
sequencing were compared to previously published CTX-M-15 gene sequences in an 
online website (http://www.lahey.org/studies/webt.stm) and 
(http://www.ncbi.nih.gov/BLAST) last access date (15th August 2012). The protein 
sequences were assembled using the EXPASY (expert analysis protein system) 
translate website (http:www.expasy.ch/tools/dna.html) last accessed (15th August 
2012). Aligning the sequencing results and the protein sequences was done by the 
Multialin web site and EMBL-EBI online websites: 
(http://www.toulouse.inra.fr/multalin.html), and (http://www.ebi.ac.uk/) 




3.4.2 Selection of strains for plasmid and genetic environment 
studies 
 
Out of the thirty-two strains selected for sequencing, twenty-five were chosen for 
the comparison of the genetic platforms and the description of possible common 
insertion sequences or other common transpositional elements. Also, the same 
twenty-five strains were used for further plasmid studies. Plasmid studies included 
the detection of the plasmid sizes carrying the blaCTX-M genes detected and the 
incompatibility grouping of the same plasmids. A list of the twenty-five strains used 
for this part of the study is summarized in Table 11.  
 
3.4.3 Genome Walking and Simplex PCR for genetic environment 
studies 
 
For the characterization of the genetic organization of the reported blaCTX-M genes 
found in this study, GW-PCR and simplex PCR were employed. Genome Walking PCR 
involved the use of specific nested primers for amplification and specific primers for 
direct sequencing as described (Pilhofer et al., 2007, Cullik et al., 2010). The primers 
sequences, annealing temperatures and PCR conditions used in GW-PCR are listed 
in Table 13 and Table 14. Simplex PCR was only performed for the characterization 
of the downstream region of blaCTX-M-1 genes. Unfortunately, with GW-PCR there 
were no results for the detection of the downstream genetic context. Therefore, 
simplex PCR was done to detect the downstream area of the reported CTX-M genes 
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in this study. The primers used for the detection of the downstream regions in the 
simplex PCR are 1166Fo 5’-GCGATCCGCGTGATACCACT-3’ and 1671Re 5’-
CGTGGCTGCCGATGACTATG-3’ (Sonnevend et al., 2006). PCR products were 















94⁰C –  Denaturation – 4 minutes 
94⁰C – 30 seconds 
63⁰C – 30 seconds              30 cyles 
72⁰C – 3  minutes 
(Cullik et al., 2010, Pilhofer et al., 
2007) 2 
94⁰C – 30 seconds 
40⁰C – 30 seconds              1 cycle 
72⁰C – 3  minutes 
3 
 
94⁰C – 30 seconds 
63⁰C – 30 seconds              30 cycle 
72⁰C – 3  minutes 




5’- GCATACAGCGGCACACTTC-3’ Direct sequencing 
 
Table 13: Primers sequences, annealing temperature and PCR conditions for GW-PCR for the detection of the up-stream environment 















94⁰C –  Denaturation – 4 
minutes 
94⁰C – 30 seconds 
63⁰C – 30 seconds              30 
cyles 
72⁰C – 3  minutes 
(Cullik et al., 2010, Pilhofer et al., 
2007) 
2 
94⁰C – 30 seconds 
40⁰C – 30 seconds              1 
cycle 
72⁰C – 3  minutes 
3 
 
94⁰C – 30 seconds 
63⁰C – 30 seconds              30 
cycle 
72⁰C – 3  minutes 





5’– GGCAGAAAGCCGTCGCGATGTATTAG-3’ Direct sequencing 
 
Table 14: Primers sequences, annealing temperature and PCR conditions for GW-PCR for the detection of the down-stream 




3.4.4 Plasmid sizing and grouping 
 
The sizing of plasmids was done using the prepared PFGE plugs containing genomic 
DNA. The method involved the use of nuclease S1 (Promega) to convert the circular 
plasmid into a linear form that allows a direct association between the distance that 
the DNA migrated in the running gels with its size. This protocol was described 
previously by Barton (1995). Ten units of nuclease S1 were used for each plug with 
the addition of 90 µL sterile distilled water and 10 µL nuclease S1 buffer (Promega). 
The plugs were incubated for 45 minutes at 37⁰C and, to stop the enzymatic 
reaction, the plugs were washed with sterile distilled water. Running conditions and 
visualization of the gels were the same as those described in section  3.1 and  3.3.1. 
 
For isolates shown to carry more than one plasmid, DNA gel extraction for each 
band was made using QIAquick gel extraction kit (Qiagen). Then, PCR amplification 
was done for each plasmid, using CTX-M primers; F 5’-
SCSATGTGCAGYACCAGTAA-3’ and R 5’-CCGCRATATGRTTGGTGGTG-3’ (Saladin 
et al., 2002). Further sequencing was done to confirm the presence of blaCTX-M 
member as described above in section  3.1. Then, PCR-based plasmid replicon typing 
was made as described previously (Carattoli et al., 2005, Garcia-Fernandez et al., 
2009). The list of primers used for plasmid replicon typing is seen in Table 15. PCR 
reaction mix and gel visualization were done as described above in section  3.1 















Table 15: Plasmid replicon typing primers with their annealing temperatures, product sizes, and references. 






5’-TCGCTTCATTCCTGCTTC AGC -3’ 
5’-GTGTGCTGTGGTTATGCCTCA -3’ 
 




































785 bp 60⁰C (Carattoli et al., 2005) 
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3.4.5 Conjugation studies 
 
The transferability of the plasmids carrying blaCTX-M genes was carried out by broth 
mating. Strains carrying different blaCTX-M (15, 86, 89, 97 and 102) were used for 
conjugation studies. Our strains were used as donors and E. coli J62.2 (RifR) as 
recipient at a ratio of 1:10. Cultures of both donors and recipient were grown in 4.5 
mL sterile nutrient broth and incubated overnight at 37⁰C. Then, 100 µL of the 
donor’s strain culture was added to 1 mL of the recipient strain. Transconjugants 
were selected on MacConkey agar supplemented with cefotaxime (32 mg/L) and 
rifampicin (50 mg/L) (Amyes and Gould, 1984). Controls were also prepared for 
donor and recipient strains by the inoculation of both onto other MacConkey plates 
with the same antibiotics. Confirmation of the success of the conjugation processes 
was done by PCR amplification mentioned in section  3.1. All of the agar and broth 
used in this experiment are from Oxoid Ltd (Basingstoke, UK). Cefotaxime and 
rifampicin used were from Sigma. 
 
Moreover, the auto-transferability of the plasmids carrying blaCTX-M genes and which 
were shown to be Incompatibility group IncFII was studied. The technique was 
followed as described previously (Amyes and Gould, 1984). The method involved 
the use of 104 dilution of strains 91, 94, and 99 were cub-cultured on a series IST 
agar plates (Oxoid) containing cefotaxime (Sigma) in 10-fold concentrations. Then, 
0.1 mL of an overnight culture broth of IST (Oxoid) of the same strains was mixed 
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with 4.5 mL a recipient strain (E. coli J62.2) of IST broth (Oxoid). The mixture was 
incubated for 24 hours at 37⁰C. Then, the recipients were selected on agar plates of 
IST with (32 mg/L cefotaxime) and (50 mg/L rifampicin).  
 
3.5 Examination of the structural models of CTX-Ms found 
 
Structural models of blaCTX-M-3, blaCTX-15, blaCTX-M-55, and blaCTX-M-117 were created 
with online protein homology/analogy recognition engine (phyre) 
(http:www.sbg.bio.ic.ac.uk/~phyre/) last access date (15th August 2012). The crystal 
structure for blaCTX-M-9 published by Nichols et al (2012) was used as a backbone 
(Nichols et al., 2012). Although, CTX-M-9 belongs to different CTX-M group than our 
reported CTX-Ms members, it had to be used as a backbone for our structure 
modelling examination because of the lack of published crystal structures of any 
member of CTX-M-1 group. Viewing of the structures was maintained using Swiss-
Pdb Viewer DeepView version 4.0.4 (http://spdbv.vital-it.ch/) last access date (15th 
August 2012). Comparison of the structures was done to view amino-acid 





4.1 Determination of MICs 
 
Following the published BSAC breakpoints for the antibiotics used (cefepime, 
cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, gentamicin, ertapenem, imipenem, 
and meropenem) (Andrews, 2012), the antibiotic profile for all of the isolates was 
determined as seen in Table 16. All of the E. coli (84) and K. pneumoniae (23) strains 
were resistant to cefotaxime and ceftazidime (100%) (Table 17and Table 18). 
Moreover, more than half of the E. coli strains (83.3%) were resistant to cefepime. 
Similarly, more than of half of the K. pneumoniae (86.95%) were resistant to 
cefepime. Also, more than half of the E. coli strains (70.23%) were resistant to 
ciprofloxacin. Likewise, more than half of the collected K. pneumoniae strains 
(73.91%) were resistant to ciprofloxacin. On the other hand, the resistant profiles of 
gentamicin of the collected K. pneumoniae isolates (73.91%) were higher than those 
for E. coli (57.14%) (Table 17 and Table 18). All of the collected isolate were 
sensitive to ertapenem, imipenem, and meropenem (Table 16). 
 Using the MDR definition set by Zhanel et al (2008), nineteen of the collected E. coli 
(22.61%) and 8 of the K. pneumoniae isolates (34.78%) had MDR patterns. The 
distribution of MICs at which 50% and 90% of the isolates were inhibited (MIC50 and 
MIC90, respectively) for cefepime, cefotaxime, cefoxitin, ceftazidime, ciprofloxacin, 
gentamicin, imipenem, meropenem, and ertapenem are given in Table 19. The 
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MIC50 and the MIC90 of both strains help us to understand the proportion of 
resistance in the collected isolates. Overall, the MIC50 and MIC90 (in mg/L) for E. coli 
were as follows: cefepime, 16 and 64; cefotaxime, 128 and 256; cefoxitin, 8 and 64; 
ceftazidime, 32 and >32; ciprofloxacin, 64 and >256; gentamicin, 32 and 32; 
imipenem, 0.03 and 0.12; meropenem, 0.03 and 0.25; ertapenem, 0.5 and 0.5. In 
addition, the MIC50 and MIC90 (in mg/L) for K. pneumoniae were as follows: 
cefepime, 16 and 32; cefotaxime, 128 and >256; cefoxitin, 8 and 16; ceftazidime, 32 
and >32; ciprofloxacin, 8 and >256; gentamicin, 32 and 128; imipenem, 0.015 and 
0.5; meropenem, 0.06 and 0.25; ertapenem, 0.5 and 0.5. The MIC50 of 
cephalosporins to E. coli were the same as those to K. pneumoniae. However, the 
MIC90 of cephalosporins (except cefepime) in E. coli were lower by 1-3 folds than 
those to K. pneumoniae. Interestingly, the MIC90 of cefepime in E. coli was one fold 
higher than the MIC90 of the same antimicrobial agent to K. pneumoniae. 
 
Regarding E. coli, major disparities were found between the MIC50 of cephalosporins 
(cefepime, cefotaxime, cefoxitin, and ceftazidime). Whereas, no major increase in 
the dilutions of MIC50 of cephalosporins to K. pneumoniae was seen. Similarly, the 
MIC90 of cephalosporins (except cefoxitin) to both strains (E. coli and K. 
pneumoniae) had no major differences in dilutions; ranging from one to two folds. 
The MIC90 of cefoxitin to E. coli was three dilution steps higher than the MIC50 of the 




In terms of the MIC50 of ciprofloxacin to both strains, the MIC50 of ciprofloxacin to E. 
coli was three dilution steps higher than that found in K. pneumoniae. On the other 
hand, the MIC90 of ciprofloxacin to both strains was the same. 
 
In case of gentamicin, the MIC90 of this antimicrobial agent to K. pneumoniae was 
two folds higher than that to E. coli. While the MIC50 of both strains was the same. 
When comparing the MIC50 and the MIC90 of carbapenems to E. coli and K. 
pneumoniae, no major difference in dilutions was observed. Notably, the MIC90 of 
imipenem to K. pneumoniae was five dilutions steps higher than the MIC50 of the 
same antimicrobial drug to K. pneumoniae strains. In addition, the MIC50 of 








Cefepime Cefotaxime Cefoxitin Ceftazidime Ciprofloxacin Gentamicin Ertapenem Imipenem Meropenem 
1  E. coli 8 32 16 32 32 0.25 0.03 0.015 0.25 
2  E. coli 16 8 4 32 0.03 32 0.03 0.008 0.25 
3  E. coli 32 128 16 32 >256 32 0.12 0.06 0.25 
4  E. coli 1 4 4 32 0.5 0.5 0.03 0.015 0.25 
5  K. pneumoniae 0.5 4 8 32 0.5 1 0.12 0.03 0.25 
6  E. coli 16 64 8 32 64 16 0.06 0.008 0.25 
7  K. pneumoniae 32 128 2 32 0.12 64 0.06 0.03 0.25 
8  E. coli 16 64 16 32 64 32 0.06 0.03 0.25 
9  K. pneumoniae 8 32 16 32 64 8 0.06 0.03 0.25 
10  E. coli 8 64 4 32 0.25 32 0.12 0.06 0.25 
11  E. coli 16 8 8 32 0.06 0.5 0.03 0.008 0.25 
12  E. coli 8 8 8 32 128 64 0.03 0.03 0.25 
13  E. coli 8 64 16 32 0.12 64 0.06 0.008 0.25 
14  E. coli 32 128 256 32 0.12 256 0.06 0.015 0.25 
15  E. coli 8 128 16 32 >256 64 0.03 0.015 0.25 
16  K. pneumoniae 16 128 4 32 4 64 0.06 0.015 0.25 
17  E. coli 32 128 16 32 128 32 0.03 0.015 0.25 
18  K. pneumoniae 16 128 8 32 64 64 0.03 0.008 0.25 
19  K. pneumoniae 8 64 8 32 0.25 32 0.03 0.012 0.25 
20  K. pneumoniae 8 32 8 32 >256 32 0.03 0.015 0.25 
21  E. coli 16 64 8 32 0.03 128 0.008 0.008 0.25 
22  E. coli 4 128 8 32 0.25 0.5 0.12 0.06 0.25 
23  E. coli 8 16 8 32 128 0.5 0.03 0.015 0.25 
24  E. coli 4 128 16 32 0.25 1 0.06 0.008 0.25 
25  E. coli 8 16 8 32 0.25 64 0.06 0.06 0.25 
26  E. coli 8 32 8 32 >256 1 0.06 0.03 0.25 







Cefepime Cefotaxime Cefoxitin Ceftazidime Ciprofloxacin Gentamicin Ertapenem Imipenem Meropenem 
28  K. pneumoniae 32 >256 16 32 256 32 0.5 0.25 0.12 
29  K. pneumoniae 1 4 4 32 4 128 0.5 0.25 0.12 
30  E. coli 8 128 4 32 0.25 32 0.5 0.12 0.12 
31  K. pneumoniae 16 256 8 32 1 1 0.5 0.03 0.12 
32  K. pneumoniae 32 256 8 32 1 0.25 0.5 0.008 0.12 
33  E. coli 16 128 8 32 32 0.25 0.5 0.015 0.12 
34  E. coli 64 >256 8 32 1 1 0.03 0.008 0.03 
35  E. coli 16 64 4 32 16 1 0.05 0.03 2 
36  E. coli 16 256 4 32 0.015 64 0.25 0.03 2 
37  K. pneumoniae 32 >256 4 32 >256 64 0.5 0.008 0.03 
38  K. pneumoniae 16 >256 2 32 4 64 0.5 0.25 0.03 
39  E. coli 16 256 8 32 8 64 0.5 0.12 0.03 
40  E. coli 16 64 4 32 256 1 0.12 0.03 0.03 
41  K. pneumoniae 4 32 4 32 32 0.5 0.5 0.12 2 
42  E. coli 4 64 4 32 32 0.25 0.03 0.008 2 
43  K. pneumoniae 32 >256 8 32 256 64 0.5 0.03 0.03 
44  K. pneumoniae 16 >256 2 32 8 64 0.5 0.008 0.06 
45  K. pneumoniae 8 64 4 32 16 64 0.5 0.008 0.03 
46  K. pneumoniae 32 >256 4 32 0.25 4 0.5 0.008 0.03 
47  E. coli 64 >256 128 32 256 64 0.03 0.03 0.06 
48  E. coli 32 256 8 32 2 32 0.5 0.03 0.03 
49  E. coli 16 256 4 32 0.5 32 0.03 0.03 0.06 
50  E. coli 16 >256 8 32 0.5 1 0.5 0.03 0.03 
51  E. coli 32 256 16 32 16 64 0.5 0.03 0.06 
52  E. coli 32 256 64 32 >256 1 0.12 0.06 0.03 
53  E. coli 32 256 64 32 >256 1 0.06 0.008 0.015 
54  E. coli 32 64 256 32 4 2 0.5 0.25 0.015 







Cefepime Cefotaxime Cefoxitin Ceftazidime Ciprofloxacin Gentamicin Ertapenem Imipenem Meropenem 
56  E. coli 32 128 16 32 128 2 0.12 0.06 0.015 
57  E. coli 16 128 32 32 >256 16 0.5 0.12 0.015 
58  E. coli 16 64 8 32 128 32 0.12 0.05 0.015 
59  E. coli 2 128 8 32 128 64 0.5 0.03 0.015 
60  E. coli 2 128 2 32 128 256 0.06 0.06 0.015 
61  E. coli 64 256 64 32 256 64 0.06 0.008 0.03 
62  E. coli 8 64 8 32 64 32 0.06 0.06 0.015 
63  E. coli 32 256 8 32 64 32 0.25 0.06 0.015 
64  E. coli 16 64 8 32 0.5 1 0.06 0.008 0.015 
65  E. coli 32 256 16 32 128 1 0.06 0.015 0.015 
66  E. coli 32 256 64 32 >256 64 0.06 0.015 0.015 
67  E. coli 4 32 8 32 64 64 0.06 0.015 0.015 
68  E. coli 16 64 8 32 64 0.5 0.06 0.015 0.015 
69  E. coli 16 128 16 32 128 16 0.06 0.008 0.015 
70  E. coli 32 256 16 32 256 32 0.5 0.008 0.008 
71  E. coli 32 256 32 32 128 0.25 0.5 0.008 0.008 
72  E. coli 8 64 4 32 128 0.25 0.5 0.12 0.008 
73  E. coli 4 32 4 32 0.5 32 0.5 0.12 0.008 
74  E. coli 32 128 32 32 256 64 0.5 0.008 0.008 
75  E. coli 16 64 8 32 128 64 0.5 0.015 0.008 
76  E. coli 16 256 16 32 256 32 0.5 0.015 0.008 
77  E. coli 32 64 8 32 256 32 0.5 0.015 0.008 
78  E. coli 16 256 8 32 256 0.25 0.5 0.015 0.008 
79  E. coli 64 64 8 32 256 64 0.5 0.015 0.008 
80  K. pneumoniae 32 256 16 32 256 32 0.5 0.008 0.008 
81  E. coli 32 256 32 32 128 0.25 0.5 0.015 0.008 
82  K. pneumoniae 32 >256 8 32 256 16 0.5 0.008 0.06 





Strain MIC (mg/L) 
Cefepime Cefotaxime Cefoxitin Ceftazidime Ciprofloxacin Gentamicin Ertapenem Imipenem Meropenem 
84  E. coli 32 256 16 32 256 32 0.5 0.008 0.008 
85  K. pneumoniae 32 256 32 32 >256 0.5 0.5 0.008 0.008 
86  E. coli 16 128 8 32 256 32 0.5 0.06 0.008 
87  E. coli 64 32 32 32 256 0.25 0.5 0.06 0.008 
88  K. pneumoniae 16 128 16 32 4 128 0.5 0.12 0.06 
89  K. pneumoniae 128 128 64 64 128 128 0.5 0.015 0.06 
90  E. coli 8 128 128 32 0.12 128 0.5 0.12 0.06 
91  E. coli 8 128 4 32 0.25 64 0.5 0.03 0.06 
92  E. coli 0.5 8 8 32 0.12 64 0.5 0.008 0.06 
93  E. coli 8 128 8 32 8 128 0.5 0.015 0.06 
94  E. coli 128 128 64 32 8 128 0.5 0.12 0.06 
95  E. coli 128 128 64 32 0.25 64 0.5 0.12 0.06 
96  E. coli 64 128 64 32 0.12 64 0.5 0.12 0.06 
97  E. coli 256 256 8 8 >256 32 0.5 0.008 0.03 
98  E. coli 32 32 8 32 >256 4 0.5 0.015 0.06 
99  E. coli 64 128 64 32 8 256 0.5 0.03 0.06 
100  E. coli 64 256 32 32 256 32 0.5 0.03 0.008 
101  E. coli 16 128 8 32 256 32 0.5 0.5 0.008 
102  E. coli 32 256 8 8 128 32 0.5 0.03 0.008 
103  E. coli 64 128 >256 32 256 0.25 0.5 0.12 0.008 
104  E. coli 64 256 64 32 128 0.25 0.5 0.5 0.008 
105  E. coli 64 128 64 32 128 8 0.5 0.008 0.008 
106  E. coli 64 256 32 32 256 32 0.5 0.008 0.25 
107  E. coli 32 128 8 32 32 32 0.5 0.12 0.008 
Table 16: Minimum inhibitory concentration values (mg/L) with four classes of antibiotics. Light blue fields highlight resistance to 
antibiotic used, pink highlighted fields are isolates with an MDR pattern selected for further studies, and green highlighted fields are 






























% of resistance 
Range of MIC 
(ml/L) 
Cefepime 70 83.3 8—256 
Cefotaxime 84 100 4—>256 
Cefoxitin 39 46.42 16—>256 
Ceftazidime 84 100 32 
Ciprofloxacin 59 70.23 8—>256 
Gentamicin 48 70.23 16—256 
Imipenem 0 0 0.008—0.5 
Meropenem 0 0 0.008—0.25 




% of resistance 
Range of MIC 
(ml/L) 
Cefepime 20 86.95 8—32 
Cefotaxime 23 100 4—>256 
Cefoxitin 9 39.13 4—64 
Ceftazidime 23 100 32 
Ciprofloxacin 17 73.91 4—>256 
Gentamicin 17 73.91 8—128 
Imipenem 0 0 0.008—0.25 
Meropenem 0 0 0.008—2 













Cefepime 16 64 8—256 
Cefotaxime 128 256 4—>256 
Cefoxitin 8 64 16—256 
Ceftazidime 32 32 32 
Ciprofloxacin 64 >256 8—>256 
Gentamicin 32 32 16—256 
Imipenem 0.03 0.12 0.008—0.25 
Meropenem 0.03 0.25 0.12—0.25 





Cefepime 16 32 8—32 
Cefotaxime 128 >256 4—>256 
Cefoxitin 8 16 4—64 
Ceftazidime 32 32 32 
Ciprofloxacin 8 >256 4—>256 
Gentamicin 32 128 8—128 
Imipenem 0.015 0.5 0.008—0.25 
Meropenem 0.06 0.25 0.008—2 
Ertapenem 0.5 0.5 0.03—0.5 




4.2 Phenotypic and molecular identification of blaCTX-M genes 
With the Vitek 2 system, all of the isolates were noted for ESBL-producer 
production. The DDD method with cefotaxime and ceftazidime confirmed the 
presence of CTX-M-production. For further conformation, PCR was used to detect 
CTX-M enzymes genotypically. Using the primers described by Saladin (2002), it was 
found that all of the isolates (107 isolates) encoded blaCTX-M genes. All of the isolates 
showed a product size of 504 bp when amplified. Some of the isolates producing 
CTX-M enzymes are seen in Figure 8. Further amplification with other primers (CTX-
M-1 group primers) listed in Table 9 showed that all of the isolates in this study 
carry blaCTX-M genes belonging to CTX-M-1 group. This can be seen in Figure 9. 
 
When using primers for CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 sub-groups, 
listed in Table 9, no bands were observed. This indicated that all of the isolates 
collected in this study encode CTX-M genes belonging to CTX-M-1 sub-group only. 





Figure 8: PCR products using CTX-M consensus primers (Saladin et al., 2002). The 
expected product size is 504 bp. +ve CTRL indicates positive control, -ve CTRL 












Figure 9: PCR products using CTX-M-1 group designed primers. The expected 
product size is 854bp. +ve CTRL indicates positive control, -ve CTRL indicates 




4.3 Pulsed-field gel electrophoresis 
4.3.1 Enhanced rapid method 
Molecular fingerprinting was done to establish the clonality of isolates collected 
over a reasonably short period of time (2006-2010). Also, the use of PFGE was 
retained to help in the choice of a representative strain from each clone for further 
identification by sequencing the members of CTX-M-1 group and eventual 
determination of the most common CTX-M-1 group-producer. All of the collected 
isolates (except for 22) showed different PFGE patterns with less than 85% similarity 
and did not share clonal relatedness was found among them, as seen in Figure 10 
and Figure 11. The remaining 22 isolates exhibited banding patterns that allowed 
grouping them into 12 distinct PFGE clusters as seen in Figure 10 and Figure 11. It is 
notable that the strains sharing ≥85% were from the same hospitals. Unfortunately, 
insufficient information during data collection was found and there was no evidence 
of genotypic relatedness in samples collected from patients from the same ward. 
Therefore, we cannot indicate the transmission of a bacterial pathogen from 
patients in the same ward and the only notification is that genotypic relatedness 


























































Figure 11: PFGE banding patterns with K. pneumoniae Strains. Strains highlighted 





4.3.2 Prolonged PFGE method 
 
The restriction banding patterns obtained by the prolonged PFGE protocol were 
analysed and compared with the results of the enhanced shortened protocol as 
seen in Figure 12, Figure 13, Figure 14, Figure 15, Figure 16, and Figure 17. In Figure 
12, the similarity values of E. coli strains provided by the traditional PFGE method 
were the same as those when using the shortened technique as seen in Figure 13. 
In addition, the similarity values of K. pneumoniae strains that are similar and 
identical are the same using both techniques (Figure 14 and Figure 15). The 
similarity values of identical/similar E. coli and K. pneumoniae strains with both 
techniques are summarized in Table 22 and Table 21. 
 
It was found that the similarity values obtained from both techniques were the 
same for the 30 unrelated E. coli strains selected for validation as seen in Figure 16 
and Figure 17. Moreover, the similarity results for the 30 unrelated E. coli strains 








Figure 12: PFGE banding patterns obtained with six E. coli strains. DNA band 
profiles show 100% similarity for three groups of two strains. 
 
Figure 13: PFGE banding patterns obtained with six E. coli strains. PFGE 









Figure 14: PFGE banding patterns obtained with four K. pneumoniae strains. DNA 
band profiles using the traditional PFGE protocol, showing 100% similarity for most 
of all of the strains. 
 
Figure 15: PFGE banding patterns obtained with four K. pneumoniae strains. PFGE 





Figure 16: PFGE banding patterns obtained with 30 E. coli strains. DNA band 





Figure 17: PFGE banding patterns obtained with 30 E. coli strains. PFGE 







Percentage of similarity 






























1-2 100% 100 
21-22 100% 100 
28-32 100% 100 
37-38 100% 100 
97-98 100% 100 
Table 21: Similarity values of identical strains pulsed by the prolonged PFGE 
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14-15 76.2 76.2 
17- (14-15) 57.1 57.1 
36- (14-15-17) 49.7 49.7 
6-13 66.7 66.7 
4-54 64.3 64.3 
56-57 72.7 72.7 
42-105 69.2 69.2 
11 - (42-105) 56.7 56.7 
100-101 66.7 66.7 
3 - (100-101) 53 53 
24-35 64 64 
66 - (24-35) 56.6 56.6 
47-107 74.1 74.1 
30-63 59.3 59.3 
55-64 64 64 
50-51 69.2 69.2 
84-56 62.5 62.5 
75 - (84-86) 43.8 43.8 
Table 22: Similarity values of epidemiologically unrelated E. coli strains pulsed by 
the prolonged PFGE method and the enhanced rapid method and analysed by 




4.3.3 Validation of the enhanced PFGE method 
 
The assessment of a typing method should fulfil the definition of the following 
terms; typeability, discriminatory power, reproducibility, and ease of performance 
and interpretation (Singh et al., 2006). In terms of typeability, the newly described 
PFGE fingerprinting protocol showed typeability by yielding interpretable PFGE 
profiles. The lengthy fingerprinting procedure, to which it was compared, was also, 
of course, considered typeable. 
 
Upon repetition of the enhanced PFGE procedure, the PFGE banding patterns 
provided were the same. Accordingly, I can define that the new technique as 
reproducible. This reproducibility was, of course, a defining feature of the lengthy 
PFGE procedure. 
 
Mainly, the validation is assessed by the comparison of restriction endonuclease 
banding patterns of epidemiologically identical strains with a more traditional 
typing method. Therefore, I validated the shortened PFGE method by comparing 
the similarity values of the epidemiologically identical strains with both techniques 
(1 and 2, 21 and 22, 28 and 32, 37 and 38, 97 and 98). Strains examined for the 
validation of the protocol (1 and 2, 21 and 22, 28 and 32, 37 and 38, 97 and 98) 
were found to be identical in both procedures, showing 100% similarity as seen in 
Figure 12, Figure 13, Figure 14, and Figure 15. From the results seen in Table 20 and 
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Table 21, I can confirm the validity of the shortened genotyping method for typing 
E. coli and K. pneumoniae.  
The discriminatory power of both techniques was assessed by the comparison of 
the similarity values of epidemiologic unrelated strains (3, 4, 6, 11, 13, 14, 15, 17, 
24, 30, 35, 36, 42, 47, 50, 51, 54, 55, 56, 57, 63, 64, 66, 75, 84, 86, 100, 101, 105, 
and 107), using BioNumerics software, version 4. The similarity values of unrelated 
strains were exactly the same with both protocols as seen in Figure 16 and Figure 
17. The similarity value results are documented in Table 22. Therefore, I can confirm 
the discriminatory power of the enhanced PFGE method in comparison with that of 
Miranda et al technique (1996). 
 
In the traditional protocol for genotyping bacterial strains, a colony from a pure 
culture is inoculated in Brain Heart broth overnight. While in the followed method 
described herein, no further inoculation of a pure culture is required. This took out 
a day from the genotyping procedure. During the lysis steps, in the original PFGE 
method the cells were lysed for two days.  On the other hand, our enhanced 
protocol involved lyses of cells only for one hour. This shortened PFGE method by 2 
days. The concentration of PK was manipulated to reach 1.5 mg/ml to reduce the 
time required for lysing the cells (Alaidan et al., 2009). Additionally, the lysis 
solution should be freshly prepared to obtain optimized action of proteinase K 
(Murray et al., 1990). Washing of the plugs was modified in terms of time required 
for each wash. Each wash was done for 15 minutes rather than 30 minutes, due to 
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the use of a shaking water bath and pre-heated washing buffers which ensure 
complete wash of the plugs (Alaidan et al., 2009). Lower concentration of TE buffer 
was used as 0.1X TE in the last two washes. The concentration of the washing buffer 
was diluted to 0.1X TE to reduce the effect of nucleolytic peracid derivatives of Tris 
salts formed, which in some cases interferes with the action of restriction enzymes 
used and in return affecting the banding pattern giving a washed out appearance 
upon running (Corkill et al., 2000, Matushek et al., 1996, Bannerman et al., 1995). 
The use of thiourea in the running buffer was indicated to prevent the DNA 
degradation of some sensitive strains. The degradation of DNA remains ambiguous 
but is thought that thiourea acts as a neutralizer to nucleolytic peracid derivatives 
produced by Tris salts in TBE buffer (Corkill et al., 2000, Koort et al., 2002, Romling 
and Tummler, 2000, Bush and Jacoby, 2010). In some reports, instead of lowering 
the concentration of Tris salts, Tris buffers were replaced by the use of HEPES to 
prevent the reaction of Tris radicals (Romling and Tummler, 2000). The 
disadvantage of such replacement lies with the cost of HEPES. The main goal of this 
method was to provide a rapid and cost-effective protocol rather than using 
expensive materials. 
  
The time required for genotyping strains with the traditional method was 6 days, 
while modifications made removed 4 days from the original procedure. This method 
was also optimized to be a cost-effective method. This typing system could be 
characterized by means of comparable reproducibility and discriminatory power. It 
could also be used in large laboratories where cost is an issue, as most of the 
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materials/buffers could be purchased in a reasonable price without the need of 
their preparation. The factors manipulated in this protocol were chosen to enhance 
the efficiency of the banding patterns obtained and acquire superior degree of 
accuracy of bacterial typing. A comparison of both methods to facilitate the changes 











Step Miranda et al method Enhanced rapid method 
Inoculation 
Take a single colony from 16-18 hrs 
incubation. Inoculate in 5 mls BHI1 broth 
without shaking at 37⁰C 
Take 5-10 colonies from 16-




Centrifuge at 4000 × g for 20 minutes & 
resuspend pellets in 2 mls PIV buffer (1 M 
tris, 1 M NaCl, pH 7.6). Allow to equilibrate 
at 50⁰C 




1.6% LMP 2 mls 
 
1.6% LMP with 1% SDS 
 
Lysis  steps 
Lyse plugs in lysis solution (1 M Tris, 1 M 
NaCl, 100 mM EDTA, 0.5% Brij58, 0.2% 
deoxycholate, 0.5% Na lauroylsarcosine, 
50 µg ribonuclease A + 1 mg/ml lysozyme, 
pH 7.6). Incubate at 37⁰C overnight. 
Incubate with ESP2 buffer (0.4 M EDTA, 1% 
SDS, 0.5 mg/ml PK) for 24 hrs at 50⁰ C 
Lyse plugs in 2 mls CLS 
(50 mM Tris, 50 mM EDTA, 
2.5 mg/ml lysozyme, 1.5 
mg/ml PK, pH8). Incubate 
for one hour at 55⁰C 
Washing 
Steps 
Wash once with 1X TE buffer with 1 mM 
PMSF at 37⁰C 
Wash 3X with with 0.1X TE buffer for half 
an hour at 37⁰C 
Wash once with pre-heated 
1X TE buffer with 1 mM 
PMSF, then twice with pre-
heated 0.1X  TE buffer all 
for 15 minutes in a shaking 
water bath at 55⁰C 
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4.4 Sequencing with plasmid and genetic environment studies  
4.4.1 Selection of strains for the detection of the most prevalent 
CTX-M family member 
 
Using primers described by Dutour (2002), all of the isolates listed in Table 24 
yielded a product size of 903 bp (Figure 18). Sequences obtained from sequencing 
facilities were identified by sequence alignment BLAST. A summary of the 
sequencing results are provided in Table 22. It was found that all of the strains 
selected, except for 86, 89, 97, and 102 shared ≥ 98% identity with blaCTX-M-15 
(GenBank accession № HQ157357.1). Other CTX-Ms found upon sequencing were 
blaCTX-M-3, blaCTX-M-28, blaCTX-M-55, and blaCTX-M-117 corresponding to isolate number 
102, 86, 89, and 97 respectively. The nucleotide sequences of all of the reported 
blaCTX-M genes are listed in Appendix (A). The amino acid sequences of all of the 
reported blaCTX-M genes are listed in Appendix (B). 
 
The strains that shared 100% similarity with blaCTX-M-15 (GenBank accession number 
HQ157357.1), were considered to share the same progenitor and acquire blaCTX-M-15 
in the same phase (strain 4, 12, 17, 20, 37, 47, 55, 57, 60, 61, 74, 88, 100, 101, and 
105) as seen in (Table 24). In contrast, the rest of the strains that share 98-99% with 
blaCTX-M-15 (GenBank accession number HQ157357.1), are thought to be from 
different origins. The amino acid sequences of the strains sharing 98-99% similarity 
with blaCTX-M-15, were compared together (Figure 19). From the sequencing and the 
alignment results of blaCTX-M-15, it was found out that there are three clones present 
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all from different origins. Strains sharing 100% similarity with the nucleotide and 
amino acid sequence of blaCTX-M-15 (strain 4, 12, 17, 20, 37, 47, 55, 57, 60, 61, 74, 88, 
100, 101, and 105) suggest that they originate from the same source (15 strains). 
While strains sharing 96 and 99% protein sequence similarity with blaCTX-M-15 (Strain 
75, 80, 82, 87, 90, 91, 92, 93, 94, 95, 96, 98, and 99) were analysed based on the 
nucleotide base. From the multi-alignment results (Figure 14), it was found that 
these strains probably derived from two origins; just one strain from a single 
progenitor (strain 99) and 12 strains from a different origin (strains 5, 80, 82, 87, 90, 
91, 92, 93, 94, 95, 96, and 98) (Figure 19). The results point out to the presence of 
silent, synonomous mutations, where mutations only occur on the nucleotide level 
and are not reflected by changes in the amino acid and therefore the protein 
structure or function. In other words, the findings suggest the existence of three 
different progenitors and the acquisition of blaCTX-M-15 genes in three different 
phases. Also, we can conclude that blaCTX-M-15 is the most prevalent CTX-M member 







Figure 18: PCR products with primers described by (Dutour et al., 2002). The 
expected product size is 903 bp. -ve CTRL indicates negative control, 15, 20, 37, 47, 
57, 61, 74, 75, 80, and 82, 86, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, and 












4 M E. coli blaCTX-M-15 HQ157357.1 100% 
15 M E. coli blaCTX-M-15 HQ157357.1 100% 
17 M E. coli blaCTX-M-15 HQ157357.1 100% 
20 M K. pneumoniae blaCTX-M-15 HQ157357.1 100% 
37 M K. pneumoniae blaCTX-M-15 HQ157357.1 100% 
47 M E. coli blaCTX-M-15 HQ157357.1 100% 
55 K E. coli blaCTX-M-15 HQ157357.1 100% 
57 K E. coli blaCTX-M-15 HQ157357.1 100% 
60 K E. coli blaCTX-M-15 HQ157357.1 100% 
61 K E. coli blaCTX-M-15 HQ157357.1 100% 
74 ID E. coli blaCTX-M-15 HQ157357.1 100% 
75 ID E. coli blaCTX-M-15 HQ157357.1 99% 
80 ID K. pneumoniae blaCTX-M-15 HQ157357.1 99% 
82 ID K. pneumoniae blaCTX-M-15 HQ157357.1 99% 
86 ID E. coli blaCTX-M-28 EU531510.1 98% 
87 ID E. coli blaCTX-M-15 HQ157357.1 99% 
88 A K. pneumoniae blaCTX-M-15 HQ157357.1 100% 
89 A K. pneumoniae blaCTX-M-55 HM748991.1 98% 
90 A E. coli blaCTX-M-15 HQ157357.1 99% 
91 A E. coli blaCTX-M-15 HQ157357.1 99% 
92 A E. coli blaCTX-M-15 HQ157357.1 99% 
93 A E. coli blaCTX-M-15 HQ157357.1 99% 
94 A E. coli blaCTX-M-15 HQ157357.1 99% 
95 A E. coli blaCTX-M-15 HQ157357.1 99% 
96 A E. coli blaCTX-M-15 HQ157357.1 99% 
97 A E. coli blaCTX-M-117 JN227085.1 98% 
98 A E. coli blaCTX-M-15 HQ157357.1 99% 
99 A E. coli blaCTX-M-15 HQ157357.1 96% 
100 IB E. coli blaCTX-M-15 HQ157357.1 100% 
101 IB E. coli blaCTX-M-15 HQ157357.1 100% 
102 IB E. coli blaCTX-M-3 GQ339102.2 95% 
105 IB E. coli blaCTX-M-15 HQ157357.1 100% 
 




 Figure 19: Nucleotide differences between isolates sharing 98-99% similarity with blaCTX-M-15 sequences. Areas in black are identical, red indicates low consensus, and green indicates neutral consensus. 
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The alignment of the protein sequences of blaCTX-M-15 can be seen in Figure 20. The 
alignment of the protein sequences of blaCTX-M-28 (Figure 21). The alignment of the 
protein sequences of blaCTX-M-55 can be seen in Figure 22. The alignment of the 
protein sequences of blaCTX-M-117 (Figure 23). The alignment of the protein 
sequences of blaCTX-M-3 can be seen in Figure 24.  
 
Moreover, all of the derivatives of blaCTX-M-15 gene were detected in the Al-Amiri 
hospital except for blaCTX-M-28 which was found in Infectious Diseases hospital. The 
detection of blaCTX-M-3 in Ibn-Sina hospital was from an isolate collected earlier in 
2006.  
 
When aligning the amino acid sequences of the reported blaCTX-M genes (blaCTX-M-3, 
blaCTX-M-15, blaCTX-M-28, blaCTX-M-55, and blaCTX-M-117) (Figure 25), the differences laid at 
positions 80, 177, 242, and 288. It is thought that blaCTX-M-15 is derived from 
blaCTX-M-3, where there is only one amino acid change laying at position 242 
(Asp-240Gly) (Baraniak et al., 2002, Cartelle et al., 2004, Girlich et al., 2009, Karim 
et al., 2001, Novais et al., 2007, Novais et al., 2008, Poirel et al., 2002a). CTX-M-28 is 
less common than CTX-M-15 but suggests in vivo mutation of CTX-M-15 (Dubois et 
al., 2010, Menezes et al., 2010). In blaCTX-M-28, Aspartate at position 288 is 
substituted by Asparagine (Asp-288Asn) (Dubois et al., 2010) (Table 25). This 
difference has been ignored by many researchers and therefore blaCTX-M-28 can be 
misinterpreted as blaCTX-M-15 (Menezes et al., 2010). On the other hand, blaCTX-M-55 is 
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different from blaCTX-M-15 by one amino acid (i.e. valine for alanine) at position 80 
(Kiratisin et al., 2007) (Table 25). This work describes the first report of blaCTX-M-55 in 
the Middle East area. Also, this work reports the first description of blaCTX-M-117 in 
Kuwait, which differs from blaCTX-M-15 by one amino acid change at position 177 (i.e. 













Alanine Proline Aspartic acid Aspartic acid 
CTX-M-15 
 
Alanine Proline Glycine Aspartic acid 
CTX-M-28 
 
Alanine Proline Glycine Asparagine 
CTX-M-55 
 
Valine Proline Glycine Aspartic acid 
CTX-M-117 
 
Alanine Glutamine Glycine Aspartic acid 





Figure 20: Alignment of CTX-M-15 protein with the translation of the amino acid sequence obtained from our strains. The black 









Figure 21: Alignment of CTX-M-28 protein with the translation of the amino acid sequence obtained from isolate 86. The black 
coloured letters indicate that both sequences share high consensus, the blue coloured letters indicate neutral consensus. The proteins 








Figure 22: Alignment of CTX-M-55 protein with the translation of the amino acid sequence obtained from isolate 89. The black 









Figure 23: Alignment of CTX-M-117 protein with the translation of the amino acid sequence obtained from isolate 97. The black 






Figure 24: Alignment of CTX-M-3 protein with the translation of the amino acid sequence obtained from isolate 102. The black 










Figure 25: Alignment of the amino acid sequence of all of the CTX-Ms found in this study. The letters represented in black colour are the 
same amino acids found in all of the CTX-Ms reported. The letters in red and green colour are the amino acids that are different in the 
reported CTX-Ms. The changes between CTX-M-28 and the rest are outlined in the red box.
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4.4.2 Selection of strains for plasmid and genetic environment 
studies 
 
Twenty-five strains were chosen for the comparison of the genetic environment and 
the detection of possible common insertion sequences or other common 
transpositional elements. Also, the 25 strains were used for further plasmid studies. 
Plasmid studies included the detection of the plasmid sizes carrying the blaCTX-M 
genes detected and the Incompatibility grouping of the very same plasmids. A list of 
the twenty-five strains used for this part of the study is summarized in Table 11.  
 
In terms of PFGE, The selected E. coli and K. pneumoniae strains for genetic 
environment studies were unrelated except for six strains (91 and 92, 95 and 96, 
and 97 and 98) as seen in Figure 26. Thirteen of the selected E. coli strains were 
unrelated and their similarity values ranged from 21.5% to 72.7%. Two of the 
remaining six E. coli strains proved to be similar (91 and 92) and four were identical 
(95 with 96 and 97 with 98) (Figure 26). On the other hand, no epidemiological 
relationship was seen in K. pneumoniae strains chosen for the genetic environment 
studies; their similarity values ranged from 29 to 67% (Figure 27). Importantly, all of 
the similar and identical strains were from the same hospital (i.e. Al-Amiri hospital) 
(Figure 26). 
 
In other words, the absence of clonal relationship among most of the collected 
strain led to selection on the basis of MDR patter, with the finding of new blaCTX-M 
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genes reported as in strain 86, 89, 97, and 102. These strains encode blaCTX-M-28, 











Figure 26: PFGE banding patterns obtained for strains selected for genetic 
















Figure 27: PFGE banding patterns obtained for strains selected for genetic 











The results of the PCRs done for the upstream genetic environment detection are 
seen in Figure 28. Genome-walking PCR succeeded in obtaining the upper flanking 
regions of all of the strains. Regardless, GW-PCR failed to detect any regions for the 
downstream genetic context of the selected strains. Rather, simplex PCR was 
employed to detect the downstream area of the described blaCTX-M genes as seen in 
Figure 29. 
 
From GW-PCR and simplex PCR, seven different genetic contexts were sought from 
the 25 strains selected for plasmid studies seen in Table 11. Both upstream and 









Figure 28: GW PCR for the upstream area. (a)Shows PCR products for strains 
collected from Al-Amiri hospital. (b) Shows PCR products for the rest of the strains 








Figure 29: PCR Results for the downstream area. (a) Downstream PCR products for 
strains collected from Al-Amiri hospital. (b) Downstream PCR products for the 




The downstream genetic environment of strain numbers 20, 90, and 93 could not 
be obtained. The majority of the strains selected for plasmid studies (numbers 37, 
47, 91, 92, 95, 96, 99, and 100) shared the genetic context identified in D (Figure 
30). This genetic arrangement was previously reported in Acinetobacter baumannii 
(A. baumannii) strain carrying blaCTX-M-15 gene reported in Haiti (GenBank accession 
number JN788267.1) (Potron et al., 2011). Nevertheless, out of the 25 strains 
selected for plasmid studies, six strains (strain number 15, 74, 75, 80, 82, and 86) 
shared the same genetic environment but with variable sizes of the hypothetical 
protein (463-471 bp) described downstream the blaCTX-M-15 gene (A) (Figure 30). A 
similar genetic orientation was previously reported in an E. coli strain reported from 
the United Kingdom (GenBank accession number AY536259.1) (Woodford et al., 
2004). Different genetic arrangements were also found in the rest of the selected 
strains in One strains showed structure (B), one strains showed structure (C), eight 
strains had the genetic context of structure (D), two strains showed to have 
structure (E), also two strains were found to share structure  (F), only one strains 
was found to have (G), and one strain as well had structure (H), one isolate showed 
to have the genetic context described in structure (I), and one isolate was found to 
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Figure 30: Genetic environments of all of the strains. The letters indicated refer to 
the genetic environment of strains ;(A) 15, 74, 75, 80, 82 and 86, (B) 20, (C) 88, (D) 
37, 47, 91, 92, 95, 96, 99 and 100, (E) 90 and 93, (F) 57 and 61, (G) 89, (H) 94, (I) 97 
and (J) 102.  
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4.4.3 Genome Walking and Simplex PCR for genetic environment 
studies 
Upon sequencing the products of walking PCR experiment seen in Figure 28, ISEcp1 
was noted to be present at the upper flanking regions of all of the described CTX-M 
genes (Figure 30). The existence of ISEcp1 in the selected strains was not 
conditional for the presence of the ‘’W’’ region. Rather, ISEcp1 could exist on its 
own at the 5’ terminus of the blaCTX-M genes. This can be seen in structure (B), (C), 
(D), (E), (I), and (J) in Figure 30, where ISEcp1 is either preceded by a 10 bp and a 
conserved spacer, blaCTX-M gene, or just by a conserved spacer. Notably, the 
distances of ISEcp1 from the start codons of the reported blaCTX-M genes are 
variable. Similarly, the sizes of ISEcp1 sequences are variable as well (Figure 30). The 
integrity of ISEcp1, in this study, was often compromised. In some strains, a 
noticeable disruption of ISEcp1 is described as seen in structure A (Figure 30). A 
similar report was documented from a strain collected from the UK carrying blaCTX-M 
gene (Woodford et al., 2004). However, in other strains the ISEcp1 is found to be 
truncated as seen in structure G (Figure 30). The direction of the orientation of 
ISEcp1 can be the same as that of the blaCTX-M gene described downstream the 
insertion sequence as seen in structures A, B, C, D, E, F, I, and J (Figure 30). In 
contrast, the ISEcp1 can be oriented in the opposite direction to that blaCTX-M gene 
as seen in structure G in Figure 30. A previous description of an inverse insertion of 
ISEcp1 was reported in an E. coli strain carrying blaCTX-M-3 gene collected from Spain 
(GenBank accession number FJ235691.1) (Diestra et al., 2009). The presence of 
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ISEcp1 can be accompanied by the existence of another insertion sequence. Most 
commonly, IS26 is reported to co-exist with ISEcp1 at the upper flanking region of 
blaCTX-M genes (Diestra et al., 2009, Kiratisin et al., 2007, Novais et al., 2007). 
Likewise, IS26 was detected upstream ISEcp1 as seen in structure F and G (Figure 
30).  
 
Interestingly, the upstream context of most of the strains collected from Al-Amiri 
hospital, carrying the blaCTX-M-15 gene, share high similarity (95-98%) with the upper 
flanking region of an A. baumannii strain collected from Haiti (GenBank accession 
number JN788267.1) (Potron et al., 2011). Moreover, two strains from the 
Maternity hospital (strain 37 and 47) and one strain from Ibn sina hospital (strain 
100) show the same upstream genetic environment as seen in Table 26. This 
indicates the circulation of a certain plasmid carrying blaCTX-M-15 gene around both 
hospitals. Another common upstream orientation is found among five strains from 
the Infectious Diseases Hospital (strain 74, 75, 80, 82, and 86) and one strain from 
the Maternity hospital (strain 15), sharing 99% similarity with the upstream genetic 
environment of an E. coli strain collected from the UK (Table 26) (Woodford et al., 
2004). A less common upstream orientation found among my strains (strain 20 and 
88) was the same as that reported in an Enterobacter aerogenes (E. aerogenes) 




Another less common organization of the upstream environment of the described 
blaCTX-M gene is seen in strain 57 and 61, collected from KOC hospital sharing 96% 
similarity with a K. pneumoniae strain collected from Hungary (GenBank accession 
number EU556755.1) (Table 26).  
 
The upper flanking region of blaCTX-M-55 was found to be unique to strain 89, sharing 
93% similarity with the upper flanking region of an E. coli strain carrying blaCTX-M-3 
(GenBank accession number FJ235691.1) (Diestra et al., 2009) as seen in Table 26. 
Another unique upstream structure was obtained from strain 102, carrying blaCTX-M-3 
gene, sharing 96% similarity with the upstream context of an E. aerogenes strain 
collected from Russia (GenBank accession number HQ214049.1) seen in (Table 26) 
 
The genome walking PCR failed to detect the downstream genetic environment of 
the selected strains. Therefore, simplex PCR was used to provide an insight of the 
flanking downstream genetic orientation of the described blaCTX-M genes in this 
study. Using simplex PCR with primers described by (Sonnevend et al., 2006), all of 
the selected strains listed in Table 11 provided a product size around 600 bp. The 
downstream area of the selected strains showed 99% similarity with a K. 
pneumoniae strain reported in Korea encoding blaCTX-M-14 gene (GenBank accession 
number JQ343851.1) (Table 26). Interestingly, the hypothetical protein observed 
downstream the described blaCTX-M genes was with variable sizes (420-471 bp). 
Nevertheless, failure to maintain the genetic environment was faced in strain 88 
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and 90. A summary of the similarities of blaCTX-M genetic environment of Kuwaiti 
isolates with non-Kuwaiti isolates can be seen in (Table 26). A schematic drawing 
representing the seven different genetic environments obtained from this work is 





Kuwait Strains Similarity of the genetic environment 
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4.4.4 Plasmid sizing and grouping 
 
Using S1 nuclease to restrict the PFGE plugs, the numbers and sizes of the plasmids 
in the selected strains were determined. After separating the plasmids, gel 
extraction kits (Qiagen) were used to slice out the plasmids from the gels and 
extract the DNA for further amplification and sequencing with primers described by 
(Dutour et al., 2002). These primers confirmed the sizes of the plasmids carrying the 
described blaCTX-M genes. Further amplification with primers described by (Carattoli 
et al., 2005) allowed the identification of the Incompatibility groups of the plasmids 
carrying the described blaCTX-M genes. The plasmids sizes encoding blaCTX-M genes 
ranged from 60 to 270 Kb as seen in Table 27. One of the selected strains (74) was 
found to have three plasmids, of different sizes (62, 154, and 270 Kb), each carrying 
the blaCTX-M-15 gene. Some strains (61 and 94) had two plasmids both encoding 
blaCTX-M-15 gene. Another strain (88) had two plasmids, but only one was shown to 
carry the blaCTX-M-15 gene. The plasmid size carrying blaCTX-M-15 gene was determined 
to be 133kb. Two strains from Al-Amiri hospital (strain 90 and 93) had plasmid DNA 
visible on gels, but when the DNA was extracted from the gel and amplified with 
primers, no products were obtained. This points out to possible existence of blaCTX-
M-15 gene on the chromosome. Most of the plasmids could not have their 
incompatibility group determined. Yet, three of which showed to belong to IncFII as 
seen in strain 91, 94, and 99. All of the results of plasmid sizes and incompatibility 






Figure 31: Sizing of plasmids obtained from strains selected for plasmid studies 









































15 M CTX-M-15 E. coli Plasmid 166 - 
20 M CTX-M-15 K. pneumoniae Plasmid 134 - 
37 M CTX-M-15 K. pneumoniae Plasmid 127 - 
47 M CTX-M-15 E. coli Plasmid 138 - 
57 K CTX-M-15 E. coli Plasmid 166 - 















75 ID CTX-M-15 E. coli Plasmid 217 - 
80 ID CTX-M-15 K. pneumoniae Plasmid 217 - 
82 ID CTX-M-15 K. pneumoniae Plasmid 162 - 
86 ID CTX-M-28 E. coli Plasmid  - 
88 A CTX-M-15 K. pneumoniae plasmid 161 - 
89 A CTX-M-55 K. pneumoniae Plasmid 133 - 
90 A CTX-M-15 E. coli Chromosome - - 
91 A CTX-M-15 E. coli Plasmid 60 IncFII 
92 A CTX-M-15 E. coli Plasmid 63 - 
93 A CTX-M-15 E. coli Chromosome - - 






95 A CTX-M-15 E. coli Plasmid 109 - 
96 A CTX-M-15 E. coli Plasmid 130 - 
97 A CTX-M-117 E. coli plasmid 138 - 
99 A CTX-M-15 
E. coli 
 Plasmid 125 
- 
IncFII 
100 IB CTX-M-15 E. coli Plasmid 194 - 
102 IB CTX-M-3 E. coli Plasmid 194 - 







4.4.5 Conjugation studies 
 
Transconjugants were obtained from isolates (15, 89, 97 and 102) indicating the 
transferability of blaCTX-M-3, blaCTX-M-15, blaCTX-M-55, and blaCTX-M-117. After amplification 
with primers described by Dutour (2002), transconjugants obtained the same genes 
that had been found in their parent strains (strain 15, 89, 97, and 102). In the 
transconjugants, plasmids carrying the same blaCTX-M-3, blaCTX-M-15, blaCTX-M-55, and 
blaCTX-M-117 had the same sizes and incompatibility groups as their parental enzymes. 
This was confirmed when using primers described by Carattoli (2005). In (Table 27), 
the plasmids of obtained from the transconjugants were sized. The sizes of the 
plasmids detected in the transconjugants were also the same as their parent strains; 


























4.5 Examination of the structural models of CTX-Ms found 
 
The examination of the structural models created showed that amino acids 
variations at positions 80, 177, 242, and 282 in blaCTX-M-3, blaCTX-M-15, blaCTX-M-55, and 
blaCTX-M-117 exerted effects on the structure of the enzyme and consequently its 
function. The variations among the reported CTX-Ms in this study are at the 
positions simplified in Table 25 were closer to the active site of the enzyme. The 
regions of the active site of all of the reported blaCTX-M enzymes and closer to the 
amino acid changes are Serine at position 70, lysine at position 73, serine at position 
130, and glycine at position 158. The active site of the blaCTX-Ms is shown in Figure 
33, Figure 34, Figure 35, Figure 36, and Figure 37. In blaCTX-M-3, blaCTX-M-15, blaCTX-M-55, 
and blaCTX-M-117, different amino-acids found at sites 80, 177, and 242 did confer 
different properties (Table 28). 





















Table 28: Properties of amino acids found at positions 78, 177, 242, and 288. 
 
 
The molecular structure of CTX-M-15 is seen in Figure 33. Glycine at position 242 is 
the amino-acid variation of CTX-M-15 from CTX-M-3. In Figure 34, residues at 
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position 78 tend to be near to the bottom of the active site cleft. Not too far from 
the active lysine at position 73. In blaCTX-M-55, valine sits at position 78, which resides 
on the base of the cleft, 8.48 Å distant from lysine of the active site. While in 
blaCTX-M-15, valine is substituted for alanine residue. The change of valine residue for 
alanine acts to change the shape of the active site cleft by reducing the amount of 
space for substrate molecules to bind to the enzyme. This can be justified by the 
hydrophobicity of valine, making it exclusively situated on the interior of the 
protein. Pulling in of the cleft will consequently reduce the binding affinity of the 
enzyme to the substrate. This implies that the MICs of ceftazidime and cefoxitin in 
blaCTX-M-55 are higher than those in blaCTX-M-15 as shown in Table 29. 
 
Table 29: A comparison of the MIC values of ceftazidime and cefoxitin in strains 






MICs of Cefoxitin 
(ml/L) 
CTX-M-15 
4, 15, 17, 20, 37, 
47, 55, 57, 60, 61, 
74, 75, 80, 82, 87, 
88, 90, 91, 92, 93, 
94, 95, 96, 98, 99, 




89 64 64 
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Figure 33: Glycine residue at position 242 in CTX-M-15. The active site of the 
















Figure 34: Valine residue at position 78 in CTX-M-55. The active site of the enzyme 
is coloured in black. The structure was viewed in DeepView. 
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In CTX-M-117 in Figure 35, glutamate at position 177 tends to form hydrogen bonds 
with serine present at the active site of the protein. This bonding is considered to be 
weak; still it would exert a considerable effect on the secondary structure of CTX-M-
117 protein by enhancing the solubility of the protein in water. Accordingly, this 
enhances the ability of the molecule to bind to the drug. In CTX-M-15, proline at 
position 177, is more likely to be able to form stable tight direction changes in the 
enzymatic molecular structure. It is mainly accomplished by the propensity of 
proline to inhibit the formation of α-helices. This results in the narrowing of the 
enzyme’s active site (i.e. glycine at position 158). Another property in which proline 
may impact on the active site is that it is largely aliphatic and hydrophobic. Most 
likely, proline is to be seen at regions of folding of the protein. Thus, it can be 
concluded that the presence of proline at this position of the enzyme decreases its 
affinity to the antimicrobial agent used (i.e. cephalosporins). As result, the values of 
the MICs to cephalosporins in strains carrying blaCTX-M-117 should be lower than those 
in strains blaCTX-M-15. This is indicated in Table 30 
 
 
Table 30: A comparison of the MIC values of ceftazidime and cefoxitin in strains 
carrying blaCTX-M-15 and blaCTX-M-117. 
  
CTX-M Strain 
MICs of Ceftazidime 
(ml/L) 
MICs of Cefoxitin 
(ml/L) 
CTX-M-15 
4, 15, 17, 20, 37, 47, 
55, 57, 60, 61, 74, 
75, 80, 82, 87, 88, 
90, 91, 92, 93, 94, 
95, 96, 98, 99, 100, 





















Figure 35: Glutamate residue at position 177 in CTX-M-117. The active site of the 




In the structural model of CTX-M-3 seen in Figure 36, the variation of the amino acid 
at position 242 was found. CTX-M-3 has aspartate residue that is likely to decrease 
the substrate’s affinity. Aspartate residue at position 242 is substituted for glycine 
in CTX-M-15. This is likely to result in decrease in the MIC values towards 
cephalosporins as seen in Table 31. Aspartate residue is closer to the active site 
serine at position 70; it is a very hydrophilic residue and contains a negative charge 
at neutral pH, making it predominantly found at the surface of the protein. 
Additionally, aspartate exhibits a great ability to form ionic bonds with other amino 
acids. Certainly, with serine present at position 70 at the active site these 
interactions pull out the top of the active site and consequently change the shape of 
the active site cleft. In contrast to aspartate, glycine at position 242 in the CTX-M-15 
β-lactamase tends to be small in size and hydrophobic. These properties enable 
glycine to be placed in regions of the protein where other amino acids are unlikely 
to occur. As a result, glycine will reduce the top of the active site cleft decreasing 
substrate affinity and relatively increasing the values of MICs to cephalosporins 
(Table 31). 
Table 31: A comparison of the MIC values of ceftazidime and cefoxitin in strains 
carrying blaCTX-M-15 and blaCTX-M-3. 
  
CTX-M Strain 
MICs of Ceftazidime 
(ml/L) 
MICs of Cefoxitin 
(ml/L) 
CTX-M-15 
4, 15, 17, 20, 37, 47, 
55, 57, 60, 61, 74, 
75, 80, 82, 87, 88, 
90, 91, 92, 93, 94, 
95, 96, 98, 99, 100, 


















Figure 36: Aspartate residue at position 242 in CTX-M-3. The active site of the 
enzyme is coloured in black. The structure was viewed in DeepView. 
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In Figure 37, the molecular structure of CTX-M-28 can be seen. The only difference 
between CTX-M-15 and CTX-M-28 lies at position 288 and it is asparagine for 
aspartate. Those two amino acids do not have considerable differences in their 
properties. Therefore, no effect can be seen on the structure of the protein and no 
change in the MICs values as well (Table 32). 
 
 
Table 32: A comparison of the MIC values of ceftazidime and cefoxitin in strains 






MICs of Cefoxitin 
(ml/L) 
CTX-M-15 
4, 15, 17, 20, 37, 
47, 55, 57, 60, 61, 
74, 75, 80, 82, 87, 
88, 90, 91, 92, 93, 
94, 95, 96, 98, 99, 






















Figure 37: Asparagine residue at position 288 in CTX-M-28. The active site of the 











5.1 Phenotypic and molecular identification of blaCTX-M genes 
It was important to elucidate the locations and the populations being served in each 
hospital in Figure 7 to show the most common CTX-M β-lactamase member not only 
as the most prevalent in the selected hospitals, but also among different 
populations and from different districts in Kuwait. Also, to describe the situation of 
nosocomial infections in Kuwait rather than focusing on a certain hospital and 
handling CTX-M prevalence from one perspective view. Moreover, the elucidation 
of the Kuwaiti hospitals on Kuwait’s map was to detect any possible transmission of 
the most common CTX-M gene among those hospitals. Nevertheless, the lack of 
epidemiologic data such as the wards of the patients, the nationality, and the 
diagnosis made the explanation and the understanding of the association of the 
prevalence of CTX-M genes in different hospitals difficult to explain. 
 
ESBL identification in Kuwaiti hospitals is usually carried out with Vitek 2 system, 
DDD method and in some hospitals with E-test strips (Al Hashem et al., 2011, Al 
Sweih et al., 2010, Al Sweih et al., 2011, Dashti et al., 2010a, Dashti et al., 2010b). 
Importantly, no genotypic identification has been done in any of the 
aforementioned hospitals. All of the strains were phenotypically identified as ESBL-
producers. Nevertheless, CTX-M-production was not identified genotypically in 
these hospitals. Rather, genotypic identification of CTX-M was carried out in the 
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Kuwait University laboratories with PCR. Interestingly, all of the strains were 
identified as CTX-M-producers, indicating the spread of cefotaxime resistance in 
Kuwaiti hospitals. The increased prevalence of CTX-M enzymes was also reported in 
other studies from Kuwait (Al Hashem et al., 2011, Al Sweih et al., 2010, Al Sweih et 
al., 2011, Ensor et al., 2009, Rotimi et al., 2008). Moreover, CTX-M enzymes are 
reported to be the most prevalent family of ESBLs (Naseer et al., 2009). The 
increased prevalence of this family of enzymes is commonly associated with E. coli 
and K. pneumoniae (Dutour et al., 2002, Eckert et al., 2006, Girlich et al., 2009, 




The findings in this work correlate with previous studies indicating that the 
prevalence of CTX-M enzymes is mainly associated with UTIs (Woodford et al., 
2009). The global description of CTX-M enzymes and the spread of the members of 
this family of enzymes indicated the presence of ‘’CTX-M pandemic’’ (Canton and 
Coque, 2006, Ensor et al., 2009, Leflon-Guibout et al., 2004). 
 
From this finding I can report the occurrence of ‘’CTX-M pandemic’’ as well as the 
need for the screening of CTX-M-production genotypically in hospital settings. This 
might assess clinicians in directing therapeutic options. Moreover, genotypic 
detection of CTX-M-production in hospitals might help in providing the infection 
control unit a proper surveillance of burgeoning antibiotic resistance pattern in 
nosocomial settings in Kuwait. In addition, genotypic detection of these enzymes 
might influence the effectiveness of antibiotic restriction policies used in Kuwait. 
 
The association of the production of CTX-M enzymes by Gram-negative bacteria in 
UTIs was reported from different hospitals around the world (Kanj et al., 2008). UTIs 
with E. coli are thought to be one of the most important hospital-acquired 
infections. The peculiar feature of E. coli is that it causes nosocomial infections with 
polyclonal features, making it difficult for infection control units to determine the 
origin and the source of the infection (Oteo et al., 2010). Another important 
hospital-acquired infection is caused by K. pneumoniae (Wang et al., 2009). K. 
pneumoniae is known to cause pneumonia, UTIs, and intra-abdominal infections 
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(Shi et al., 2009, Bagattini et al., 2006). Therefore, in sample collection I focused on 
nosocomial infections caused by E. coli and K. pneumoniae strains. CTX-M-
production associated with E. coli and K. pneumoniae has been increasingly 
reported worldwide (Dutour et al., 2002, Eckert et al., 2006, Naseer et al., 2009, 
Woodford et al., 2006). and a similar situation is present in Kuwait, where CTX-M-
production is increasingly associated with E. coli and K. pneumoniae. Not only this 
study reports such association, but also previous, less comprehensive studies from 
Kuwait support this finding (Al Hashem et al., 2011, Al Sweih et al., 2010, Al Sweih 
et al., 2011, Ensor et al., 2009, Rotimi et al., 2008).  
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5.2 Pulsed-field gel electrophoresis 
 
PFGE is considered to be one of the essential and highly discriminatory tools used in 
the field of molecular biology (Maslow et al., 1993, Singh et al., 2006, Lahti, 1996). It 
also serves as a tool for sizing and profiling plasmids and chromosomal mapping of 
different prokaryotes (Maslow et al., 1993). Within hospital laboratories, the use of 
PFGE is required in monitoring the spread of infections and tracking diseases 
causing outbreaks in different settings (Bannerman et al., 1995, Barrett et al., 1994, 
Bohm and Karch, 1992, Gautom, 1997, Lahti, 1996). 
 
In this work, PFGE was performed to detect the source or to track the spread of 
cefotaxime resistance in some Kuwaiti hospitals. Moreover, PFGE was done to find 
the clonal relationship among the collected isolates and use a representative strain 
from each clone for further sequencing, plasmid, and genetic environment studies. 
The representative strains would have helped in seeing the full picture of 
cefotaxime resistance in Kuwait with further studies. Unfortunately, poly-clonality 
was observed. In addition, the results of PFGE seen in Figure 10 and Figure 11, 
indicated the spread of blaCTX-M genes by means of HGT mediated by mobile genetic 
elements like ISEcp1. Few strains were identical and similar (22 strains). 
Consequently, no representative strain was selected for further studies in this work. 
Instead, selected isolates were chosen on the basis of their resistance profiles. 
Traditional PFGE is inconvenient in terms of time and laboour (Alaidan et al., 2009, 
Gautom, 1997). PFGE is technically demanding, requiring up to 6 days procedure 
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from the day of isolating the bacterial strain (Goering and Winters, 1992, Matushek 
et al., 1996, Miranda et al., 1996). Therefore, a rapid and cost-effective method was 
developed to overcome these drawbacks. The protocol described in this study was 
assessed by modifying the method described by Durmaz et al (Durmaz et al., 2009) 










5.3 Sequencing with plasmid and genetic environment studies 
 
Upon PCR amplification, blaCTX-M-15 was found to be the most prevalent member of 
CTX-M family (Table 24). Previous studies from Kuwait reported the presence of 
blaCTX-M-15 (Al Hashem et al., 2011, Al Sweih et al., 2010, Al Sweih et al., 2011, Ensor 
et al., 2009, Rotimi et al., 2008). The first description of blaCTX-M-15 was reported 
from India (Karim et al., 2001). Ever since, blaCTX-M-15 has gained a global reputation 
spreading into different continents (Novais et al., 2007, Pitout, 2010). Moreover, 
CTX-M-15 gene has been fairly reported in association with E. coli and K. 
pneumoniae strains (Coelho et al., 2010, Woodford et al., 2006). Also, previous 
reports indicated that the most prevalent type of ESBLs is blaCTX-M-15 gene with MDR 
pattern (Nicolas-Chanoine et al., 2008, Peirano and Pitout, 2010). The results in this 
study agree with previous studies, confirming that the most prevalent member of 
ESBLs in Kuwait is blaCTX-M-15 (Coque et al., 2008, Ensor et al., 2009, Dashti et al., 
2010b, Al Sweih et al., 2010, Al Sweih et al., 2011). The sequencing results are 
suggestive the acquisition of blaCTX-M genes in three different phases and from three 
different ancestors. Fifteen isolates encoding blaCTX-M-15 belonging to one progenitor 
(isolate 4, 15, 17, 20, 37, 47, 55, 57, 60, 61, 74, 88, 100, 101, and 105), 12 isolates 
belonging to different progenitor (isolate 75, 80, 82, 87, 90, 91, 92, 93, 94, 95, 96, 
and 98), and one isolate (isolate 99) belonging to a different proginator from the 
previous two. This could be explained by the nucleotide differences described when 
comparing all of the isolates encoding blaCTX-M-15 as seen in Figure 19. The 
nucleotide differences found among the reported blaCTX-M-15 genes are indicative of 
176 
 
synonymous mutations. These mutations do not change the amino acid sequences 
and consequently have no effect on the protein’s structure or function. They only 
point to possible different diversification processes or origins and support the poly-
clonality of E. coli strains found and the poly-clonality described in the PFGE results 
(Figure 10). Moreover, when the isolates share the same clone it does not 
necessarily mean having the same genetic context. This can be seen in isolate 15 
and 74 with isolate 80 and 82. The first two isolates proved to be from the same 
clone and the second two from another. Yet, both sets of isolates share the same 
genetic context (A) in Figure 30. Also, the same event can be seen in isolate 91 and 
92 with isolate 95 and 96, where the first two isolates share the same clone 
indicated by the nucleotide sequences differences in Figure 19 and the last two 
coming from a different clone. Regardless, both sets of isolates share the same 
genetic platform. The synonymous mutations are also indicative of recent in vivo 
mutations being exerted by the antibiotic selective pressure which was 
hypothesized from the resistance profile of the isolates used in this study. This 
finding is additionally supported by the presence of blaCTX-M-3 in an earlier collection 
in 2006 (Table 6). There is one study that indicated that blaCTX-M-3 is the parent 
enzyme of CTX-M-1 sub-group rather than blaCTX-M-1 (Novais et al., 2010). Therefore, 
it can be assumed that the reported blaCTX-M-3 is the parental enzyme of some of the 
CTX-Ms found in this study and the extensive use of cefotaxime and ceftazidime 
probably acted as a driving force for the diversification of blaCTX-M-3 gene into blaCTX-




The spread of blaCTX-M-15 gene is possibly linked to the presence of the insertion 
sequence, ISEcp1. Strong association between blaCTX-M-15 and ISEcp1 has been 
reported in literature (Ma et al., 2009, Naseer et al., 2009, Poirel et al., 2003, 
Sonnevend et al., 2006). Moreover, the acquisition of CTX-M genes is mainly 
mediated by ISEcp1 (Yu et al., 2007, Yu et al., 2011, Zheng et al., 2012). Insertion 
sequences are DNA segments that encode proteins and enzymes required for 
mediating the movement of adjacent DNA sequences between replicons (Frost et 
al., 2005). ISEcp1, a member of IS380 family have been extensively reported in 
literature to be associated with members of blaCTX-M-1, blaCTX-M-2, blaCTX-M-9, and 
blaCTX-M-25 families (Smet et al., 2010, Yu et al., 2007, Yu et al., 2011, Zheng et al., 
2012). These insertion sequences are responsible for the capture, mobilization, 
transposition, and expression of different blaCTX-M genes (Sonnevend et al., 2006, 
Sun et al., 2010, Zong et al., 2010). ISEcp1 was present in the upstream sequences 
of all of the CTX-Ms reported in this work, but with variable distances (Figure 30). 
Similar observations were reported in previous studies (Dhanji et al., 2011, Kiratisin 
et al., 2007, Novais et al., 2007). This gene was carried on IncFII plasmid that is 
known for its narrow host range compatibility but being pandemic and highly 
associated with the spread resistance genes in E. coli strains (Diestra et al., 2009, 
Peirano and Pitout, 2010). Regarding other isolates with ISEcp1 upstream blaCTX-M-15, 
but without a spacer sequence in between, is similar to previous studies reporting a 
similar structure (Ma et al., 2011, Sun et al., 2010). Additionally, the size of the 
ISEcp1 being found (400bp) was also the same as those previous studies. These 
structures are seen in (D) and (E) in Figure 30 (isolate 37, 47, 90, 91, 92, 93, 95, 96, 
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99, and 100) (Gonullu et al., 2008, Oteo et al., 2006). This study confirms the 
findings of others by describing various variable distances between ISEcp1 and 
blaCTX-M-15 (Dhanji et al., 2011, Kiratisin et al., 2007, Novais et al., 2007). The variable 
distances between ISEcp1 and the downstream blaCTX-M genes indicate separate 
escape events of the blaCTX-M gene from the origin and the acquisition of genes in 
different phases (Woodford et al., 2009). This provide further support of the 
different progenitors of the blaCTX-M-15 genes found as they vary in their distance 
from the upstream ISEcp1 (49bp, 10 bp with a conserved spacer, conserved spacer 
only, no distance) (Figure 30). In other words, the point of insertion of ISEcp1 is 
different and it is not consistent even in the same gene (i.e. blaCTX-M-15). This finding 
contradicts that of Ma et al (2011), which suggests that the point of insertion of 
ISEcp1 upstream blaCTX-M gene is dependent on the CTX-M-type. By contrast, this 
study suggests that there is no preferential point of insertion of ISEcp1 for a certain 
blaCTX-M gene. One study by Novais (2007) indicated that different locations of 
ISEcp1 insertion upstream blaCTX-M-15 onto different plasmids platforms are 
suggestive of the occurrence of independent mobilization events but originating 
from the same ancestor (Novais et al., 2007). 
 
From Figure 30, ISEcp1 is the most common factor present in the genetic context of 
blaCTX-M-15 gene, and it is leading for its mobilization. ISEcp1, also play a role in HGT 
and evolutionary process of CTX-M family of enzymes (Ensor et al., 2009, Gangoue-
Pieboji et al., 2005). In this work, the tnpA gene of the Tn3 transposon is disrupted 
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by the ISEcp1 upstream blaCTX-M-15 gene as seen in structure (B), (C), (D), (E), and (F) 
in Figure 30. These structures are found in most of the isolates encoding blaCTX-M-15 
(isolate 20, 37, 47, 57, 61, 88, 90, 91, 92, 93, 94, 95, 96, 99, and 100) and are 
indicative of transpositional processes mediated by ISEcp1. These findings agree 
with a previous study by Smet (2010). Another evidence of transpositional 
processes mediated by ISEcp1, is the presence of 5 bp target site duplication, that is 
usually A-T rich (Smet et al., 2010, Woodford et al., 2009). One of the target site 
duplication is TATGA (Smet et al., 2010). This 5 bp signature of transpositional 
processes mediated by ISEcp1 can be seen in the upstream sequence of blaCTX-M-15 
gene in isolates; 20, 47, 75, 80, 82, and 102 (Table 26). Another signature is 
‘’TATTG’’ described by Woodford et al (2009) is also seen in the upstream sequence 
of blaCTX-M-15 gene of isolates; 37, 61, and 89 (Table 26). Two different 5 bp 
sequences were described by Smet (2010) and were also seen in isolate 37, these 
sequences are ‘’ATATA’’ and ‘’TTATA’’ (Table 26). In isolate 37, the presence of 3 
signatures of transpositional processes indicates the occurrence of three 
transpositional events happening in different timings. Consequently, this may justify 
further diversification of blaCTX-M-15 gene and the development of CTX-M-15 
derivatives such as blaCTX-M-28, blaCTX-M-55, and blaCTX-M-117. 
 
Further evidence of mobilization is the presence of partial sequences of ORF477 
(Zong et al., 2010). This finding is also seen in most of the strains carrying blaCTX-M-15 
gene seen in structure (A), (B), (D), and (F) in Figure 30. These partial sequences are 
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seen in the downstream genetic contexts of blaCTX-M-15 gene of isolates; 15, 20, 37, 
47, 57, 61, 74, 75, 80, 82, 86, 91, 92, 95, 96, 99, and 100 (Table 26). These 
sequences are suggestive of a preliminary capture of blaCTX-M-15 gene followed by a 
mobilization process and a transpositional event mediated by ISEcp1 (Sun et al., 
2010, Zong et al., 2010). These pieces of evidence of transposition signatures and 
remnants of sequences further point to the mobilization, transpositional events, 
and diversification of blaCTX-M-15 among the collected isolates (Canton et al., 2012, 
Coelho et al., 2010, Lartigue et al., 2004).  
 
The role of ISEcp1 is not only restricted to capturing and mobilizing blaCTX-M-15; it also 
acts in increasing the expression of the downstream blaCTX-M-15 genes (Dutour et al., 
2002, Eckert et al., 2006, Ma et al., 2011, Peirano and Pitout, 2010). One study by 
Ma (2011) suggested that ISEcp1 adjacent to the blaCTX-M-15 gene and with shorter 
distances to that blaCTX-M-15 gene are necessary for the maintenance of high level 
expression of that blaCTX-M-15 gene (Ma et al., 2011). A –35 and –10 promoter 
sequence described by Poirel (2003) ‘’TTGACA’’ and ‘’TAAACT’’ was also found in 
the upstream sequences of blaCTX-M-15 of isolate; 20, 37, and 40 (Table 26). Another 
promoter sequence described by Lartigue (2004) ‘’TGCAG’’ was found in the 
upstream sequence of blaCTX-M-15 of isolates; 20, 47, and 61. Upon analysis, the 
closest promoter sequences found in the upstream genetic contexts of blaCTX-M-15 
were found to be residing in the ‘’W’’ sequences. Additionally, the promoter 
sequence described by Dhanji (2011) ‘’TTCATG’’ was found in the ‘’W’’ region of all 
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strains with structures containing this region. These isolates are; 15, 37, 57, 61, 74, 
75, 80, 82, 94, and 100 (Table 26) and are seen in structure (A), (F), and (H) in Figure 
30.  Most importantly, no promoter sequences were found in the conserved spacers 
described in isolate 20 and 88 that is structure (B) and (C) respectively in Figure 30. 
The function of the conserved spacer and possible explanation of its existence 
upstream blaCTX-M-15 remains ambiguous. Further investigation of the ‘’W’’ region 
was approached in this work. The analysis of the ‘’W’’ region showed that it did not 
only carry promoters required for the expression of the downstream blaCTX-M genes. 
Also, it had the Shine-Dalgarno ribosomal binding sequence ‘’AAGGAA’’ adjacent to 
the start codon of the downstream blaCTX-M gene (Shine and Dalgarno, 1974). The 
function of this sequence is involved in protein translation. It recruits ribosomes to 
mRNA for the initiation of protein synthesis by aligning it with the start codon (ATG) 
of the downstream gene. This sequence was found to be in all of the ‘’W’’ 
sequences upstream the reported blaCTX-M genes reported in this project. 
 
To answer more questions of the specificity of the ‘’W’’ region to blaCTX-M-15 gene 
than other CTX-M family members present in this study (like blaCTX-M-55 gene), all of 
the ‘’W’’ sequences found upstream of the CTX-M genes in this work were taken 
and aligned with the ‘’W’’ region of blaCTX-M-55 published from Thailand (accession 
number DQ885477) using the multi align web interface. The results indicated that 
all of the ‘’W’’ sequences present upstream blaCTX-M-15 are identical to the ‘’W’’ 
region present upstream blaCTX-M-55 reported in this work and from a previous study 
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as well (Kiratisin et al., 2007) (Figure 38). Only on nucleotide difference was present 
in the ‘’W’’ sequence upstream blaCTX-M-15. Mutations in the Shine-Dalgarno 
ribosomal sequence result in reducing the translation process of the downstream 
gene, and therefore reducing the expression of that gene. This can be noticed from 
the MIC of ceftazidime of isolate 89 carrying the upstream environment of GenBank 
accession number FJ235691.1. Therefore it can be presumed that this is responsible 
for the lower MIC of ceftazidime than that found in CTX-M-15 β-lactamase-
producing strain. Instead, the levels of MICs of ceftazidime in this strain are higher 
than those in CTX-M-15. This could be explained by the mutational effect in blaCTX-M-
15 that led to certain changes in the biochemical properties of the enzyme’s active 
site and consequently ncreasing the binding of the enzyme’s active site by 
ceftazidime. Yet, another explanation of the action of the mutational in the Shine-
Dalgrano ribosomal sequence is the lower prevalence of this enzyme than blaCTX-M-
15. Eventually, blaCTX-M-55 gene is not expressed as efficient as blaCTX-M-15 gene. 
 
Nevertheless, the alignment indicated that the sequence of the ‘’W’’ region could 
be variable, in terms of few nucleotide changes, even in the same blaCTX-M member 





Figure 38: Alignment of the ‘’W’’ region present upstream blaCTX-M-15 and blaCTX-M-
55. Nucleotides in black colour are with high consensus, red with low consensus, and 
green with neutral consensus. Shine-Dalgrano is highlighted in the green box. 
 
Presumably, the promoter sequences found in the ‘’W’’ regions act in increasing the 
expression of the downstream blaCTX-M-15 gene as suggested earlier. This could 
justify the high level of resistance to cefotaxime in the collected isolates. 
Additionally, this could further explain the presence of the ‘’W’’ region upstream 
blaCTX-M-15 gene. It is noteworthy, that the presence of the ‘’W’’ region, though it is 
important for the expression of blaCTX-M-15 gene, is not conditional for the existence 
of blaCTX-M-15 gene as seen in structure (D) and (E) in Figure 30. Moreover, the ISEcp1 
could be present upstream blaCTX-M-15 gene without the presence of the ‘’W’’ 
sequence seen in structure (B), (C), (D), and (E) in Figure 30. Above all, the ‘’W’’ 
region is not specific to a certain strain carrying blaCTX-M-15 gene, as it is reported in 
this work to be upstream blaCTX-M-15 gene encoded by E. coli and K. pneumoniae in 
isolate 15 and 80 respectively (Table 26). The presence of the ‘’W’’ region was also 
observed upstream blaCTX-M-15 and blaCTX-M-3 genes described in French, India, and 




From the sequencing results and from the analysis of the ISEcp1 provided herein, I 
can confirm and agree with previous studies that ISEcp1 is a key factor in the 
increased spread and expression of blaCTX-M-15 gene. Admittedly, ISEcp1 is the main 
cause of the widespread of CTX-M-15 enzyme in Kuwaiti hospitals along with the 
extensive use of cefotaxime and ceftazidime acting as the driving force. 
 
This is the first work from Kuwait describing the genetic conformation of Kuwaiti 
isolates carrying blaCTX-M-15 gene. Nevertheless, previous studies indicated the 
presence of ISEcp1 and IS26 upstream blaCTX-M-15, but did not elucidate further 
genetic sequences and orientation upstream and downstream blaCTX-M-15 gene (Al 
Hashem et al., 2011, Al Sweih et al., 2010, Al Sweih et al., 2011, Coque et al., 2008, 
Dashti et al., 2010b, Ensor et al., 2009, Rotimi et al., 2008). 
 
From the genetic contexts of blaCTX-M-15 sought in this work, variability is well 
observed and no consistent genetic platform for blaCTX-M-15 gene was documented. 
In fact, five different genetic environments for blaCTX-M-15 gene were represented in 
structure (A), (B), (D), (F), (G), and (H) (Figure 30). Not only has this work showed 
the variability of the genetic environments of blaCTX-M-15 gene, but also other studies 
indicated comparable findings though in different countries (Dhanji et al., 2011, 
Oteo et al., 2006). The most common genetic context of blaCTX-M-15 gene in E. coli 
strains was represented in structure (D) (Figure 30). This genetic arrangement was 
observed in eight strains (isolate 37, 47, 91, 92, 95, 96, 99, and 100). Notably, this 
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structure was not observed in any of the collected K. pneumoniae strains encoding 
blaCTX-M-15 gene. Furthermore, this genetic platform was previously reported in a 
study from Haiti in A. baumannii strain carrying blaCTX-M-15 gene (Potron et al., 2011). 
Features of this structure are; the presence of a truncated ISEcp1 sequence of 339 
bp long linked directly to blaCTX-M-15 gene. The direction of the ISEcp1 upstream is 
opposite to the downstream blaCTX-M-15 gene. The inverse direction of ISEcp1 extend 
conclusion that isolates sharing this genetic structure have acquired blaCTX-M-15 gene 
in separate escape events than isolates with ISEcp1 in the same direction as the 
downstream blaCTX-M-15 gene. A previous study related the inverse direction of the 
ISEcp1 upstream the blaCTX-M gene to different mobilization events (Smet et al., 
2010). The plasmid sizes carrying blaCTX-M-15 gene with this genetic context ranged 
from 60-130 Kb and most of them were not typed into a certain incompatibility 
group. However, I maintained to determine the incompatibility grouping of two 
isolates and both belonged to InFII. In fact, IncFII are known for being narrow-host 
range plasmids (del Solar et al., 1996). Also, it has been described that IncFII 
plasmids have conjugative properties (Coelho et al., 2010). The presence of blaCTX-M-
15 gene has been noted to be associated with IncFII plasmids in different reports and 
this work agree with these studies (Canton et al., 2012, Golebiewski et al., 2007, 
Lavollay et al., 2006, Naseer et al., 2009, Peirano and Pitout, 2010). Probably, the 
inability to detect the incompatibility grouping of other plasmids in this study was 
due the complexity of these plasmids. The complexity of plasmids increases with 
their sizes, in which they might contain, co-integrated compatible replicons. 
Therefore, the inability to measure plasmid competition might be justified by failure 
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of designing appropriate molecular probes to detect these co-integrated compatible 
replicons (Frost et al., 2005). 
The second most common genetic arrangement of blaCTX-M-15 found was 
represented in structure (A) (Figure 30). This genetic arrangement was described in 
six isolates encoding blaCTX-M-15 gene. Moreover, this genetic context was also 
previously reported to be ‘’the international blaCTX-M-15 genetic environment’’ 
(Diestra et al., 2009). The international genetic environment of blaCTX-M-15 gene was 
not specific for E. coli strains only (isolate 15, 74, 75, and 86). Instead, it was also 
found in two K. pneumoniae strains (isolate 80 and 82). Consequently, structure (A) 
in Figure 30 is common to different bacterial strains carrying blaCTX-M-15 gene. It is 
noteworthy that the latter genetic arrangement was not described in other genes 
belonging to blaCTX-M-1 group. Accordingly, this showed the uniqueness of this 
genetic context to the blaCTX-M-15 gene.  In other words, the international genetic 
environment of blaCTX-M-15 is not common to blaCTX-M-3 (a possible parent of blaCTX-M-
15), which suggests the occurrence of separate transpositional and escape events far 
from blaCTX-M-3 gene were the source of blaCTX-M-15. Common elements of the 
international genetic environment of blaCTX-M-15 gene are; the ‘’W’’ region, a 
disrupted ISEcp1 sequence with promoters in that sequence increasing the 
expression of the downstream blaCTX-M-15 gene, and the presence of ORF 477 
downstream the blaCTX-M-15 (Dhanji et al., 2011). In this work, the downstream 
genetic environment of all the reported CTX-Ms was found to be a hypothetical 
protein of variable lengths (430-470 bp) encoding ORF 477 (Figure 30). It was not 
possible to determine the downstream genetic environment in isolates 88, 90, and 
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93. The last two isolates (90 and 93) are thought to carry chromosomally-encoded 
blaCTX-M-15 genes with the absence PCR amplicons upon amplification of the plasmids 
DNA bands with primers described by Dutour (2002). 
 
The genetic environments sought for isolate 20 and 88 are the same, except in the 
downstream genetic environment of isolate 88 which was not determined as seen 
in structure (B) and (C) respectively in Figure 30. A similar genetic context was 
described in Ent. aerogenes encoding blaCTX-M-15 gene from Russia (Table 26). 
Moreover, the same finding was described by Diestra (2009) in an E. coli strain 
encoding blaCTX-M-3 gene from Spain. Both findings show the presence of a truncated 
ISEcp1 upstream blaCTX-M-15 gene and a linking sequence consisting of a 10bp 
sequence with a conserved spacer of 47bp in length. The role of spacer sequence 
could not be determined, but one study by Ma (2011) indicated that the spacer 
sequences upstream the blaCTX-M gene have promoters helping to increase the 
expression of the downstream blaCTX-M genes. The shorter the sequence, the closer 
to the bla gene and the enhanced activity towards cephalosporins is expressed (Ma 
et al., 2011). Additional analysis of the spacer sequence indicated the presence of 
the Shine-Dalgarno ribosomal sequence in the 10 bp near the 5’ prime terminus of 
the start codon of the blaCTX-M-15 gene. As indicated earlier that this sequence 




Two E. coli isolates (isolate 57 and 61) encoding blaCTX-M-15 gene share a genetic 
confirmation reported by Dhanji (2011) to be related to travellers coming from India 
and Pakistan to the United Kingdom.  
 
As seen in structure (F) in Figure 30, same elements found in the international 
genetic environment of blaCTX-M-15 gene are found in this genetic context but with 
additional presence of a truncated IS26 upstream ISEcp1. This genetic arrangement 
was also reported in a K. pneumoniae strain encoding blaCTX-M-15 gene in Hungary. 
The presence of IS26 was also reported to be associated with blaCTX-M-15 gene, but 
less commonly than ISEcp1 (Montesinos et al., 2010). In fact, IS26 was found to be 
present upstream blaCTX-M-15 gene on IncFII plasmids with variable sizes described in 
different reports from Asia and Europe (Novais et al., 2007). This study confirms 
with an earlier study from Kuwait by Ensor (2009), the association of the presence 
of blaCTX-M-15 gene with IS26. This work also suggests and confirms that IS26 is not 
necessarily required for the widespread of blaCTX-M-15 gene (Ensor et al., 2009). 
Rather, IS26 was thought to mobilize CTX-M-15 gene by means of homologous 
recombination than transposition. Additionally, IS26 was thought to facilitate 
mobilization of chromosomal fragments as well as DNA from other plasmids and 
consequently playing a major role in plasmid plasticity and acquiring different AR 
genes. This could be explain the MDR pattern of isolates 57 and 61 carrying IS26 
that might be due to the presence of AR genes other than blaCTX-M-15 gene mobilized 




The last genetic confirmation described in this work for blaCTX-M-15 gene is seen in (H) 
in Figure 30 is the same as the most common genetic context of blaCTX-M-15 gene but 
with a smaller ISEcp1 size. This genetic arrangement was observed in E. coli isolate 
(isolate 94). It was also reported to be in E. coli strain encoding blaCTX-M-15 in Tunisia 
(Rejiba et al., 2011).  
 
The results of this study also describe the first report of blaCTX-M-28, blaCTX-M-55, and 
blaCTX-M-117 in Kuwait and in the Middle East. The CTX-M-3 β-lactamase found in one 
of the collected strains (strain 102) gene was previously described in the Middle 
East in Turkey (Acikgoz et al., 2008, Agin et al., 2011, Bahar et al., 2006, Galimand et 
al., 2005, Nazik et al., 2008, Samuelsen et al., 2009). 
 
Sporadic reports have been describing the presence of blaCTX-M-28 gene, one report 
from Netherlands (Hasman et al., 2005), two reports from China (Tian et al., 2012, 
Yu et al., 2007), one report from India (Kingsley and Verghese, 2008), one from 
Tunisia (Ben Achour et al., 2009), one from France (Dubois et al., 2010), one from 
Brazil (Lopes et al., 2010), and one from Korea (Tian et al., 2012). The first report of 
blaCTX-M-28 was documented in 2005 in Salmonella spp isolated in the Netherlands. It 
was indicated that blaCTX-M-28 was present on conjugative plasmids and in animal 
reservoirs (Hasman et al., 2005). Later, in 2007, another report of blaCTX-M-28 was 
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documented from China, describing the presence of this gene in E. coli and K. 
pneumoniae strains on conjugative plasmids as well. Additionally, the presence of 
ISEcp1 upstream blaCTX-M-28 was also mentioned (Yu et al., 2007). This finding agrees 
with our results in describing the presence of blaCTX-M-28 in E. coli strain on a 
conjugative plasmid (Table 27). Interestingly, this strain was collected in the same 
year of the first report of blaCTX-M-28 (i.e. 2007), but identified later. This finding 
indicates a concomitant appearance of the same gene in two different countries. 
Therefore, the assumption that blaCTX-M-28 gene was present in this study due to 
possible immigration from China could be disregarded. Rather, the development of 
blaCTX-M-28 could be due to the use of ceftazidime acting as a selective pressure on 
blaCTX-M-15 and driving mutations in a certain direction leading to the evolution of 
blaCTX-M-28. Also, un-predicted transpositional events were acquired by the presence 
of the disrupted ISEcp1 (i.e. 338 bp long) upstream blaCTX-M-28 gene. The presence of 
ISEcp1 might drive the evolution of blaCTX-M-15 gene into blaCTX-M-28 gene. Evidence of 
transpositional processes is the presence of a 5bp repeat in the insertion sequence 
ISEcp1 present upstream blaCTX-M-28 (Gangoue-Pieboji et al., 2005). Another support 
of the hypothesis that blaCTX-M-28 originated from blaCTX-M-15 by transposition is the 
similar genetic context of blaCTX-M-28 with blaCTX-M-15 encoded by strains collected 
from the same hospital (IDH) in the same year (strain 75, 80, and 82) (Figure 30). 
Yet, the cause of diversification and the mutation of blaCTX-M-15 into blaCTX-M-28 
around amino acid position 288 cannot be explained, especially when previous 
studies indicated mutational hot-spots in CTX-M family members. These studies did 
not describe amino acid position 288 as being one of the mutational hot-spots 
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whereby mutational events are more likely to occur and develop. These mutational 
hot-spots are; Asn104, Asn132, Ser237, and Asp240 (Gniadkowski, 2008, Perez et 
al., 2007). Nevertheless, the position 288 in CTX-M-1 group family members was 
documented recently to be lying under positive selection pressure (Novais et al., 
2010). This probably explains the mutational event occurring at amino acid 
positions 288 leading to the diversification of blaCTX-M-15 into blaCTX-M-28. Moreover 
the driving force of the extensive use of ceftazidime promoted the mutation of 
blaCTX-M-15 into blaCTX-M-28 (Table 25). It is noteworthy that the genetic environment 
of blaCTX-M-28 has not been previously been reported in the literature and this work 
describes novel report of the genetic context of this gene. Moreover, the presence 
of blaCTX-M-28 in the Middle East and specifically in Kuwait is also novel in Kuwait and 
has not been described earlier. 
 
This work also describes the first description of blaCTX-M-55 gene in the Middle East 
area and thus in Kuwait. Most reports of blaCTX-M-55 gene have been from Asia 
(China, Japan, Korea, and Thailand) (Harada et al., 2012, Kiratisin et al., 2007, Li et 
al., 2010, Ma et al., 2012, Shi et al., 2009, Sun et al., 2010, Tamang et al., 2012, Tian 
et al., 2012, Yu et al., 2011, Zhang et al., 2011, Zheng et al., 2012). One report was 
documented from the USA and England (Sjolund-Karlsson et al., 2011, Snow et al., 
2012). All reports of blaCTX-M-55 gene were from Enterobacteriaceaeae and mainly 
from E. coli. Importantly, blaCTX-M-55 gene proved to be carried in animals and pets 
acting as reservoirs for this enzyme (Harada et al., 2012, Li et al., 2010, Ma et al., 
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2012, Snow et al., 2012, Sun et al., 2010, Tamang et al., 2012, Zheng et al., 2012). 
Additionally, CTX-M-55 was reported to be located on conjugative plasmids, some 
of which could not be typed and others were of incompatibility group FII, 70 kb in 
size (Kiratisin et al., 2007, Ma et al., 2012, Sjolund-Karlsson et al., 2011, Sun et al., 
2010, Tamang et al., 2012, Yu et al., 2011, Zheng et al., 2012). These findings agree 
with results described in this project, as the blaCTX-M-55 gene was found to be located 
on conjugative plasmids that could not be typed by conventional incompatibility 
grouping protocols and sized 133 kb (isolate 89). Only three reports described the 
upstream genetic conformation of blaCTX-M-55 gene, one of which reported the 
downstream genetic arrangement as well. This work shows the first description of 
IS26 as a part of the upstream region of blaCTX-M-55 gene structure (G) in Figure 30. 
Here, I report the presence of a truncated ISEcp1 that is 49 bp upstream of the start 
codon of blaCTX-M-55 gene as seen in structure (G) in Figure 30. This findings correlate 
with other studies from Thailand and China (Kiratisin et al., 2007, Zheng et al., 
2012). In addition, sequence analysis revealed the presence of unusual tnpA gene as 
part of IS26 rather than ISEcp1 identified by Kiratisin et al (Kiratisin et al., 2007). The 
presence of two insertion sequences as well as a transposon gene indicates the 
action of different and separate mobilization events and recent mutational 
processes leading to the emergence of blaCTX-M-55. Interestingly, intervening 
promoter sequences were not seen upstream at the 5’ terminus of blaCTX-M-55, which 
are usually known to control the expression of the blaCTX-M genes. Another 
indication of acquiring blaCTX-M-55 threw different transpositional events is the 
direction of the ISEcp1 that is opposite to the translation direction of the 
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downstream blaCTX-M-55 gene as represented in structure (G) in Figure 30. The 
downstream genetic context of blaCTX-M-55 was seen a hypothetical protein of 462 bp 
in length encoding ORF477. This was previously indicated in a study from China of 
blaCTX-M-55 found in E. coli (Zheng et al., 2012). The same genetic context of blaCTX-M-
55 was found in two isolates (57 and 61) in this work, but with different orientation 
of the ISEcp1, which was in the same direction of the downstream blaCTX-M-15. This 
provided more evidence of the hypothesis of the diversification of blaCTX-M-15 into 
blaCTX-M-55 by different and separate transpositions. 
 
Regarding blaCTX-M-117 gene, this work also describes the first report of this gene in 
the Middle East and thus in Kuwait. It is also considered to be only the second 
report of this gene in world. The first report of blaCTX-M-117 was by Geser et al (Geser 
et al., 2012). The later report only indicated the presence of blaCTX-M-117 in animals, 
but it did not show any information regarding the genetic environment of this gene. 
Regardless, this project elucidated the genetic conformation of blaCTX-M-117 gene 
represented in structure (I) in Figure 30. The absence of the ‘’W’’ sequence was 
noted with only the presence of a truncated ISEcp1 of 339 bp. This genetic context 
upstream the gene was the same as one described upstream blaCTX-M-15 gene in A. 
baumannii strain in Haiti (Potron et al., 2011). The same genetic environment was 
also present upstream other strains of this work and it was the most commonly 
found upstream genetic environment of blaCTX-M-15 gene (isolate 37, 47, 91, 92, 95, 
96, 99, and 100) represented in structure (D) in Figure 30. Moreover, blaCTX-M-117 
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gene was located on a conjugative plasmid of 130 kb (Table 27). The incompatibility 
group of this group could not be detected. 
 
The last genetic context of blaCTX-M gene to be discussed in this work is that of blaCTX-
M-3. The genetic context seen in structure (J) in Figure 30, is noted to be unique to 
blaCTX-M-3 in this work. Other structures in this project of blaCTX-M-15 found to have a 
conserved spacer sequence also had a 10 bp sequence downstream the conserved 
spacer rather than a conserved spacer only as seen in structures (B) and (C) in 
Figure 30. The size of the conserved spacer is crucial for the expression levels of the 
downstream blaCTX-M gene. Moreover, the shorter distance of the conserved spacer 
sequence, the higher the level of expression of the downstream blaCTX-M gene. 
Nevertheless, one study proved that the promoters found within the ISEcp1 are 
more important than those found in the spacer sequence (Ma et al., 2011). The 
Shine-Dalgarno ribosomal sequence ‘’AAGGAA’’ was also found upstream the blaCTX-
M gene. All of the Shine-Dalgarno sequences found in this work were the same 
regardless of the bacterial species (E. coli or K. pneumoniae). 
 
The reported blaCTX-M-3 gene was located on a conjugative plasmid of 194 kb in size 





5.4 Examination of the structural models of the CTX-Ms found 
 
Upon mutational effects analysis, point mutations of the reported blaCTX-M enzymes 
(blaCTX-M-3, blaCTX-M-15, blaCTX-M-28, blaCTX-M-55, and blaCTX-M-117) were clustered in five 
areas nearby the active site of the ESBL enzymes. These amino acid positions were; 
80, 177, 242, and 282 (Table 25). 
 
The consensus pattern of the active site of Ambler class A ESBLs is [FY]-x-[LIVMFY]-
{E}-S-[TV]-x-K-x(3)-{T}-[AGLM]-{D}-{KA}-[LC]. In CTX-Ms, the active site (S-K-S-E) was 
found at amino acid positions 70, 73, 130, and 158. The amino acid changes were 
near the active site of the reported enzymes and in some manner altered the shape 
of the active site indirectly. Some changes reduced the binding of β-lactamase to 
cephalosporins such as the changes in blaCTX-M-117. Other changes increased the 
binding of β-lactamase to cephalosporins such as the changes found in blaCTX-M-15 
and in blaCTX-M-55. Other changes did not affect the active site’s shape and 
consequently did not exert any effect on the enzyme’s function which could be seen 
in changes occurring in blaCTX-M-28. The data suggesting the influence of specific 
amino acid changes effects are poor. Moreover, the absence of valuable kinetic 
studies of CTX-M-1 group of enzymes with amino acid changes and rate of spectrum 
was noticed. However, one study by Novais et al (Novais et al., 2010), indicated 
areas under positive selection of CTX-M-1 group of enzymes with spectrum of 
activity towards cephalosporins. The amino acid positions being under positive 
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selection were; 77, 114, 167, 240, and 288. In the latter study, point mutations at 
those positions produced successful mutants with increased ceftazidime and/or 
cefotaxime activity. Ceftazidime was identified as a selective pressure and the 
driving force for the production of these mutations. 
 
Accordingly, and based on the biochemical properties of the amino acid mutations 
along with the resistance profiles that were reported for blaCTX-M enzymes, this work 
showed that ceftazidime hydrolysis pattern changed in relation to mutations and 
amino acid changes. 
 
The structure-function relationship was studied in the light of the values of the MICs 
of cefoxitin and ceftazidime. Also, the identification of the properties of amino acids 
changes helped in predicting the effect on the active site structure and the function 
of the enzyme. This method used in this project proved to be useful for the 
construction of the structural models of the CTX-M enzymes reported in this work. 
 
It is probable that more change would have been seen if there were available 
crystal structures of any of the CTX-M-1 group of enzymes. Therefore I used the 
crystal structure for CTX-M-9 enzyme published by Nichols et al (2012). The CTX-M 
models were constructed by the sequences of these enzymes with the use of CTX-
M-9 as a backbone. This approach made it possible to visualize the structural 
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mutations and it was useful for defining different amino acid changes and proximity 
to the active site. Nevertheless, the method could not detect major changes to the 
proteins’ backbone that might be due to differences between CTX-M-9 and CTX-M-1 
group enzymes reported in this study. Regardless, structural changes were detected 
at positions 80, 177, 242, and 282. 
 
The examination of the structural models allowed the explanation and confirmation 
of the effect of different amino acid changes on the active site and hence the 
function of the CTX-M enzyme described. Importantly, amino acid changes 
occurring at position 80, 177, and 242 occurring in CTX-M-55, CTX-M-117, and CTX-
M-15 respectively change the hydrolytic profile of these enzyems to ceftazidime 
and cefoxitin. 
 
When the amino acid changed in relation to the occurrence of the mutation, the 
properties of the amino acids changed as well. The different properties of the later 
amino acids indirectly exerted an effect on the structure of the active site. The 
amino acid change closest to the active site with different biochemical properties 
affected the structure of the active site and as a result the function of the active site 
in binding to β-lactam cephalosporins. Changes of the biochemical properties of the 
different amino acids at positions where mutations occurred in the reported CTX-M 
enzymes are explained in Figure 39. 
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The amino acid change at position 80 from Alanine to Valine increased the 
hydrolytic activity towards cephalosporins. The MIC levels were higher of 
ceftazidime and cefoxitin in isolates carrying CTX-M-55 than those carrying CTX-M-
15 (Table 29). The increased hydrolytic activity towards ceftazidime was also 
reported in other studies (Harada et al., 2012, Kiratisin et al., 2007, Ma et al., 2012, 
Tamang et al., 2012, Yu et al., 2011, Zheng et al., 2012). On the other hand, 
decreased activity towards cephalosporins seen in amino acid changes occurring at 
position 177 (Prolineglutamine) in CTX-M-117 was reported in this study (Table 
30) and in one other study (Geser et al., 2012).  
 
Changes occurring at amino acid position 242 (AspartateGlycine) in CTX-M-15, 
CTX-M-28, CTX-M-55, and CTX-M-117 will increase the hydrolytic profile of the 
enzymes with this mutation towards cephalosporins. The increase in the MIC of 
ceftazidime and cefoxitin can be seen when comparing the MICs of the isolate 
carrying blaCTX-M-3 gene and other isolates with blaCTX-M-15, blaCTX-M-28, blaCTX-M-55, and 
blaCTX-M-117 (Table 29 to Table 32). 
 
The mutation at position 282 (Aspartateasparagine) seen in CTX-M-28 seemed to 
exert no effect on the MICs to ceftazidime or cefoxitin (Table 32). 

















Figure 39: CTX-M reported in this study with mutations and hydrolytic activity towards ceftazidime. A indicates Alanine, D indicates 





In this work, the detection of cefotaximases was done by two means; phenotypic 
and genotypic. The screening of cefotaxime-resistance was carried out by Vitek 2 
system as well as DDD method with cefotaxime and clavulanic acid. The spread of 
cefotaxime resistance in Kuwaiti hospitals was found to be worrisome. For further 
detection and conformation of the ESBL-enzyme producing-cefotaximases, PCR was 
implemented. The results showed that CTX-M-ESBL-producers were responsible for 
cefotaxime resistance in all of the collected E. coli and K. pneumoniae. 
To fulfil the second objective of this project, the MICs were determined using four 
different classes of antibiotics. The determination of MIC was carried out namely by 
the double agar dilution method described by BSAC. Interestingly, co-resistance to 
flouroquinolones and aminoglycosides was found to be significantly increased  in 
both strains. Additionally, resistance to other generations of cephalosporins was 
also reported. Surprisingly, all of the collected E. coli and K. pneumoniae were found 
to be susceptible to carbapenems. 
The spread of CTX-M-producers led to the need of the detection of possible 
relatedness among the collected isolates. Therefore, PFGE was maintained to study 
the clonality of the study isolates. The original PFGE method described by Miranda 
et al (1996) was thought to be time-consuming and demanding for typing a large 
number of isolates. Therefore, an enhanced PFGE method was developed and used 
to type the study isolates. The enhanced PFGE method could be described as rapid, 
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producible, time and cost-effective method that can be used for epidemiologic 
studies. Nevertheless, the results of PFGE indicated poly-clonality of the collected 
isolates. Hence, indicating the spread of CTX-ESBL enzymes by HGT mediated by 
MGE. 
Upon further amplifications, this work confirmed that blaCTX-M-15 is the most 
prevalent enzyme in Kuwaiti hospitals and the causative enzyme of cefotaxime 
resistance. Fatherly, the results of this work agree with previous studies from 
Kuwait describing CTX-M-15 to be the commonest ESBL present in Kuwait. In 
addition, this work reports the first description of other CTX-M-1 group enzymes 
such as blaCTX-M-28, blaCTX-M-55, and blaCTX-M-117 in the Middle East and in Kuwait. 
Despite of the wealth of reports from Kuwait reporting the increased prevalence of 
blaCTX-M-15, factors leading to their increased spread and acquisition were not 
studied in depth. Therefore, this project focused on studying the genetic platforms 
of blaCTX-M-15 and possible genetic elements associated with its spread. GW-PCR, 
simplex PCR, plasmid sizing and conjugation studies served this purpose. The results 
of GW-PCR indicated that the commonest element of the upstream arrangement of 
all of the reported blaCTX-M-15 genes and some CTX-M-1 group enzymes was ISEcp1. 
ISEcp1 could possibly be the main factor for the increased spread of blaCTX-M-15 and 
responsible for HGT. The genetic environment studies also proved the variability of 
the genetic platforms carrying blaCTX-M-15. Additionally, all of the reported CTX-M-1 
enzymes in this work were found to be transferrable. 
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To accomplish the last objective of this project, studying the mutational effects was 
done by structural analysis. In this work, the mutational changes of the reported 
CTX-M-1 group enzymes with different amino acids were visualized using 
specialized software. From structural modelling, these amino acid changes could 
possibly affected the conformation of the active site of the describe enzymes and 
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Nucleotide sequence of isolates with blaCTX-M-15 gene. This sequence is obtained 
from isolate number 4, 15, 17, 20, 37, 47, 55, 57, 60, 61, 74, 75, 80, 82, 87, 88, 90, 
91, 92, 93, 94, 95, 96, 98, 99, 100, 101, and 105. The start codon is highlighted in 
green colour, while the stop codon is coloured in red. Our isolates share ≥ 98% 






































Nucleotide sequence of isolates with blaCTX-M-28 gene. This sequence is obtained 
from isolate number 86. The start codon is highlighted in green colour, while the 
stop codon is coloured in red. Our isolate shares 98% identity with CTX-M-28 gene 





































Nucleotide sequence of isolates with blaCTX-M-55 gene. This sequence is obtained 
from isolate number 89. The start codon is highlighted in green colour, while the 
stop codon is coloured in red. Our isolate shares 98% identity with CTX-M-55 gene 






































Nucleotide sequence of isolates with blaCTX-M-117 gene. This sequence is obtained 
from isolate number 97. The start codon is highlighted in green colour, while the 
stop codon is coloured in red. Our isolate shares 98% identity with CTX-M-117 gene 







































Nucleotide sequence of isolates with blaCTX-M-3 gene. This sequence is obtained 
from isolate number 102. The start codon is highlighted in green colour, while the 
stop codon is coloured in red. Our isolate shares 98% identity with CTX-M-3 gene 





Met V K K S L R Q F T L Met A T A T V T L L L G S V P 
L Y A Q T A D V Q Q K L A E L E R Q S G G R L G V A L 
I N T A D N S Q I L Y R A D E R F A Met C S T S K 
V Met A A A A V L K K S E S E P N L L N Q R V E I K K 
S D L V N Y N P I A E K H V N G T Met S L A E L S A A 
A L Q Y S D N V A Met N K L I A H V G G P A S V T A F 
A R Q L G D E T F R L D R T E P T L N T A I P G D P R 
D T T S P R A Met A Q T L R N L T L G K A L G D S Q R 
A Q L V T W Met K G N T T G A A S I Q A G L P A S W V 
V G D K T G S G G Y G T T N D I A V I W P K D R A P L 
I L V T Y F T Q P Q P K A E S R R D V L A S A A K I V 














Protein sequence of isolates encoding blaCTX-M-15. Met is the start codon ATG; 





Met A T A T V T L L L G S V P L Y A Q T A D V Q Q K L 
A E L E R Q S G G R L G V A L I N T A D N S Q I L Y R 
A D E R F A Met C S T S K V Met A A A A V L K K S E S 
E P N L L N Q R V E I K K S D L V N Y N P I A E K H V 
N G T Met S L A E L S A A A L Q Y S D N V A Met N K L 
I A H V G G P A S V T A F A R Q L G D E T F R L D R T 
E P T L N T A I P G D P R D T T S P R A Met A Q T L R 
N L T L G K A L G D S Q R A Q L V T W Met K G N T T G 
A A S I Q A G L P A S W V V G D K T G S G G Y G T T N 
D I A V I W P K D R A P L I L V T Y F T Q P Q P K A E 
















Protein sequence of isolates encoding blaCTX-M-28. Met is the start codon ATG; 





Met V K K S L R Q F T L Met A T A T V T L L L G S V P 
L Y A Q T A D V Q Q K L A E L E R Q S G G R L G V A L 
I N T A D N S Q I L Y R A D E R F A Met C S T S K 
V Met A A A A V L K K S E S E P N L L N Q R V E I K K 
S D L V N Y N P I A E K H V N G T Met S L A E L S A A 
A L Q Y S D N V A Met N K L I A H V G G P A S V T A F 
A R Q L G D E T F R L D R T E P T L N T A I Q G D P R 
D T T S P R A Met A Q T L R N L T L G K A L G D S Q R 
A Q L V T W Met K G N T T G A A S I Q A G L P A S W V 
V G D K T G S G G Y G T T N D I A V I W P K D R A P L 
I L V T Y F T Q P Q P K A E S R R D V L A S A A K I V 
















Protein sequence of isolates encoding blaCTX-M-55. Met is the start codon ATG; 





Met V K K S L R Q F T L Met A T A T V T L L L G S V P 
L Y A Q T A D V Q Q K L A E L E R Q S G G R L G V A L 
I N T A D N S Q I L Y R A D E R F A Met C S T S K 
V Met A A A A V L K K S E S E P N L L N Q R V E I K K 
S D L V N Y N P I A E K H V N G T Met S L A E L S A A 
A L Q Y S D N V A Met N K L I A H V G G P A S V T A F 
A R Q L G D E T F R L D R T E P T L N T A I P G D P R 
D T T S P R A Met A Q T L R N L T L G K A L G D S Q R 
A Q L V T W Met K G N T T G A A S I Q A G L P A S W V 
V G D K T G S G D Y G T T N D I A V I W P K D R A P L 
I L V T Y F T Q P Q P K A E S R R D V L A S A A K I V 













Protein sequence of isolates encoding blaCTX-M-117. Met is the start codon ATG; 





Met V K K S L R Q F T L Met A T A T V T L L L G S V P 
L Y A Q T A D V Q Q K L A E L E R Q S G G R L G V A L 
I N T A D N S Q I L Y R A D E R F A Met C S T S K 
V Met A V A A V L K K S E S E P N L L N Q R V E I K K 
S D L V N Y N P I A E K H V N G T Met S L A E L S A A 
A L Q Y S D N V A Met N K L I A H V G G P A S V T A F 
A R Q L G D E T F R L D R T E P T L N T A I P G D P R 
D T T S P R A Met A Q T L R N L T L G K A L G D S Q R 
A Q L V T W Met K G N T T G A A S I Q A G L P A S W V 
V G D K T G S G G Y G T T N D I A V I W P K D R A P L 
I L V T Y F T Q P Q P K A E S R R D V L A S A A K I V 













Protein sequence of isolates encoding blaCTX-M-3. Met is the start codon ATG; 
highlighted with green colour. The Stop codon is TAA
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Characterization of IncFIA, IncFIB, and IncN Plasmids Carrying CTX-M-3, -15, -55 β-
lactamases from Escherichia coli and Klebsiella pneumoniae Strains from 5 Major 
Kuwaiti Hospitals 
N. M. ALMARAGHI1, A. D. DASHTI 2, A. H. HAMOUDA 1, S.G.B. AMYES1. 
Molecular Chemotherapy, Centre for Infectious Diseases, University of Edinburgh, 
Scotland, United Kingdom1, Department of Medical Laboratory Sciences, Faculty of 
Allied Health Sciences, Health Science Centre, Kuwait University.  Kuwait2. 
 
Objectives: To characterize plasmids carrying CTX-M-3, -15, -55 in E. coli and K. 
pneumoniea strains isolated from 5 major hospitals in Kuwait. Methods: Ten strains 
of E. coli and 6 K. pneumoniae with ESBL production were collected from 5 major 
hospitals in Kuwait. Further detection of CTX-M enzyme activity was determined 
using PCR (Dutour et al., 2002). The minimum inhibitory concentrations (MICs) of 
the selected strains were determined using four classes of antibiotics; 3 different 
generations of cephalosporins, fluoroquinolones, aminoglycoside, and carbapenems 
(Andrews, 2010, Andrews, 2009, Andrews, 2001). The epidemiologic relatedness of 
the selected strains was determined by pulsed-field gel electrophoresis (PFGE) 
(Durmaz et al., 2009). The strains were fatherly sequenced and their plasmids were 
typed with PCR-based replicon typing method (Carattoli et al., 2005).  Results: With 
PCR, all of the studying strains were shown to express CTX-M enzyme activity. All of 
the strains were highly resistant to all antibiotic classes except for carbapenems. 
Using PFGE, there was no epidemiologic relatedness among the studying strains. 
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Upon sequencing, CTX-M-15 was found in 14 strains, CTX-M-3 and CTX-M-55 in one 
strain each. The gene was carried on IncFIA, IncFIB, and IncN plasmids. Conclusion: 
CTX-M-15 was found to be predominant among all of the strains. The strains were 
shown to express increased resistance to all antibiotic classes, which directs 
treatment regimens towards carbapenems. The absence of epidemiologic 
relatedness among the studying strains suggests the variability of the plasmids 
carrying blaCTX-M-15 gene. This result is supported by the presence of different 
plasmid types carrying blaCTX-M-15 gene. 
 
 
